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A large amount of evidences indicate that dysregulation of protein methylation is 
linked to the genesis and progression of several human diseases, including cancer. 
Therefore over the past years small-molecule modulators targeting Protein 
Methyltransferases (PMTs) have been actively developed as anticancer drugs as 
well as chemical tools to better understand the biological and physiological roles 
of protein methylation. In this thesis the design, synthesis and biological 
evaluation of three different classes of compounds, designed as isozyme-selective 
PRMT inhibitors, are reported. (1) Inspired by the structure-activity relationships 
(SAR) of pyrazole and indole compounds, the most potent PRMT4 inhibitors, we 
developed a series of pyrrole-based compounds, designed as inhibitors of 
PRMT4. A potent inhibition was observed when testing pyrrole derivatives 
against PRMT4 (i.e. EML 438, IC50 = 2.42 µM), nevertheless they didn’t prove a 
significant cellular activity, due to their poor transcellular permeability. 
Therefore, in order to increase the activity and the lipophilicity of these 
compounds and supported by computational studies, we started a process of 
structural optimization of this class of compounds. Novel derivatives have been 
designed and selected. (2) Furthermore, in collaboration with Professor Nathaniel 
Martin from the University of Utrecht, we have successfully synthesized a set of 
novel PRMT4 bisubstrate inhibitors. Preliminary screening of their biological 
activity revealed a nanomolar inhibition of PRMT4 (P2-C3-unsat, IC50 = 43 nM) 
with about 900-fold selectivity for CARM1 over PRMT1. This data confirm our 
hypothesis that a potent and selective enzymatic inhibition is achieved by 
compounds characterized by structural features able to bind both the enzymatic 
substrate binding sites, thereby mimicking the transition state. (3) We also started 
a program aiming at developing inhibitors of PRMT3. Three series of indole-
based compounds were prepared and their activity against a panel of PRMTs was 
assessed. EML598 and EML599 showed a selective inhibition of PRMT3 at 
fixed dose (70% at 100 µM). Further biophysical assays are still ongoing in order 








































Epigenetics is the study of heritable changes in genome function that occur 
without alterations to the DNA sequence. Most of these changes are 
established during differentiation and are stably maintained through multiple 
cycles of cell division, enabling cells to have distinct identities while 
containing the same genetic information. Unlike the genome itself, epigenetic 
modifications are cell specific, plastic, and responsive to environmental 
influences. There are many examples in our everyday lives where common 
inputs result in differential outcomes, depending on specific control 
mechanisms. Consider, for example, how a talented musician can produce a 
wide variety of music on a guitar. A particular piece of music is encoded by 
the sequence and timing of notes, that are typically transcribed onto sheet 
music. The guitarist translates the sheet music by spatial and temporal 
modifications to the guitar strings; that is, he/ she holds down different strings, 
at different frets, at different times to produce the music. In an analogous 
manner, gene expression is spatially and temporally controlled within cells by 
specific epigenetic modifications that can signal the cell to turn on or turn off 
the transcription of particular genes.  
There are three reasons for the intense interest in Epigenetics: (1) epigenetic 
mechanisms are involved in many fundamental areas of biology, and are often 
underpinned by novel, interesting mechanisms. (2) Epigenetic regulation plays 
a central role in gene expression, so is involved in (and occasionally 
responsible for) initiating disease processes. (3) A large number of enzymes 
and protein complexes are involved in epigenetic processes, and are potential 
targets for small-molecule inhibition. To date, two classes of drugs with 
epigenetic targets have been approved for cancer chemotherapy, but similar 
‘epigenetic therapies’ are likely to be developed for a broad range of diseases 
in the medium term. 
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1.2. Chromatin modifications and Histone code 
The chromosomes within eukaryotic cell nuclei are packaged together with 
structural proteins, histones, to form the complex known as chromatin. This 
macromolecular complex has a straightforward modular structure based on a 
single repeating building block known as nucleosome, which consists of eight 
histone proteins (two copies of each histones H2A, H2B, H3 and H4), around 
which DNA is wound almost twice (Figure 1.0).1 
 
Figure 1.0. Structure of nuclesome 
The chromatin exists in two main conformational states: heterochromatin and 
euchromatin (Figure 1.1). The chromatin can fold upon itself to compact the 
nucleosomes, forming a highly condensed structure, referred to as 
heterochromatin. This provides an effective mechanism for storing a large 
quantity of DNA in a very small volume. However, in order for genes to be 
transcribed into mRNA molecules, portions of the gene (referred to as 
promoter regions) need to interact with particular proteins, such as 
transcription factors that initiate the process of mRNA transcription. In the 
condensed heterochromatin structure these promoter regions are largely 
inaccessible to the transcription factors; hence protein production is inhibited. 
Therefore, to initiate protein production (also referred to as gene expression) 
the heterochromatin structure needs to be relaxed in a specific and controlled 
manner, so as to expose the promoter regions of particular genes that need to 
                                                                                 Chapter 1: Introduction 
3 
 
be transcribed at specific times and under specific conditions during the 
lifetime of a cell. This more relaxed state is referred to as euchromatin.  
Notably, the transition between the two conformational states of chromatin is 
accomplished by changing the structure of the nucleosomes by adding or 
removing small chemical units (e.g., acetyl groups, methyl groups, phosphate 
groups and ubiquitin groups)2 at specific locations on the histones (Figure 
1.1). 
 
Figure 1.1. Two main conformational states: heterochromatin and euchromatin. The transition 
between the two states is regulated by post-translational modifications 
 
Histones, the core components of the nucleosome, are basic proteins 
characterized by a comparable overall structure, with a globular hydrophobic 
internal region, around which the DNA sequence is rolled up, and a flexible 
charged amino termini (histone tail) protruding out the nucleosome, that 
represents the platform whereby the post-translational modifications (PTMs) 
occur  (Figure 1.2). 
 
Figure 1.2. Representation of the post-translational modifications (PTMs) that occur on the 
histone tail  
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These reversible epigenetic modifications, performed by selective epigenetic 
enzymes within the cell, constitute the main features of the so-called “histone 
code”.2 The proposed function of this code is to integrate exogenous and 
endogenous signals into a diverse set of PTM patterns to enable the epigenetic 
control of gene expression, through a remodeling of the chromatin structure. 
Indeed, the chromatin modifications physically enhance or weaken the 
noncovalent interactions between histones or between histones and DNA, 
determining accessibility to specific DNA loci, providing also an informative 
platform for the recruitment of epigenetic regulators.  
The epigenetic enzymes can be divided into distinct groups based on their 
broad functions: epigenetic writers, erasers and  readers (Figure 1.3).3 
 
Figure 1.3. Epigenetic writers, readers and erasers 
1.2.1. Epigenetic writers, readers and erasers 
The epigenetic writers catalyze the addition of chemical groups onto either 
histone tails or the DNA itself. These modifications are known as epigenetic 
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marks, and are integral to gene expression and silencing. One such group of 
epigenetic writers is histone methyltransferases; these enzymes catalyze the 
transfer of a methyl group onto a lysine or arginine residue on histone tails. In 
addition to methyl marks, histone lysine residues may also undergo acetylation 
through the activity of histone acetyltransferases.4 The transfer of an acetyl 
group from the cofactor acetyl-CoA to lysine residues on histone tails 
neutralizes the positive charge of lysine, thereby weakening the affinity of the 
histone tail for the DNA and reducing chromatin condensation. Since a more 
relaxed, open chromatin architecture enables the recruitment of transcription 
factors and polymerases, histone acetylation results in the promotion of gene 
expression.  
Enzymes that catalyze the phosphorylation of histone tails are also important 
epigenetic writers.5 For example, phosphorylation of histone H3 (H3Y41) by 
JAK2 disrupts binding of the heterochromatin protein HP1α to chromatin, 
leading to increased DNA accessibility and the transcription of the oncogene 
Lmo2. A further epigenetic mark that alters gene expression is ubiquitination.6 
Lysine residues on histone proteins H2A and H2B can undergo 
monoubiquitination through the concerted actions of E2 ubiquitin conjugases 
and E3 ubiquitin ligases.  
DNA can also undergo methylation through different mechanisms. The 
addition of a methyl group to a nucleotide by DNA methyltransferases 
(DNMTs) occurs at the major groove of the DNA double helix, and prevents 
transcription by blocking the binding of transcription factors and 
polymerases.7 There are two known types of DNA methylation – de novo and 
maintenance methylation. De novo methylation, predominantly carried out by 
DNA methyltransferases DNMT3A and DNMT3B, catalyzes the addition of 
methyl groups onto cytosine nucleotides. Since cell replication does not 
preserve such methylation, maintenance methylation copies these marks from 
the parent DNA onto the daughter DNA strands. The high affinity of DNMT1 
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for hemimethylated DNA in vitro suggests that this enzyme is primarily 
responsible for maintenance DNA methylation in vivo. 
Epigenetic marks are not necessarily permanent modifications; instead, they 
can be removed by a group of enzymes known as epigenetic erasers in order 
to alter gene expression. There are multiple categories of epigenetic erasers 
that target histones; these include histone deacetylases,8 histone 
serine/threonine/tyrosine phosphatases, histone deubiquitinases and histone 
lysine/ arginine demethylases.9 The removal of acetyl groups through the 
actions of histone deacetylases (HDACs) is an important mechanisms for 
increasing chromatin condensation and therefore repressing gene transcription. 
HDACs can be divided into two groups termed group I and group II.  
Histone phosphatases can target either phosphorylated serine, threonine or 
tyrosine residues on histone proteins.10 Protein Serine/Threonine phosphatases 
PP1, PP2A and PP4, amongst others, have been reported to dephosphorylate 
histone proteins.  
The removal of ubiquitin groups from histone lysine residues is catalyzed by 
proteases known as deubiquitinating enzymes (DUBs).10 These proteins target 
histones H2A and H2B, where they regulate transcription, DNA repair, gene 
expression and cell cycle progression. Compared to other histone modifica-
tions, the functions of histone ubiquitination are less well understood, yet 
increasing evidence points to an important role for this epigenetic modification 
in the DNA damage response.  
The first histone lysine demethylase to be discovered was lysine-specific 
demethylase 1 (LSD1),11 also known as KDM1. LSD1 contains an amino 
oxidase domain that binds the cofactor, flavin adenine dinucleotide (FAD), 
crucial for demethylation. A further family of lysine demethylases have since 
been identified; these are termed Jumonji C domain-containing demethylases 
(JMJD). JMJD do not require FAD as a cofactor but instead are dependent on 





/2-oxoglutarate (2-OG) for catalysis. As yet, only one enzyme with 
arginine demethylase activity has been identified, JMJD6, which is a 2-OG-
dependent JMJD.  
In contrast to the well-defined mechanisms of the removal of epigenetic marks 
from histones, the mechanism by which methyl groups are removed from 
DNA remains poorly understood. What is known, however, is that DNA 
demethylation can occur both actively and passively.11 Passive DNA demeth-
ylation involves the failure of maintenance DNA methyltransferases to 
methylate newly synthesized DNA strands during mitosis, whilst the 
molecular machinery that catalyzes active DNA demethylation occurs is yet to 
be elucidated. Since demethylation of DNA is crucial for processes such as 
epigenetic reprogramming in germ cells, further research into the mechanisms 
of active DNA demethylation may identify novel targets for stem cell 
research.  
Additionally, epigenetic reader domains can be thought of as effector proteins 
that recognize, and are recruited to specific marks on histones or nucleotides.12 
Enzymes which write or erase epigenetic marks may also contain such reader 
domains, leading to the coordination of ‘read-write’ or ‘read-erase’ epigenetic 
processes. The structure of reader domains typically provides a cavity or 
surface groove in which to accommodate a specific epigenetic mark.  
Proteins that contain reader domains can be broadly classified into four 
groups:12 chromatin architectural proteins; chromatin remodeling enzymes; 
chromatin modifiers and adaptor proteins that recruit other machinery 
involved in gene expression. The first group of these, chromatin architectural 
proteins, binds to nucleosomes and can either directly induce chromatin 
compaction or alternatively act as a shield to prevent the binding of proteins 
involved in RNA transcription.  
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In contrast to chromatin architectural proteins, chromatin remodeling enzymes 
prompt a more open chromatin architecture. The increased accessibility of 
chromatin facilitates DNA transcription, promoting gene expression.  
Many other proteins that contain reader domains cannot directly influence 
chromatin architecture, but instead serve to recruit secondary chromatin 
modifiers to further modify chromatin or to reverse an existing chromatin 
modification.  
The final class of reader domain-containing proteins is adaptor proteins: the 
principal function of these domains is to recruit factors that are linked to DNA 
metabolism processes including transcription, DNA damage repair, DNA 
recombination, DNA replication and RNA processing. 
 
1.3. Protein Methyltransferase (PMTs) 
Histone methylation by Protein Methyltransferases (PMTs) is one of the most 
studied post-translational modifications since it is implicated in 
heterochromatin formation and maintenance, transcriptional regulation, DNA 
repair, X-chromosome inactivation, and RNA maturation.13  
Protein Methyltransferases (PMTs) catalyze the methylation of lysine or 
arginine residues on the histone or non-histone substrates.14 15 They can be 
divided into two classes: Protein Lysine Methyltransferase (PKMT) and 
Protein Arginine Methyltransferase (PRMT) (Figure 1.4). The PKMT is 
responsible for the generation of mono-, di-, and trimethylated lysine residues, 
while the PRMT is responsible for the generation of monomethyl arginine 
(MMA), symmetric dimethylarginine (SDMA), and asymmetric 
dimethylarginine (ADMA; Figure 2). The PKMT is a large class of enzymes 
with more than 50 members and can be divided into eight groups (KMT1-
KMT8). Whereas, the PRMT can be distinguished into three subtypes based 
on the methylation products:16 type I (PRMT1, 4, 6, 8) for ADMA and MMA 
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generation, type II (PRMT5 and PRMT9) for SDMA and MMA generation, 
and type III (PRMT7) for MMA generation only.  
 
Figure 1.4. Methylation States of Lysine and Arginine Residues 
Even though lysine or arginine methylation does not change the charge state of 
the residue side chain, the increased bulkiness and hydrophobicity of the 
methylated moiety would affect protein-protein interactions and protein 
recognition, thus gene expression and transcription regulation. Alterations of 
the post-translational modifications of arginine and lysine residues could have 
dramatic effects on cell signaling and, like other histone modifications, 
contribute to disease pathogenesis. Indeed, there are increasing experimental 
evidences to suggest that the deregulations of arginine and lysine modifying 
enzymes play pivotal roles in cancer, inflammatory diseases, 
neurodegenerative diseases, and other conditions.9 On these bases, PMTs have 
been increasingly recognized as potential therapeutic targets and there is 
                                                                                 Chapter 1: Introduction 
10 
 
growing interest in the scientific community to discover and develop selective 
small-molecule modulators of these enzymes.  
Yet today there are tool compounds and clinical candidates17  reported for < 
15% of these enzymes. The PMTs for which small molecule modulators have 
been reported represent those enzymes with some of the best pathobiological 
validation, as is appropriate in novel target space. Nevertheless, the relative 
paucity of chemical coverage of this target class severely limits chemical 
biology approaches for understanding the biological and pathobiological roles 
of these enzymes more fully. A breakthrough in this area will be truly exciting 
and is keenly awaited. 
 
1.3.1 Protein Lysine Methyltransferases (PKMT) 
As previously mentioned protein methylation may occur on lysines and 
specifically on the ᶓ amino groups of their side chains. This covalent 
reversible modification is inserted by a distinct family of methyltransferases, 
called Protein Lysine Methyl Transferases (PKMTs). This enzymes are 
capable of a substrate selectivity being able to modify only distinguishing 
lysinic residues of their substrates, and moreover of a product specificity being 
endowed to methylate these residues only to a characteristic state as mono- 
(me1), di- (me2) and trimethylated (me3). As well as protein arginine 
methyltransferases, the PKMTs catalyze the methylation transfer using SAM 
or S-Adenosyl-L-Methionine (AdoMet) as cofactor and affording SAH or S-
Adenosyl-L-Homocysteine (AdoHcy) and the methylated substrate as products 
(Figure 1.4).  
More than 50 human lysine methyltransferases have been identified and 
characterized so far (Figure 1.5). According to structural and sequence criteria 
of their catalytic domain, these can be classified into two families: the DOT1-
like (DOT1L) and the SET-domain-containing methyltransferases. To date 
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only the DOT1L enzyme belongs to the former family, which is distinguished 
by the presence of seven-stranded β-sheet motif, which also structurally 
characterizes the PRMTs family. 18Another aspect that makes DOT1L unique 
is the fact that it is the only methyltransferase catalyzing the methylation 
reaction of Lysine 79 on histone H3 (H3K79), which differs from the other 
lysines as it is located in the inner part of the nucleosomes. H3K79 
methylation is a transcriptional activating histone mark playing pivotal roles in 
early embryonic development, and DOT1L has been found involved in MLL 
translocation effects in mixed lineage leukemia.19 
Most of the PKMTs belong to the SET-domain-containing protein subset 
which is in turn organized into different subfamilies according to their 
founding member: EZ, RIZ, SET1, SET2, SMYD3 and SUV39  (Figure 1.5).  
 
Figure 1.5. Phylogenetic tree of Protein Methyl Transferases (PMTs). 
 
The SET domain is a sequence of 130 amino-acids and it takes its name from 
the Drosophila genes Su(var)3-9, E(z) (Enhancer of zeste) and Tritorax where 
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it was initially identified. Within the SET domain the substrate and the 
cofactor bind in different sites, flanking each other, and meet at the core of the 
domain through a narrow hydrophobic channel, where the methyl transfer 
takes place. Albeit SET domain is the responsible for the methyltrasferase 
activity, the catalysis also relies on the simultaneous presence of other 
domains that act as “framework” for the recruitment of the substrate or other 
partners within large multiunit complexes or modulate the catalytic step, like 
for example in the Polycomb Repressive Complex 2 (PRC2), where the 
catalytic subunit EZH2 displays a methyltransferase activity only in complex 
with the non-catalytic partners EED and SUZ12. All these surrounding 
domains can be divided into two subsets: the I-SET and post-SET motifs 
(respectively inserted within and C-terminal shifted respect to the SET 
domain) that participate to the substrate recognition and extent to the cofactor 
binding; and the Pre-SET (cysteine-rich also referred to as a CXC domain), 
MYND (between I-SET and SET) and CTD (C-terminal to Post-SET) 
domains, which are thought to be interfaces for the interaction with other 
proteins and DNA. The pre-SET motif seems to play an important role also in 
the catalytic event.20 According to this, distinct domains with different 
sequence and structure may decorate the SET fold in assorted combinations to 
obtain selective recruitment of interaction partners and therefore specific 
functions. Being involved in the substrate recognition, the I-SET and post-SET 
domain are always found in the SET methyltransferases. Even if the amino 
acidic sequence can change, the I-SET sequence has a overall conserved 
structural organization, while the Post-SET domain is more dynamic and can 
adopt different conformations.  
As far as the substrate recognition is concerned, different mechanistic analysis 
has displayed that the Lys- and Arg-rich electropositive histone tails and the 
overall electronegative substrate-binding groove, spatially defined by pre-
formed I-SET and the open folded Post-SET, initially interplay through a long 
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range electrostatic interactions. Once this loose complex has been formed, 
SAM binding induces a partially folded Post-SET conformation which keeps 
close the PKMT and the substrate, allowing the sequence specific recognition 
to start. In this proposed model, the PKMT slides along the substrate peptide, 
with I-SET domain acting as a reading template. Once specific interactions 
have been established, the lysine substrate looses a proton to the solvent and 
fits into the hydrofobic channel. The loose complex thus turns into a 
catalytically competent conformation and the substrate peptide is further fasten 
by the Post-SET domain, which closes on it and shields the active site from the 
surrounding solvent. Owing to a tyrosine residue, the deprotonated ε-amino 
group of lysine substrate aligns its lone pair with the assailable methyl-sulfur 
bond and methyltransfer takes place.21 
The structure of the active site are peculiar of each PKMTs and suggest that is 
theoretically possible to develop selective PKMTs inhibitors. As previously 
stated SET-domain containing methyltransferases not only exhibit a substrate 
selectivity but also a product specificity. EZH2 has the greatest catalytic 
activity in mono-methylating the H3K27 but can achieve all three methylated 
states of this lysine, SET7/9 affords only monomethylated H3K4 (H3K4me1) 
after one round of catalysis, while G9a and GLP are either mono- and 
dimethyltransferases for H3K9 (H3K9me1/me2).22 This product specificity 
can be realized on the basis of structural and sequence explanations: the ability 
to mono-, di- and trimethylate lysine substrates seems to be correlated to a 
“tyrosine-phenylalanine switch” and in general to the steric crowding of the 
hydrophobic channel, since some PKMTs (Dim5, G9a) change their 
specificity following point mutations from tyrosine to phenylalanine, and vice 
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1.3.1.2. Physiopathological role of PKMT 
The protein lysine methyl transferases exert their activity mainly on histones 
even if other proteins have been identified as PKMTs substrates.24, 25, 26A 
extensive example may be represented by the tumour suppressor protein p53, 
which can be targeted by different PKMTs with opposing cellular outcomes 
depending on the site of lysinic methylation: p53-responsive genes may be 
transcriptionally repressed after methylation at K370 by SMYD227 or on K382 
by SETD8,14 while methylation of K372 by SET7/9 result in transcriptional 
activation;15 p53 may be also inactivated because of the methylation on K373 
by G9a and GLP.28  
Histones represent the main site of action of lysine methyltransferases which 
are therefore referred to as Histones Lysine Methyl-Transferases (HKMTs). 
As epigenetic “writers” they are correlated with both transcriptional activation 
and silencing, depending on the specific residue involved and on the extent of 
methylation, since lysine may be methylated up to three times. Nonetheless, 
generally methylation on H3K4, H3K36 and H3K79 is associated with 
activation of transcription whereas methylation at H3K9, H3K27 and H4K20 
is correlated with transcriptional silencing.29 Differently from the lysinic 
acetylation, whose transcription-activating mechanism is essentially based on 
the neutralization of the positive charge of the lysine side chains (which in turn 
interrupts the electrostatic interaction with phosphate groups of DNA 
backbone); lysine methylation doesn’t affect the overall charge of the residues. 
Methyl groups rather seem acting as “hubs” for the recruitment of highly 
evolved methyl-lysine-binding proteins able to  distinguish distinct level of 
methylation and the surrounding amino acid sequence, especially along 
histone tails. The most remarkable biological consequences of the enhanced 
specificity of HKMTs is that each component of the former family of enzymes 
controls genes expression in a narrower group of cell types, being them normal 
or cancerous, thus proving to be more promising targets for drug development. 
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In this concern a multitude of evidences draw attention to the wide spreading 
involvement of HKMTs in the human diseases related biochemical pathways 
including oncogenic transformation, inflammation, metabolic and 
neuropsychiatric disorders, finally in the handling of stem cells as tools for 
regenerative medicine.30 
HKMTs may contribute to the diseases development or maintenance by 
gaining aberrant activity due to mutations, altered expression or translocations 
that directly affect cellular genes expression, or being involved in altered 
upstream cellular signals.  
In cancer, MLL1 (mixed –lineage leukemia 1) methyltransferase is subject of 
more than 50 chromosomal translocations, especially in human lymphoid and 
myeloid leukemias, where these are associated with very poor prognosis.31 
Despite the translocations are responsible for the loss of the carboxy-terminal 
SET domain, the N-terminal fusion proteins upregulate expression of several 
target genes including HoxA7, HoxA9 and the Hox factor MEIS1 that are 
important for proliferation and final differentiation of hematopoietic cells.32 
During normal hematopoiesis, expression of HoxA7, HoxA9 and HoxA10 
promote stem cell self-renewal, and the downregulation of these genes 
correlates with terminal differentiation.33 The inappropriate transcriptional 
activation seems to arise from the interplay with transcriptional elongation 
partners like AFF4, AFF1, AF9, and ENL, and other epigenetic factors such as 
the methyltransferase DOT1-like protein (DOT1L). MLL-DOT1L and MLL-
AF10 fusion proteins lead to the abnormal expression of leukemia-relevant 
genes, like Hox9A, and the transcriptional “prime” due by H3K79 instead of 
H3K4 methylation, respectively own of DOT1L and MLL1 
methyltransferases, could be the prompting signal for oncogenic 
transformation in hematopoietic cells.34 Other MLL fusion proteins can 
interact with factors that promote malignancy: MLL-AF9 fusion protein holds 
AF9 (also know MLLT3) capacity to recruit YEATs domain-containing 4 
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(YEATS4), which is upregulated in neuroblastoma and is required for the 
aberrant inactivation of p53106.35 Being composed of multipotent precursor 
cells interested by cellular differentiation and clonal expansion following a 
triggering stimulus (antigens), which then turn into specialized lymphocytes, 
the adaptive immune system shows all the hallmarks of a cellular process that 
can be regulated by epigenetic pathways. Though acetylation is the most 
firmly recognised histone modification playing important role in these 
mechanisms, the immune system regulation represents a new field of 
application of histone lysine methylation; in particular, G9a has been found to 
silence specific genes in the endotoxin shock through its H3K9 
dimethylation.36  
SET-domain-containing protein 7 (SETD7) and Suppressor of Variegation 3-9 
homolog 1 (SUV39H1), two other lysine methyltransferases, contribute to 
hyperglycaemic memory. Together with LSD1, they maintain the glucose 
response-related upregulation of p65 gene (a subunit of NF-kB), which is 
associated with diabetic vascular injury.37  
Modulation of epigenetic proteins find application also in the newest 
regenerative medicine, as they can direct the differentiation of embryonic stem 
cells and induce a pluripotent stem cellular state starting from somatic cells. 
Small modulators of epigenetic proteins, including HDACs, PKMTs and 
Histone Lysine Demethylases (HDMs), when associated with biological 
techniques like transduction with transcription factors (OCT3, SOX2, MYC 
and KLF4), give the same cellular output, improve the reprogramming 
efficacy and avoid the risk of carcinogenesis. For example the G9a inhibitor 
BIX-01294 improves the stem cell reprogramming process in neural 
progenitors when in association with only OCT3 and KLF4.38 
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1.3.2. Protein Arginine Methyltrasferase (PRMT) 
Protein arginine methylation is a common post-translational modification that 
regulates numerous cellular processes, including gene transcription, mRNA 
splicing, DNA repair, protein cellular localization, cell fate determination, and 
signaling.39, 40 , 41, 40 Notably, it was shown that about 2% of the total arginine 
residues isolated from rat liver nuclei are dimethylated.42 The methylation of 
arginine residue does not perturb the overall positive charge of the arginine 
guanidinium group, but changes potential hydrogen bond interactions, since 
the number of added methyl groups reduces the hydrogen bond donor sites, as 
well as imparts bulkiness to the arginine side chain, thus influencing the 
protein-protein interactions both positively and negatively. 
The formation of this PTM is catalyzed by a family of methyltransferases 
referred to as PRMT (Protein Arginine Methyltransferase). In mammal cells, 
nine protein arginine methyltransferases (PRMTs), divided into three different 
classes, have been identified so far.43 Type I (PRMT1, PRMT2, PRMT3, 
PRMT4/CARM1, PRMT6 and PRMT8) and Type II (PRMT5 and PRMT7) 
enzymes both catalyze the formation of monomethylarginine (MMA) as an 
intermediate, but while Type I enzymes facilitate the formation of ω-NG,NG-
asymmetric dimethylarginine (ADMA), Type II members lead to the 
formation ω-NG,NG-symmetric dimethylarginine (SDMA) (Figure 1.4). Upon 
certain substrates PRMT7 seems to generate only ω-NG-monomethylation 
(MMA) arginines thus being classified as a Type III enzyme too (Figure 1.4); 
44  while PRMT9 activity has not been well characterized yet.45 To date, no 
enzymes forming both asymmetric and symmetric dimethylarginines have 
been identified. 
The different PRMT subfamilies are characterized by common structural 
features. All of them possess a single catalytic core region of approximately 
310 amino acids, which comprises five highly characteristic signature motifs 
including (1) motif I (VLD/EVGXGXG), which forms the base of the SAM-
                                                                                 Chapter 1: Introduction 
18 
 
binding site and is structurally homologous to sequences found in other 
nucleotide-binding proteins, (2) post I (L/V/IXG/AXD/E), which is important 
for hydrogen bond formation to each hydroxyl of the ribose part of SAM via 
the carboxylate of the acidic residue, (3) motif II (F/I/VDI/L/K), which 
stabilizes motif I by the formation of a parallel β-sheet, (4) motif III 
(LR/KXXG), which forms a parallel β-sheet with motif II, and (5) the THW 
loop, which is close to the active site cavity and helps stabilize the N-terminal 
helix, which is important for substrate recognition.16 Moreover several PRMTs 
possess additional domains (e.g., SH3, Zn finger, TIM barrel, and TPR) that 
have been suggested to diversify the substrate specificity of the enzymes and 










Figure 1.6. Schematic depiction of the human PRMT family. The SAM-binding 
methyltransferase region is highlighted in olive green. All family members contain the 
methyltransferase signature motifs I, post-I, II, and III and the conserved THW loop, labeled 
as red bars, respectively. Sequence motifs with low or no sequence similarity are depicted in 




                                                                                 Chapter 1: Introduction 
19 
 
The crystal structures of several PRMTs revealed that these proteins mainly 
exist as homodimeric head-to-tail protein complexes (Figure 25A).46, 47, 48, 49 It 
was proposed that the dimer is critical for proper substrate binding and 
therefore is required for activity.35 By contrast, PRMT7, the only known type 
III methyltransferase, is unusual in that. It, indeed, contains two PRMT core 
units arranged in tandem. The catalytic core region consists of three 
structurally and functionally distinguishable regions as exemplified by the 
structure of PRMT1 (Figure 1.7). The most critical is the SAM-binding 
domain, which is highly conserved in other SAM-dependent 
methyltransferases.50 This SAM-binding domain adopts a typical Rossmann 
fold and is followed by the β-barrel domain, which is quite unique to the 
PRMT family and is thought to be important for substrate binding.51 
Moreover, the β-barrel domain contains an α-helical insertion that acts as a 
dimerization arm. Despite the variation in amino acid sequences, the crystal 
structures of several PRMTs reveal highly similar general folds. In addition, 
key structural features such as the active site double E-loop, which is critical 
for guanidinium binding, as well as the SAM-binding residues and several β-
strand-forming signature motifs, are conserved among all PRMTs. 
 
Figure 1.7. PRMT1 exists as a head-to-tail dimeric protein that comprises four characteristic 
functional regions, as indicated 
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PRMTs employ a bisubstrate mechanism,52  transferring the methyl group of 
SAM to specific arginine residues in histone and nonhistone protein substrates, 
resulting in mono- and dimethylated arginine residues and the byproduct S-
adenosyl-L-homocysteine (SAH or AdoHcy). Once activated, these enzymes 
endow themselves with an ordered sequential kinetic mechanism, in which 
SAM binds prior to the substrate.48 The substrate binding pocket and the 
cofactor binding site, almost flanking each other, are joined by a narrow 
hydrophobic channel, large enough to allow the terminal amino group of the 
substrate to come within bonding distance of the cofactor. Two conserved 
residues (Glu-100 and Arg-54 in PRMT1) interact with the two ribose 
hydroxyls and carboxylate from SAM, respectively, placing the 
methylsulfonium group of the cofactor at the base of the channel where 
arginine side chain of the substrate raises. In the same manner two hydrogen 
bonds by other invariant glutamate residues (Glu-144 and Glu-153 of PRMT1) 
are established with the guanidinium side chain of the arginine substrate. 
These two H-bonds are critical interactions as they are supposed to concentrate 
the delocalized positive charge onto an only one nitrogen of the guanidinium 
group, leaving the lone pair of the other one available for the nucleofilic 
substitution (SN2 mechanism) to the methylsulfonium group(Figure 1.8).51  





Figure 1.8. Proposed PRMT “SN2-like” bisubstrate mechanism with key active site residues 
shown (PRMT1 numbering scheme). AdoMet is presented in blue and the arginine residue of 
a target peptide is presented in red. 
 
Interestingly, the catalytic domain of PRMT5 which catalyzes SDMA 
formation, is also highly similar to that of the ADMA-generating type I 
enzymes.53, 54 However, the molecular basis for their distinct product 
formation paths is largely unknown. Recent reports proposed that a conserved 
phenylalanine (F327) in the active site of PRMT5 is important for directing 
symmetric dimethylation, while a methionine (M48) residue in Type I PRMT 
confers specificity toward asymmetric dimethylation. 
1.3.2.1.  Physiopathological role of PRMTs 
PRMTs are generally ubiquitously expressed and govern important cellular 
processes that affect cell growth, proliferation and differentiation. They 
methylate numerous cellular protein substrates, including nuclear proteins 
such as transcription factors, other coregulators, and histones. The importance 
of this PTM to cellular growth is probably best exemplified by the fact that 
both PRMT1 and CARM1 mouse knockouts are embryonically lethal. The 
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diversity of arginine methylation sites on histone proteins provides multiple 
routes to directly link arginine methylation to the epigenetic regulation of gene 
expression. In addition, the methylation of arginine residues in several 
transcriptional coactivators (e.g., the histone acetyltransferases p300 and CBP) 
provides an indirect route to influence the epigenetic state of affected genes. 
Originally, it was assumed that the methylation of histone arginine residues 
was associated with gene activation, as the dimethylation of histone H4R3 by 
PRMT1 facilitates transcriptional activation by a variety of nuclear hormone 
receptors.55 More recently, however, it became apparent that arginine 
methylation can be either an activating or a repressing mark that regulates the 
expression of multiple genes. Each members of PRMT family present a 
characteristic distribution patterns and has been demonstrate that deregulation 
of these enzymes seems to be implicated in the pathogenesis of several 
different diseases, including cancer. Specifically, PRMT1, PRMT2, PRMT3, 
PRMT4, PRMT5, PRMT6 and PRMT7 have been shown to be overexpressed 
or otherwise contribute to tumorigenesis. Below are highlighted the 
physiopathological roles of each isoforms. 
 
PRMT1 was the first mammalian PRMT to be cloned56 and is the 
predominant type I enzyme57 found in all embryonic and adult tissues 
examined so far.58 Due to alternative splicing, there are seven isoforms of the 
protein, all varying in their N-terminal domain, which are expressed in a 
tissue-specific manner and have distinct subcellular localization patterns.59 
PRMT1 has broad substrate specificity with over 40 targets, most being RNA 
processing proteins, and multiple interacting partners.60As it is previously 
mentionated, targeted PRMT1 knockout in mice results in embryonic lethality, 
thus showing that loss of PRMT1 activity is incompatible with life.61 
Nevertheless, alteration of PRMT1 expression, mostly upregulation, has been 
observed in various types of human cancers. For example aberrant methylation 
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of arginine 3 of Histone 4 (H4R3me2a) is positively correlated with increasing 
tumour grade and can be used to predict the risk of prostate cancer 
recurrence.62 Although the underlying mechanisms that link H4R3me2a to 
active chromatin states have not been completely elucidated, is well known 
that the methylarginine effector molecule TDRD3 interacts with this mark.63 
Interestingly, TDRD3 (Tudor Domain Containing 3)  has been identified as 
one of the candidate genes for a prognosis scoring system of breast cancer.64 
Higher expression of TDRD3 is linked to poor prognosis for the survival of 
patients with breast cancer. Additionally the methylation of the DNA repair 
pathway proteins MRE1165 and p53 binding protein (53BP1)66 might also 
contribute to the linkage of PRMT1 and cancer. The mammalian MRE11–
RAD50–Nijmegen breakage syndrome 1 (NBS1) complex, known as the 
MRN complex, has crucial roles in homologous recombination repair (HRR) 
of DNA double-strand breaks (DSBs) that are induced by ionizing radiation or 
that occur during DNA replication. Methylation of MRE11 within its GAR 
motif regulates its exonuclease activity on double-stranded DNA. Further 
investigation showed that cells containing hypomethylated MRE11 displayed 
intra-S phase DNA damage checkpoint defects. Likewise, 53BP1, which is 
involved in the early events of detection, signaling and repair of damaged 
DNA, also has a GAR motif and is methylated by PRMT1. Blocking of 53BP1 
methylation by treating cells with methyltransferase inhibitors perturbs 53BP1 
localization to damaged DNA and forms fewer γH2AX foci. 
Moreover, PRMT1 methylation of estrogen-receptor α (ERα) cause an 
activation of signal transduction pathway, through an activation of the SRC-
PI3K-FAK (respectively Proto-oncogene tyrosine-protein kinase Src - 
Phosphoinositide 3-kinase –Focal Adhesion Kinase) cascade thus coordinating 
cell proliferation and survival. It has been demonstrated that hypermethylation 
of ERα in breast cancer might cause hyperactivation of this signalling 
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pathway, thus ascribing a selective survival advantage to tumor cells, even in 
the presence of anti-oestrogen drugs. 67 
Two independent studies have implicated PRMT1 in the regulation of 
leukemia development. First, it was demonstrated that PRMT1 has a role in 
mixed lineage leukaemia (MLL) by transducing mouse primary 
haematopoietic cells with the MLL–EEN gene fusion product. These 
transduced cells display enhanced self-renewal abilities and can form compact 
colony-forming unit–granulocyte, erythrocyte, monocyte, megakaryocyte 
(CFU–GEMM)-like colonies in vitro.68 
A second study involved the acute myeloid leukaemia 1 (AML1; also known 
as RUNX1–ETO)  fusion gene that encodes a transcription factor that has a 
role in the development of acute myeloid leukaemia.68 PRMT1 interacts with 
this fusion protein and is crucial for AML1–ETO-mediated transcriptional 
activation, and knockdown of PRMT1 suppresses the proliferative potential of 
this fusion in mouse bone marrow cells. These studies suggest that 
PRMT1-specific inhibitors might have a therapeutic effect on leukaemia 
development. 
 
PRMT2 transcripts have been found in most human tissues, with highest 
levels in heart, prostate, ovary and neuronal system.69 PRMT2 was found 
predominantly in the nucleus and to a lower degree in the cytoplasm of 
mammalian cells.70 Based on the observation that it catalyzes the formation of 
MMA and ADMA residues on histone H4, PRMT2 was recognized as a type I 
enzyme.71 PRMT2 may act in cooperation with PRMT8, since its SH3 domain 
binds the N-terminal domain of the latter enzyme.72 Some of the known targets 
of PRMT2, besides the aforementioned histone H4, are the STAT3 (signal 
transducer and activator of transcription 3) protein,73 the estrogen receptor 
alpha,74 the androgen receptor, the retinoblastoma gene product,75 and the 
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heterogeneous nuclear ribonucleoprotein (hnRNP) E1B-AP5.76 In contrast 
with PRMT1 knockouts, PRMT2 null mice are viable and grow normally.  
PRMT2 is also implicated in breast cancer relating to its ability to act as a 
transcriptional coactivator of ERα. In breast cancer cell lines, the levels of 
PRMT2 and a splice variant, PRMT2L2, were shown to be increased in ER+ 
lines.  
 
PRMT3 was first identified as a PRMT1-binding partner. It is widely 
expressed in human tissues and has a predominantly cytosolic subcellular 
localization. PRMT3 possesses a zinc finger domain that assists in its binding 
to ribosomal proteins, including the S2 protein of the small ribosomal subunit 
(RPS2). 77 Although RPS2 is the primary substrate for PRMT3, it is not its 
only substrate. The von Hippel–Lindau (VHL) tumour suppressor protein can 
interact with PRMT3, and in the presence of ARF (Alternate Reading Frame ) 
this protein complex methylates p53,78 however the biological importance of 
these interactions and methylation event is unclear.  
Another tumour suppressor protein, DAL1, interacts with PRMT3 and inhibits 
its methyltransferase activity.79 Epigenetic down regulation of DAL1 has been 
reported in several cancers,80 and in these tumors PRMT3 displays an 
increased activity.  
Additionally, PRMT3 with PRMT1 methylates the recombinant mammalian 
nuclear poly(A)-binding protein (PABPN1)81 and has been implicated in 
oculopharyngeal muscular dystrophy, which is caused by polyalanine 
expansion in PABPN1.82 Moreover PRMT3 has been shown to be  
overexpressed in human myocardial tissues from patients with coronary heart 
disease.83  
 
CARM1 also known as PRMT4 was the first PRMT to be functionally linked 
to transcriptional regulation. It regulates a number of additional cellular 
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processes, including mRNA splicing,84, 85 cell cycle progression,86 and the 
DNA damage response.87 CARM1 achieves these functions by methylating 
histones,88,89 transcriptional factors 89 , co-regulators, 90, 91, 92, 93 splicing factors 
and RNA polymerase II.94 CARM1 levels are elevated in castration-resistant 
prostate cancer,95, 96 as well as in aggressive breast tumours. It also has a role 
in determining ERα-dependent breast cancer, cell differentiation and 
proliferation.97 The aggressive breast tumours that overexpress CARM1 also 
have high levels of the oncogenic co-activator AIB1 (amplified in breast 
cancer) (also known as NCoA3). Overexpression of AIB1 has been reported in 
breast cancer and is clearly associated with poor prognosis.98 Importantly, 
CARM1 methylates AIB1, thereby regulating its activity and stability. 
CARM1 recruitment to ERα-regulated promoters relies on the presence of 
AIB1, and is essential for estrogen induced proliferation of the MCF-7 breast 
cancer cell line.99 Thus, the oncogenic properties of AIB1 may be attenuated 
by inhibiting CARM1 activity. The histone acetyltransferases (HATs) CREB-
binding protein (CBP; also known as CREBBP) and p300 are also arginine 
methylated by CARM1.100 Notably, methylation increases the HAT activity of 
CBP and stimulates its autoacetylation. Whereas methylation of p300-R2142 
inhibits its interaction with glucocorticoid receptor-interacting protein 1 
(GRIP1; also known as NCoA2)130, which is required for responses to DNA 
damage. The absence of CARM1 methyltransferase activity leads to the loss 
of cell cycle arrest in response to DNA damage. CARM1-mediated 
methylation of p300, specifically at R754 in the KIX domain, is required for 
the induction of cell cycle regulators such as p21 and growth arrest and DNA 
damage-inducible protein-α (GADD45α).  
CARM1 is also recruited to the promoter of E2F1 (which encodes a cell cycle 
regulator) as a transcriptional co-activator. CARM1-mediated upregulation of 
E2F1 expression might also contribute to the oncogenic DNA damage and 
tumour suppressive apoptosis that are often observed in cancer. CARM1 is 
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also an important positive modulator of WNT–β-catenin-driven 
transcription.101 Depletion of CARM1 expression in colorectal cancer cells 
suppresses clonal survival and anchorage-independent growth,90 supporting 
the observations from clinical samples which show that 75% of colorectal 
cancers have CARM1 over- expression.102 
 
PRMT5 was the first PRMT type II to be identified. PRMT5 is widely 
expressed in mammals, and more extensively in heart, muscle and testis. 
PRMT5 is located both in the nucleus and in the cytoplasm.103 Interestingly, 
PRMT5 is localized in the Golgi apparatus (GA) and its loss disrupts the GA 
structure, thereby suggesting that this enzyme plays a role in the maintenance 
of GA architecture.  In addition, PRMT5 is involved in the maintenance of the 
spliceosome integrity.104 PRMT5 targets histones, transcriptional elongation 
factors, chromatin remodelers and co-repressors.105 In mice, loss of PRMT5 
results in early embryonic lethality. 
H3R8me2s and H4R3me2s are the key repressive histone methylation marks 
that are deposited by PRMT5. It is in this context as a transcriptional repressor 
that PRMT5 has oncogene-like properties because of its ability to repress the 
expression of tumour suppressor genes. Indeed, the levels of ST7 and NM23 
(also known as NDKA) expression are clearly reduced when PRMT5 is 
overexpressed.106  The transcriptional repressor functions of PRMT5 are also 
crucial for the process of epithelial–mesenchymal transition (EMT), which has 
an important role in tumour progression. As a consequence of EMT, cancer 
cells can migrate and invade much more efficiently, and this process probably 
has an active role in metastasis. A hallmark of EMT is the loss of E-cadherin 
expression; E-cadherin expression is actively repressed by the transcription 
factor SNAIL, and PRMT5 interacts with SNAIL through a bridging 
molecule, AJUBA.107 Importantly, small interfering RNA (siRNA)-mediated 
PRMT5 knockdown results in increased E-cadherin expression. These data 
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indicate that PRMT5 is a crucial co-repressor of SNAIL. In addition, PRMT5 
overexpression promotes anchorage-independent cell growth, supporting the 
idea that PRMT5 might be an oncoprotein. Consistently, PRMT5 levels are 
elevated in a number of cancer types. 
High expression levels of the tumour suppressor protein programmed cell 
death protein 4 (PDCD4) are generally correlated with a better outcome in a 
number of different cancer types.108 However, there are exceptions to this rule: 
under certain circumstances PDCD4 displays oncogenic properties, and it 
seems that PRMT5 is a key player in switching this function. PRMT5 interacts 
with PDCD4 and methylates GAR motifs that are present in its N terminus. In 
an orthotopic breast tumour model, overexpression of PRMT5 enhances 
tumour growth; this depends on the presence of PRMT5 enzymatic activity 
and an intact PDCD4 methylation site.109 Thus, high levels of PDCD4 are 
protective against tumorigenesis, unless PRMT5 is also highly expressed. 
Additionally, PRMT5 was originally described as JAK2-binding protein 1110 
and the functional importance of this interaction in cancer has been realized. 
Most patients with myeloproliferative neoplasms express a constitutively 
activated form of JAK2: JAK2-V617F150. This mutant form of JAK2 
interacts with PRMT5 more strongly than does the wild-type form, and 
furthermore JAK2-V617F phosphorylates PRMT5.111 Phosphorylation of 
PRMT5 greatly diminishes its arginine methyltransferase activity by blocking 
its interaction with its co-regulator MEP50. Knockdown of PRMT5 in human 
CD34+ cells increases colony formation and PRMT5 overexpression 
significantly decreases colony formation, providing evidence that the 
phosphorylation of PRMT5 (and thus its inactivation) contributes to the 
JAK2-V617K-induced myeloproliferative phenotype. In a second example of 
PRMT5–MEP50 regulation, it was found that cyclin D1–CDK4 
phosphorylates MEP50 at T5, and this phosphorylation increases the activity 
of PRMT5.112 This increase in PRMT5 activity results in an increase in the 
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repressive epigenetic marks deposited by PRMT5 and in the silencing of 
CUL4A and CUL4B expression, thus providing a key mechanistic insight into 
the neoplastic activities of the cyclin D1–CDK4 kinase. CUL4A and CUL4B 
are E3 ubiquitin ligases that direct the degradation of the replication licensing 
protein CDT1. Thus, increased PRMT5 activity will cause the accumulation of 
CDT1 and will facilitate DNA replication, which activates DNA damage 
checkpoints and predisposes to malignant transformation 
 
PRMT6 is the smallest family member (316 amino acids) and is localized 
predominantly in the nucleus. PRMT6 functions are not completely 
understood, however, a role for PRMT6 in the regulation of cell proliferation 
and senescence, through transcriptional repression of tumor suppressor genes, 
has been reported.113 Its primary targets are histone H3 (generating 
H3R2me2a)114, 115and DNA polymerase β.116 As a transcriptional repressor, 
PRMT6 suppresses the expression of thrombospondin 1 (TSP1; also known as 
THBS1), which is a potent natural inhibitor of angiogenesis and endothelial 
cell migration.117 
 
PRMT7 is present mainly in thymus, dendritic cells and testis. It has both 
nuclear and cytosolic localizations. PRMT7 is involved in the modulation of 
sensitivity to DNA damaging agents,118 methylation of male germline 
imprinted genes, and embryonic stem cell pluripotency.119  
PRMT7-mediated methylation of H2AR3 affects DNA damage repair. The 
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1.4. Chemical probes – inhibitors of PRMTs 
Since PRMTs affect a plethora of different target genes, it is unsurprising that, 
when dysregulated, they play an important role in human disease. In fact, 
dysregulation of PRMT activity has been causally linked to the development 
and progression of numerous cancers, as well as to viral replication and 
cardiovascular disease. Therefore, PRMTs constitute promising targets for 
drug discovery, and inhibitor development is the frontline of current PRMT 
research. Selective PRMT modulators not only serve as potential therapeutics 
but also are useful chemical probes for further investigations of PRMTs 
physiopathological roles. 
 
1.4.1. SAM analogues as inhibitors of PRMTs 
One of the earliest described PRMT inhibitors to be discovered is 
autogenerated by the enzyme during catalysis. As described above 
(paragraph 1.3.), the methyl donor substrate SAM is converted to SAH (1) 
(Figure 1.9), which represents a potent feedback inhibitor of PRMT activity, 
and accumulates as an inevitable byproduct of protein methylation. However, 
it can be degraded into adenosine and homocysteine by SAH hydrolase. 
Therefore, in cellular studies, SAH hydrolase inhibitors such as adenosine 
dialdehyde (2) are used as SAM-dependent inhibitors by blocking the 
degradation of SAH. Moreover, SAM analogues, such as methylthioadenosine 
(3) and sinefungin (4), also function as general PRMT inhibitors (Figure 1.9). 
The SAM analogues and SAH exhibit limited specificity due to their structural 
homology to SAM. Thus, they inhibit numerous other SAM dependent 










Figure 1.9. SAM analogues, a non selective inhibitors of PRMTs 
 
1.4.2. Small molecule inhibitors of PRMTs 
To obtain PRMT-selective inhibitors, several approaches, including both 
virtual and high-throughput screening, as well as substrate analogue inhibitor 
design were conducted. One of the first high-throughput screens directed 
against the yeast type I PRMT, Hmt1p, resulted in the identification of several 
arginine methyltransferase inhibitors, denoted as AMI.121 Most of these 
inhibitors were highly nonspecific and also blocked the activity of the protein 
lysine methyltransferases. AMI-1 (5), however, a symmetric 
naphthalenesulfonate molecule, inhibited PRMT1 with an IC50 of 8.8 μM, but 
did not diminish the activity of distinct lysine methyltransferases (Figure 
1.10). Subsequently the EMCL Group (Epigenetic Medicinal Chemistry 
Laboratory) of Professor Gianluca Sbardella, where I performed the current 
PhD project, being interested in discovery of small-molecule modulators of 
epigenetic targets, 122, 123, 124, 125, 126, 127,128, 129, 130, 131, 132, 133, 134, 135, 136 focused 
its attention on AMI compounds and realized that AMI-1 should be optimized 
as it is likely to have low bioavailability and would probably not penetrate the 
blood–brain barrier due to the bisanionic structure. Therefore, were 
synthesized a number of derivatives, structurally related to AMI-1 and was 
found that the substitution of the sulfonic groups, involved in pleiotropic 
interactions, with the bioisosteric carboxylic group together with the formal 
shift of the ureidic function from the C-7 to the C-6 position of the 
naphthalene ring, resulted in the generation of even more potent SAM 
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noncompetitive inhibitors, that showed specificity for PRMTs over PKMTs 
(Figure 1.10).137  
 
 
Figure 1.10. Inhibitors of PRMTs 
 
Moreover, pursuing our efforts toward the identification of potent and 
selective PRMT inhibitors, we replaced the hydroxynaphthalene moiety of 
EML73 with the bioisosteric indole framework, with the aim to obtain a more 
versatile and synthetically handy scaffold for the future development of more 
potent inhibitors (Figure 1.11. A).126 Thus, we prepared  a series of ureido 
acetamido indole derivatives (dubbed Uracandolates) that, however, showed a 
peculiar activity against PRMTs. They selectively enhanced the methylation 
activity of CARM1 both in in vitro and cellular settings  (Figure 1.11. B). We 
also assessed the activity of EML105 over a panel of PRMTs and SET7, a 
lysine methyltransferase. This compound together with a positive modulation 
of CARM1, showed a scarcely, but defined inhibitory activity against PRMT3, 
as it is illustrated in Figure 1.11. Notably, we have taken into account this data 
for developing PRMT3 inhibitors (see Chapter 2, Aim of the work). 
 
 





Figure 1.11. A) Structural optimization of EML73 that led to EML105, an activator of 




By Fragment-based virtual screening, Spannhoff and coll. identified RM65 (9) 
(Figure 1.12) as a cell-permeable PRMT1 inhibitor.138 Docking studies 
suggest that compound 9 is a competitive inhibitor, occupying both the SAM 
binding and the substrate arginine binding sites. RM65 was also shown to 
reduce histone H4R3 methylation in HepG2 cancer cells at concentrations 
above 100 μM. Using a similar virtual docking and pharmacophore-based 
filtering approach, the Jung group identified the diamidine stilbamidine (10) 
and allantodapsone (11) as PRMT1 inhibitors (Figure 1.12).138 Both 
compounds are competitive for the protein substrate, but not for the cofactor 
SAM. Moreover, these inhibitors are active in a functional assay of estrogen 
receptor activation and also reduced the cellular methylation of R3 in histone 
H4 at concentrations below 50 μM, while having minor effects on the lysine 
methylation at H3K4. Further optimization resulted in the generation of even 
more potent inhibitors, such as thedapsone derivative 12, which inhibits 
PRMT1 with an IC50 of 1.5 μM (Figure 1.12).
139 










Figure 1.13. Non selective inhibitors of PRMT identified by Fragment-based virtual screening 
and synthetic optimization.  
 
1.4.3. Bisubstrate inhibitors of PRMTs 
The ability of PRMTs to chemoenzymatically generate an effective bisubstrate 
analogue inspired the development of defined bisubstrate derivatives (Figure 
1.13). In this respect, the partial-bisubstrate analogue 13, which comprises an 
arginine containing peptide fragment that was linked to the amino acid moiety 
of SAM, was shown to block PRMT1 activity with an IC50 of 14 μM (Figure 
1.13).140 This compound shows limited PRMT selectivity and also blocks 
PRMT4 and PRMT6 with similar efficiency. In addition, Dowden and 
colleagues reported the development of SAM derivatives conjugated to a 
guanidinium group via varying carbon linkers (14−16).141 Comparison of the 
generated derivatives revealed that a four carbon spacer, present in 15 between 
the guanidinium group and the SAM analogue, is most suited for efficient 
PRMT1 inhibition (IC50 = 2.9 μM). Though the selectivity of this inhibitor for 
other PRMTs was not evaluated, it did not show substantial inhibitory activity 
against the lysine methyltransferase SET7. The Martin group developed a 
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partial bisubstrate inhibitor where the SAM adenosine moiety is connected to 
the guanidinium group (17).142 Interestingly, 17 was more potent than the 
previously described (partial) bisubstrate inhibitors with IC50 values of 1.3 
μM, 560 nM, and 720 nM for PRMT1, PRMT4, and PRMT6, respectively. 
Moreover, this compound did not display any measurable inhibitory effect on 
the lysine methyltransferase G9a; however, it also did not show any inhibitory 







Figure 1.13. SAM analogue inhibitors 
 
1.4.4. Selective inhibitors of type I PRMTs 
 
Although bisubstrate analogues represent interesting tools to analyze PRMTs 
activity, they comprise several limitations, including lack of selectivity within 
the PRMT family. Therefore, recently, great efforts have been taken to yield 
potent and isozyme-selective PRMT inhibitors. 
In 2014, Yan et al. reported compound 18, a diamidine containing PRMT1 
inhibitor (Figure 1.14).143 It inhibited PRMT1 with an IC50 of 9.4 μM and was 
selective for PRMT1 over CARM1 (more than 42-fold), PRMT5 (around 18-
fold), and PRMT6 (around 30-fold). Compound 18 inhibited the proliferation 
of several leukemia cell lines. It was also found that cell lines derived from 
Down syndrome patients and MLL-AF9 patients (CMY, CHRF-288-1, and 
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MOLM-13 cells) were more sensitive to compound 18 treatment than other 
cell lines tested (HEL, Jurkat, and HL-60).  
In 2015, Eram et al. discovered MS023 (compound 19)144 as a potent and cell-
active inhibitor of type I PRMTs, including PRMT1, -3, -4, -6, and -8 (Figure 
1.14). In biochemical assays, MS023 was highly potent and selective for type I 
PRMTs, over a broad range of epigenetic modifiers including type II and type 
III PRMTs, PKMTs, DNMTs, histone lysine demethylases, and methyl-lysine 
and methylarginine reader proteins. Moreover, after treating MCF7 and 
HEK293 cells with compound 19 for 2 days, was observed a significant 
decrease in global levels of arginine asymmetric dimethylation (Rme2a) and a 
concurrent increase in global levels of arginine monomethylation (Rme1) and 
arginine symmetric dimethylation 
 
 
Figure1.14. Compound 18 is selective inhibitors of PRMT1, whereas a compound 19 is a 
selective inhibitor of type I PRMTs 
 
1.4.5. Allosteric inhibitors of PRMT3 
With respect to PRMT3, Siarheyeva et al. employed a library screening 
approach to identify selective inhibitors targeting this enzyme and reported the 
discovery of 1-(benzo[d] [1,2,3]thiadiazol-6-yl)-3-(2-cyclohexenylethyl)urea 
(compound 20, Figure 1.15 A), the first selective inhibitor of PRMT3.144b 
Notably, this inhibitor is noncompetitive with respect to both SAM and the 
peptide substrate, but it occupies an allosteric binding site revealed by the X-
ray crystal structure of compound 20 in complex with PRMT3. There the 
benzothiadiazole moiety of 20 forms a buried hydrogen bond with T466, the 
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urea group forms hydrogen bonds with the side chains of E422 and R39, 
whereas the cyclohexyl arm extends out of the allosteric pocket and makes 
hydrophobic interactions with the α-Y-helix, inducing conformational 
constraints on this motif that prevent the formation of a catalytically 
competent state (Figure 1.15 B). Subsequent mechanism of action (MOA) 
studies confirmed that this inhibitor is noncompetitive with both the peptide 
substrate and the cofactor.  
 
 
Figure 1.12. A) PRMT3 inhibitor. B) Key interactions of compound 20 within the allosteric 
binding pocke of PRMT3. 
 
To improve the potency of compound 20 (PRMT3, IC50 = 2.5 μM) and 
demonstrate that potent and selective inhibitors can be generated by exploiting 
the allosteric binding site of PRMT3, Jin and collaborators in 2013 reported 
extensive structure-activity relationship studies of benzothiadiazolic 
compounds, which resulted in discovery of several PRMT3 inhibitors with 
submicromolar potencies. 145 Below are analyzed in detail the efforts of Hit to 
Lead optimization of this series of compounds, given the important role that  
these SAR studies played for us regarding the development of PRMT3 indole 
inhibitors  (see Chapter 2 Aim of the work). 
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1.4.5.1 SAR of benzothiadiazole derivatives 
The replacement of the uncommon cyclohexenylethyl group of compound 20 
with a more common and potentially stable group, the cyclohexylethyl moiety 
(Compound 21, IC50 = 1.0 µM), led to an improvement of PRMT3 inhibition 
(Figure 1.13). 
 
Figure 1.13. The replacement of cyclohexenylethyl group with cyclohexylethyl moiety led to 
an improvement of PRMT3 inhibition. 
 
On the other hand the replacement of the benzothiadiazole ring with other 
fused bicyclic aromatic groups (Figure 1.14), like benzothiazole (compound 
22), benzotriazole (compound 23) and indazole (compounds 24 and 25), led to 
total loss of potency, suggesting that, in addition to making the hydrogen bond 
interaction with T466, the benzothiadiazole moiety is particularly well 
accommodated by the PRMT3 allosteric binding pocket due to its unique 
electronic nature and steric fit. Interestingly, has not been taken into account 
the replacement effect of the benzothiadiazole ring with the indole, which is 
considered a privileged scaffold for drug discovery. 
 
Figure 1.14. Replacement of benzothiadiazole moiety with other fused bicyclic aromatic 
groups 
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Further investigations involved the middle urea moiety of compounds 21. The 
X-ray crystal structure of the inhibitor 20−PRMT3 complex reveals that the 
carbonyl group of the middle urea moiety forms a hydrogen bond with the 
guanidinium group of R396 whereas the two amino groups of the urea moiety 
form two hydrogen bonds with the carboxylate of E422 (glutamate 422) 
(Figure 1.12 B). The replacement of the ureidic moiety with urea bioisosteres 
and more rigid analogues (Figure 1.15), as diaminosquarate (compound 26), 
cyanoguanidine (compound 27) and aminotriazole (compound 28), led to total 
loss of potency, suggesting that this group is ideal for interacting with the 
allosteric binding pocket of PRMT3. 
 
 
Figure 1.15. Effect of the substitution of the ureidic moiety. 
 
As far as the cyclohexylethyl group is concerned, replacements of this moiety 
are well tolerated. Indeed aliphatic or aromatic moieties, with varying steric 
and electronic characteristics, were introduced instead of the cyclohexylethyl 
group; leading in same case to a significant increase in potency (for example 
compounds 42 and 43, Figure 1.16). 




Figure 1.16. Effect of the replacement of the cyclohexyl ring 
 
The replacement of the cyclohexyl ring with different heterocycles such as 
tetrahydropyran (compound 31, IC50 = 3.6 µM), and 1-piperidine (compound 
32, IC50 = 5.2 µM) generally resulted in a slight decrease in potency, allowing 
to conserve a good potency. Similarly, the introduction of para substituted 
aromatic ring (compounds 33, 34 and 35 with IC50 values of 4, 3.1 and 1.8 µM 
respectively) gave slightly lower or either similar potency compared with the 
cyclohexylethyl group (compound 21, IC50 = 2.4 µM). On the other hand the 
introduction of pyridine (compound 36, IC50 > 10 µM), methyl (compound 
37g, IC50 > 15 µM) or tert-butyl groups (compound 38, IC50 > 10 µM) led to a 
significant decrease in potency. Interestingly, the introduction of a longer 
chain (three carbons versus two carbons) between the ureidic moiety and the 
aliphatic or aromatic groups allowed to conserve a good potency against 
PRMT3 (compounds 39 – 41, IC50 = 2.2, 5.3, 3.3 µM), suggesting that the 
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allosteric pocket of PRMT3 is able to accommodate compounds endowed an 
endowed a greater length. 
Interestingly, the introduction of an additional carbonyl group on the ethylene 
chain led to the identification of the most active compounds, 42 (IC50 = 0.48 
µM) and 43 (IC50 = 0.23 µM), which contain a ketone and amide moieties 
respectively.  
In 2015 the group of Jin, pursuing the efforts toward the identification of 
potent and selective PRMT3 allosteric inhibitors, performed further structural 
optimization of benzothiadiazole derivatives revealing a potent, selective, and 
cell-active allosteric inhibitor of PRMT3 (compound 44, Figure 1.17).146 This 
compound is highly selective for PRMT3, and detailed structural analyses 
showed that binds to an allosteric pocket at the base of the dimerization arm 
between the two PRMT3 subunits, as the others benzothiadiazolic compounds.  
Compound 44 engages PRMT3 and potently inhibits its methyltransferase 
activity in cells. It is also bioavailable and suitable for animal studies. This 
well characterized chemical probe is an excellent tool to further study the role 
of PRMT3 in health and disease. 
 
Figure 1.17. Optimization of the initial hit compounds revealed inhibitor 20 
1.4.6. Selective inhibitors of CARM1 
High-throughput screening efforts led to the identification of pyrazole and 
Benzo[d]imidazole derivatives as selective PRMT4 inhibitors (Figure 
1.18).147, 148 Based on these derivatives, Hits to Lead efforts were done to 
further improve the potency of these derivatives.  
 
 







Figure 1.18.  Pyrazole (45) and Benzo[d]imidazole (46) compounds identified as selective 




Inspired by the structural information of these compounds (Pyrazole and 
Benzo[d]imidazole derivatives), we set out to design pyrrole inhibitors of 
CARM1 (Chapter 2, Aim of the work). Therefore, given the important role 
that the SAR information of Pyrazole and Benzo[d]imidazole derivatives have 
played for us, below are analyzed in detail their structure activity relationships.  
1.4.6.1. SAR of pyrazole inhibitors of Coactivator Associated Arginine 
Methyltrasferase 1 (CARM1) 
As it is previously mentioned Purandare et al. identified a pyrazole amide 
inhibitor of CARM1 by High-throughput screening (Compound 45, Figure 
1.18). This compound showed a modest activity in CARM1 mediated 
methylation assay, therefore, to further improve the potency of this compound 
structural optimization efforts were performed.149, 150, 151 
First the glycinamide portion of 45 was examined. As it is shown in Figure 
1.19,  α-amino acids (compound 47, IC50 = 0.16 µM) were found to be 
preferred over either β (compound 50, IC50 > 20 µM) or α, α’ di-substituted 
amino acid amides (compound 49, IC50 > 30 µM). Within the subset of analogs 
prepared from α -amino acids, the (S)-enantiomer (47, IC50 = 0.16 µM) was 
about 150-fold more active than the corresponding (R)-enantiomer (48, IC50 = 
20.1 µM), suggesting that the (S)-alanine benzyl-amide is optimal for CARM1 
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enzymatic activity. Moreover, simple modifications as an introduction of ethyl 
group between the phenyl ring and the aminoacidic portion (51, IC50 > 20 µM) 
as well as the methylation of the terminal amino group of (S)-alanine (52, IC50 
> 20 µM) were not tolerated. 
 
 
Figure 1.19. Substitution of glycinamide portion 
 
Next, retaining the (S)-alanine benzyl-amide portion on the phenyl ring 
(Compound 47, Figure 1.19) was evaluated the effect of the substitution of the 
biphenyl amide moiety (Figure 1.20). The introduction of a benzyl-amide 
portion (compound 54, IC50 = 0.08 µM) was found to be superior to phenyl-
amide portion (compound 53, IC50 = 1.32 µM) in term of potency, indeed 
compound 54 was about 20-fold more potent than compound 45 (IC50 = 1.8 
µM) and 53 (IC50 = 1.32 µM). Interestingly, the functionalization of the 
benzylamide group had different effect on the enzymatic activity. The o-OMe 
insertion on the aromatic ring (Compound 55, IC50 = 0.06 µM) provided an 
improvement of activity, whereas the introduction of o-NH2 (compound 57, 
IC50 > 10 µM) or  m-OMe (compound 57, IC50 = 0.37 µM) moieties had a 
negative effect, reducing the CARM1 activity. In addition, alternative linkage 
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for the benzyl-amide side chain (compound 59, IC50 = 1.1 µM) was evaluated, 
assessing that a major length of this moiety was detrimental for the activity.  
Compounds 54 (IC50 = 0.08 µM) and 55 (IC50 = 0.06 µM) bearing the 
benzylamide group at C-5 position of pyrazole ring provided the best activity 
toward CARM1 in vitro assay, however these compounds lack of cellular 
effect on CARM1 due to a modest permeability (PAMPA assay, Pc of 54 < 15 
nm/s). Therefore in order to improve the pharmacokinetic properties of 
pyrazolic derivatives the benzylamide moiety was replaced with the 1, 3, 4-
oxadiazole ring, a potentially bioisosteric group of the amide moiety 
(Compounds 60 and 61). This modification improved the cytopermeability 
(PAMPA assay Pc of 60 = 106 nm/s) versus benzylamide, also leading to a 
slight improvement of the in vitro potency (Compound 61, IC50 = 0.04 µM), 
suggesting that the introduction of bulky substituents was well tolerated by the 
CARM1 binding site. However, also these compounds didn’t revealed activity 









Figure 1.20. Replacement of biphenyl- amide moiety 
 
Further SAR exploration centered on compounds 54 and 55 (Figure 1.21) 
involved the replacement of the central core phenyl ring with various 
heterocycles (Figure 1.21). 2, 4- and 2, 5-disubstituted thiophene analogues 
(compounds 62 and 63 respectively) were synthesized. These modifications 
didn’t lead to a CARM1 cellular inhibition, however, compared with 55 (IC50 
= 0.06 µM), an equipotent PRMT4 inhibition in vitro was observed for 
compound 62 (IC50 = 0.06 µM). Other heterocycles were introduced instead of 
the phenyl ring, like thiazole (compound 64, IC50 = 2.20 µM) and bicyclic 
benzofurane (compounds 65, IC50 > 10 µM). The thiazole analogue was 36-
fold less active than 55, whereas compound 65 was devoid of activity.  




Figure 1.21. SAR exploration of central core phenyl ring 
 
In conclusion, was investigated the role of the 3-trifluoromethyl-pyrazole 
scaffold. Retaining the same substituents and dispositions of compound 60 
(Figure 1.22), various five-membered heterocycles were evaluated 
(Compounds 66 – 68, Figure 1.22). The 3-trifluoromethyl substituted pyrazole 
was found to be the preferred core from other five-membered-heterocycles, 
suggesting that this scaffold is particularly well accommodated by the PRMT4 
binding pocket, due to its unique electronic nature and steric fit. Notably, it 
was not investigated the effect of the pyrrole ring, probably due to a not 
immediate synthetic accessibility.  
 
Figure 1.22. SAR exploration of 3-trifluoromethyl- pyrazole scaffold 
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1.4.6.2. SAR of Benzo[d]imidazole inhibitors of Coactivator Associated 
Arginine Methyltrasferase 1 (CARM1) 
During the High-throughput screening campaign, Wan et al. in 2009 identified 
a benzo[d]imidazole derivative as Hit with modest activity (IC50 0.84 µM) in 
the CARM1 mediated methylation assay (Figure 1.18, compound 46).  Based 
on this hit, was started Hit to Lead optimization efforts to further improve the 
in vitro potency of this series of compounds. 
 
Figure  1.23. Benzo[d]imidazole Hit 
 
SAR exploration of the west end of the hit (Figure 1.23) was performed. Very 
close modifications such as introduction of α-methyl group (as in 70 and 71) 
as well as removal of internal nitrogen atom or abolishing basicity of either of 
nitrogen atoms (data not shown) led to a significant loss of potency (Figure 
1.24). This observation suggests that the binding pocket near the West end is 






Figure 1.24. SAR exploration of west end of compound 46 
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Then was explored the SAR of the East end of 46. SAR from this study 
showed that almost all of the substituted phenyl and pyridyl groups were 
tolerated (only partial data displayed). Interestingly, an unsubstituted phenyl 
group was not tolerated (compound 72, IC50 = 4.6 µM). Within the set of 
substituted phenyls, compounds with 2, 6-disubstituted phenyl group were 
preferred (as in 74, IC50 = 0.07 µM and 75, IC50 = 0.26 µM), indicating 
conformational preferences for the activity. Generally, phenyl ring bearing at 





Figure 1.25. SAR exploration of east end of compound 46 
 
Furthermore, was investigated the core region of 46 (Figure 1.26). Towards 
this end, were synthesized analogs 76 and 77 to understand the effect of a 
methyl group at the 4- and 1-position of the benzo[d]imidazole. The 4-
desmethyl analog (77, IC50 = 1.2 µM)) was slightly less potent while 1-methyl 
substitution at the nitrogen of the benzo[d]imidazole (76, IC50 = 2.9 µM) 
resulted in further loss of activity. Introduction of a nitrogen atom (78, IC50 = 
0.7 µM) however was tolerated but did not offer any additional advantage. 
 
 





Figure 1.25. SAR exploration of core region of compound 46 
 
Further structural optimization of 46 led to the identification of indole 
derivative, the most active compounds of this series,  with submicromolar 
activity in vitro methylation assay (IC50 = 0.04 µ) (Figure 1.26). 
1 The 
benzo[d]imidazole/indole derivatives, like pyrazole inhibitors, lack of cellular 
activity, probably due to cytotoxic problems. Therefore further developments 
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1.4.6.3. Structural basis for CARM1 inhibition by indole and pyrazole 
inhibitors 
In 2012 Sack et al. reported crystal structures of the CARM1 catalytic domain 
in complex with cofactors [SAH (S-adenosyl- L-homocysteine) or SNF 
(sinefungin)] and indole (compound 79, Figure 1.26) or pyazole (compound 
61, Figure 1.20) inhibitors, also known in literature as CMPD1 and CMPD2 
respectively (Figures 1.27 and 1.28). Interestingly, both of these inhibitors 
bind to the substrate arginine-binding cavity of PRMT4 and require the 
presence of bound cofactor SAH or sinefungine. 152 
Structural studies of PRMT4 in complex with sinefungin and CMPD1 
(Figures 1.27 ) revealed that the N-methylethanamine moiety of the inhibitor 
is directed toward the bottom of the arginine-binding cavity and directly 
interacts with the active site residue E258. The piperidine group is positioned 
at the entrance of the active site cavity and hydrogen bonds to H415 of the 
THW loop, whereas the indole moiety makes hydrophobic interactions with 
several aromatic side chains of PRMT4 and forms a water-mediated hydrogen 
bond to the main chain carbonyl of K471 and the side chain of N266.  
 
Figures 1.27. View of CMPD-bound in the active site of CARM1 




The crystal structure of PRMT4 bound to CMPD2 (Figures 1.28) revealed 
that the terminal L-alaninamide moiety mimics the arginine guanidinium 
group and makes several polar interactions with PRMT4, including the 
carboxyl groups of the double E-loop residues E258 and E267. In addition, the 
alanylmethyl group of CMPD2 forms CH···O hydrogen bonds to the hydroxyl 
oxygen of Y154 and the backbone carbonyl oxygen of M260, while the 
carbonyl oxygen of the L-alaninamide hydrogen bonds with one of the 
imidazole nitrogens of H415. Notably, the (trifluoromethyl)- pyrazole, 1,3,4-
oxadiazole, and indole scaffolds are thought to mainly interact with PRMT4 
via shape complementarity rather than by polar interactions, except for two 
hydrogen bonds formed between the side chain of Y262 and the oxadiazole 






Figures 1.28. View of CMPD-2 bound in the active site of CARM1 
  


























































2.1. Aim of the Work 
The human Protein Methyltransferases (PMTs) constitute a large class of 
epigenetic enzymes, which include two different families: the Protein Lysine 
Methyltransferases (PKMTs) and the Protein Arginine Methyltransferases 
(PRMTs). They are involved in many cellular processes and it has been 
demonstrated that dysregulation of PMT activity contributes to different 
pathological states, including cancer.  
Yet today there are clinical candidates 17 reported only for PKMTs and not for 
PRMTs, although the selective PRMT inhibitor discovery field is gaining 
momentum. A breakthrough in this area will be truly exciting and is keenly 
awaited. In this regard the present PhD project was focused on design, 
synthesis and biological evaluation of new small-molecule modulators of two 
PRMT isozymes: PRMT3 and CARM1 (Coactivator associated Arginine 
Methyltransferase 1), also known as PRMT4.   
The research activities of my PhD project could be divided in three main 
topics: 
 
1) Design, synthesis and biological evaluation of pyrrole inhibitors of 
CARM1. 
2) Design, synthesis and biological evaluation of bisubstrate inhibitors of 
CARM1. 














2.2. Design of CARM1 pyrrole inhibitors  
For the design of CARM1 pyrrole-based inhibitors we have taken into account 
the information obtained from the structure-activity relationships (SAR) of 
indole and pyrazole compounds (see Chapter 1, paragraphs 1.4.6, pag. 41), the 
most potent and selective enzymatic inhibitors of PRMT4, which, however, 
lack activity in cell-based assays, due to a low cytopermeability and probably 
for cytotoxicity problems. Therefore, in an attempt to developed a new class of 
CARM1 inhibitors characterized by inhibition activity both in vitro and in 
cellular setting, we designed and synthesized a small set of pyrrole derivatives 
structural related to the pyrazole inhibitors of CARM1. With the aim to obtain 
a versatile and synthetically handy scaffold, we identified the pyrrole ring as 
the central core of our derivatives. This “privileged” structural motif, 
commonly found in pharmaceutical drugs and natural products, could be 
considered as a result of isosteric substitution of pyrazole together with 
opening and simplification of the indole ring, which represent the two central 
scaffolds of the aforementioned classes of CARM1 inhibitors (Figure 2.1). 
 
 
Figure 2.1. Selection of pyrrole scaffold 
 
Moreover, considering the low cytopermeability of some pyrazole inhibitors 
(i. e. compounds 54 and 55, Chapter 1, paragraph 1.4.6.1, pag.42), we 
hypothesized that the replacement of the nitrogen at position 2’ of the pyrazole 
ring (which by crystallographic studies seems to be not involved into 
interactions with the enzyme) with a carbon should increase the lipophilicity 
and therefore the cytopermeability of the molecules. In addition, within the 
extensive SAR studies of pyrazole compounds (reported in Chapter 1, 




paragraph 1.4.6.1) the effect of the substitution of the pyrazole core with a 
pyrrole ring was not investigated, probably due to a not immediate synthetic 
accessibility.  
Once identified the central scaffold we started the process of scaffold 
decoration. 
2.2.1. Design of pyrrole analogue of pyrazole lead I 
The first pyrrole compound (analogue of lead compound I) was obtained by 
the replacement of the pyrazole scaffold with a pyrrole, retaining the same 
substitution patterns of pyrazole derivative 54, identified as our lead 
compound (Figure 2.2). This modification was performed in an attempt to 
verify whether the isosteric substitution of the two heterocycles was also 
bioisosteric.  
Concerning the substituent at the south end of analogue of lead compound I 
(Figure 2.2) we decided to retain the (S)-alanine moiety of 54, because, as it is 
demonstrated by SAR studies of pyrazole compounds (Chapter 1, paragraph 
1.4.6.1, pag 43), this group is essential for a potent inhibition activity toward 
CARM1. This warhead exploits the arginine binding cavity of CARM1 and 
has been verified that its modifications are not tolerated. Also the replacement 
with its enantiomer is detrimental for the activity; hence, in the new scaffold 
contemplated, we introduced the (S)-Alanine at the South end of the 
derivative. 
Furthermore, at position 2 of the pyrrole ring (East end), the benzyl-amide 
moiety was selected as substituent (Figure 2.2). It has been demonstrated by 
SAR studies of pyrazole compounds (widely described in Chapter 1, 
paragraph 1.4.6.1, pag. 45) that this moiety allowed to obtain a high potency, 
preserving an ease of synthesis.  





Figure 2.2. The replacement of pyrazole ring with pyrrole one led to the design of the pyrrole 
analogue of lead compound I 
2.2.2. Design of Series II derivatives 
Next, maintaining the East and South ends of the analogue of lead compound 
I, we explored the position 4 of the pyrrole core. In order to investigate the 
nature of the interactions toward CARM1, the trifluoromethyl moiety was 
replaced with COOEt, COOH or H groups, thus obtaining a series of N-Phenyl 
pyrrole derivatives (Series II, Figure 2.3). In the framework of this series, 
unlike the analogue of lead compound I, we considered both the 
enantiomeric forms of the alanine moiety, in order to assess if the 
stereospecific activity found for pyrazole compounds (Chapter 1, paragraph 
1.4.6.1) also applies to pyrrole derivatives.  
In addition, compounds of Series II were divided in two subsets, IIa and IIb, 
according to the presence or absence of a methylene group (highlighted in 
green in Figure 2.3) between the phenyl and aminoacidic moieties at the south 
end of the molecules. As it is depicted in Figure 2.3, the elimination of this 
short spacer provided the compounds of Subseries IIb. We assumed that the 
elimination of this methylene unit could positively enhance the positioning of 
the (S)-alanine group within the enzyme pocket. Indeed, biological evaluation 
of these compounds (Chapter 4) confirmed our hypothesis. 





Figure 2.3. Design of N-Phenyl pyrrole derivatives (Series II) 
 
2.2.3. Design of Series III derivatives 
Furthermore, in order to evaluate the effect on the activity resulting from an 
increase in conformational flexibility, another set of molecules was designed 
by replacing the N-Phenyl pyrrole scaffold of Series II derivatives with N-
Benzyl pyrrole one (Figure 2.4). The aim of this approach was to evaluate if a 
higher degree of flexibility could lead the side chains of the molecules to 
match the binding sites of the protein in a most optimal way. As it is possible 
to see in Figure 2.4, also this series of compounds was divided in two 
subseries (Series IIa and IIb), according to the presence or absence of the 
methylene unit between the phenyl ring and the basic moiety at the south end. 





Figure 2.4. Design of N-benzyl pyrrole derivatives 
 
2.2.4. Design of new pyrrole derivatives 
Once that the biological investigations of pyrrole compounds were completed 
(Chapters 4 and 5), we realized that the replacement of the pyrazole ring with 
the pyrrole one allowed to conserve a good activity; indeed a potent inhibition 
was observed when testing pyrrole derivatives against CARM1 (i.e. EML 438, 
IC50 = 2.42 µM). However, although our compounds were more lipophilic 
than pyrazole lead, they didn’t prove a significant cellular activity, due to their 
low transcellular permeability. Therefore, in order to improve the lipophilicity 
of compounds here described, we employed structural optimization efforts, 
according to the computational studies performed by the research group of 
Professor Giuseppe Bifulco from the University of Salerno. This approach 
should also ensure an improvement of the enzyme binding properties, since 
binding pose investigations of pyrrolic compounds demonstrated that they 
were able to occupy only a portion of the binding site of the enzyme. To this 




end, starting from the most active pyrrole-based derivatives (EML 438 and 
EML 446), we introduced an alkyl moiety at the East end of the molecules 
(Series A) or a second heterocycle at right or left sides of the pyrrolic central 















2.3. Design of bisubstrate inhibitors of CARM1   
Pursuing our efforts toward the development of selective inhibitors of 
CARM1, in collaboration with the group of Professor Nathaniel Martin from 
the University of Utrecht, where I performed a short research period as visiting 
PhD student, we designed and synthesized a set of novel PRMT4 bisubstrate 
inhibitors. It is conceivable that bisubstrate analogs have the potential to afford 
increased potency and selectivity by combining the free binding energies of 
the cofactor and substrate interactions without suffering entropic reaction 
(Figure 2.6). Ideal bisubstrate inhibitors should have an effective linker 
between the two fragments that mimic the transition state of the methyl 
transfer reaction, with one fragment of the inhibitor targeting the SAM-
binding site and the other targeting the substrate-binding site.  
 
Figure 2.6. Schematic illustration of CARM1 bisubstrate inhibitor concept 
As illustrated in Figure 2.7, CARM1, like other PRMTs, operates via a 
bisubstrate mechanism wherein the guanidine group of an arginine-containing 
peptide substrate is precisely orientated (via a hydrogen-bond network with 
Glu257 and Glu266) in proximity to the electrophilic methylsulfonium group 
of AdoMet leading to an “SN2-like” substitution reaction. Key structural 
features such as the active site double E-loop, which is critical for guanidinium 
binding, as well as the SAM-binding pocket residues, are conserved among all 
PRMTs. Within the active site there are a number of conserved residues that 
are important for SAM binding, catalysis, and maintaining the overall 




architecture of the CARM1 active site (Figure 2.7). These residues include 
Glu244 and Val243, which directly interact with the SAM adenine ring and 
Glu160 which forms a bidentate hydrogen bond to the ribose moiety. 
Regarding the guanidine group of the arginine-containing peptide substrate 
(Figure 2.7), it makes a bidentate interaction with Glu266 and single hydrogen 
bond with Glu257. Both of these residues are thought to recognize and align 
the arginine guanidinium substrate for proper catalysis to occur. 
 
Figure 2.7. Hypothesized PRMT bisubstrate transition state. 
The remaining interactions between CARM1 and its peptidic substrate are 
distinct from others PRMTs and are responsible for the substrate recognition. 
CARM1 is able to mono- and di- methylate multiple histone (H3R17 and 
H3R26153) and non histone substrates (SRC-3,91 NCOA2,99 PABP1154 and 
SmB.84) with diverse sequences, exhibiting a preference for distinct substrate 
motifs compared to those preferred by other type I PRMTs. Understanding 
how CARM1 achieves this catalytic promiscuity and what the common 
recognition determinants are for its various substrates is a critical unanswered 




question. However, have been reported by Copeland at al. 155 three crystal 
structures of human CARM1 with the SAM mimic sinefungin and different 
peptide sequences from histone H3 and PABP1, in which are elucidated the 
main interactions between the enzyme and the peptide sequences. In particular 
it has been shown that CARM1 makes several hydrogen bonds with the 
backbone residues of the peptide substrates. These interactions seem to be 
largely substrate sequence independent and involve Glu266, Asn265, Tyr476, 
Asn161 and Tyr416 residues (Figure 2.8). 
 
Figure 2.8. Schematic illustration of CARM1-peptide interactions.  
Considering these structural features of CARM1 binding sites, we designed a 
series of novel bisubstrate inhibitors of CARM1. These compounds are 
composed by an Arginine containing peptide fragments covalently linked, 
through a variable guanidine linkers, to adenosine ring (Compounds 80 – 85, 
Figure 2.9).  
 





Figure 2.9. Illustration of CARM1 bisubstrate inhibitors. 
 
As peptide fragments we used two short peptide sequences (P1: 
FQNMPGAIRPAAP and P2: PAAPRPPFSTM) taken from PABP1 (Poly (A)-
binding protein 1), a non histonic substrate of PRMT4. It has been 
demonstrated by Bedford M. T. and collaborators154 that those sequences are 
recognized and methylated efficiently by the enzyme.  
In order to engage also the cofactor binding site, the two peptide sequences 
were coupled with a set of compounds containing the adenosine moiety, 
previously developed as partial bisubstrate inhibitors of PRMT4 by Martin N. 
I. and collaborators (Figure 2.10).142 These compounds (17a – c), 
characterized by an adenosine ring connected through an aliphatic linkers with 
a guanidine group, showed a preferential activity toward CARM1. They are 
considered partial bisubstrate inhibitors because are able to exploit the SAM 
binding site of CARM1 and only a portion of the enzymatic pocket involved in 




















17a 11.09 ± 2.77 0.12 ± 0.02 20.23 ± 8.67 >50 
17b 1.30 ± 0.38 0.56 ± 0.25 0.72 ± 0.33 >50 
17c 16.96 ± 3.73 0.15 ± 0.05 5.15 ± 1.27 >50 
Figure 2.10. Partial bisubtrate inhibitors identified by Martin et al. 
2.3.1. Asymmetrically dimethylated peptides  
It has been demonstrated by Bedford and coll.154 that the two peptide 
sequences (FQNMPGAIRPAAP and PAAPRPPFSTM) are recognized as 
substrates by PRMT4. Therefore, taking into account the effect of product 
inhibition, we decided to synthesized the same sequences with the arginine 
residue asymmetrically dimethylated (Figure 2.11). 
 
Figure 2.11. Conversion of peptide substrates into inhibitors 
 




2.4. Design of PRMT3 indole inhibitors of PRMT3 
In 2012, during a project with the aim to identify selective inhibitors of 
PRMTs, we were pleased to discover a Series of indole-based compounds 
referred to as “Uracandolates” (aryl ureido acetamido indole carboxylates), 
which selectively and potently enhanced the methylation activity of CARM1 
both in in vitro and cellular settings (Figure 2.12). Moreover, as it is possible 
to see in Figure 2.12, these compounds showed a defined, albeit lower, 
inhibition activity against PRMT3. Therefore, taking into account this 
information, we decided to prepare novel indole derivatives, structural related 
to Uracandolate compounds, in order to develop novel PRMT3 inhibitors and 
simultaneously extent the structure-activity relationships of the 
CARM1activators. 
 
Figure 2.12. Development of Uracandolates 
 
This project was then supported by the subsequent discovery of 
benzathiadiazole/isoquinoline derivatives, designed by Jin and coworkers as 
potent and selective allosteric inhibitors of PRMT3 (Chapter 1, see paragraph 
1.4.5). Interestingly, both the classes of PRMTs modulators, Uracandolates 
and benzathiadiazole/isoquinoline compounds, display some common 
structural features; therefore we evaluated the possibility of integrating their 
structural information for the development of new modulators of PRMTs. In 
particular both the series of compounds are characterized by: 




 A byciclic aromatic region (highlighted in red in Figure 2.13) 
 A central linker of 5 or 6 elements, bearing a carbonyl moiety and an 
ureidic function (highlighted in blue) 
  A right end of the molecule, bearing different substituents (showed in 
green in Figure 2.13).  
 
 
Figura 2.13. Structural correlation between Uracandolates and Benzothiadiazole/isoquinoline 
inhibitors. In red is highlighted the byciclic aromatic region, in blue the ureidic linker and in 
green the right end of the molecule 
 
Hence, inspired by the SAR information of  benzathiadiazole/isoquinoline 
compounds and considering the experimental data in our hands about the 
PRMT3 inhibition by Uracandolates, we decided, starting from the backbone 
of Uracandolate compounds, to integrate the structural information of both the 




classes of PRMTs modulators in order to develop new indole-based 
compounds.  
Three Series of derivatives were designed (Figure 2.14), all of them share the 
indolic scaffold and the same substituents at the right end of the molecule, 
instead, differ for the central ureidic linkers. 
 
Figure 2.14. Design of new indolic derivatives 
 
2.4.1. Indolic scaffold 
The indole ring, substituted at positions 2 or 3 with COOEt or H, was selected 
as central scaffold of the new derivatives. This core, considered as privileged 
scaffold for drug discovery, is the central core of Uracandolate compounds; 
therefore we decided to use the same heterocycle for the new derivatives. 
Moreover, within the SAR studies of the benzathiadiazole/isoquinoline 
derivatives the effect of the replacemt of the central scaffold with an indolic 
ring was not investigated, despite SAR efforts focused on the substitution of 
the benzathadiazole and isoquinoline rings were performed. 




2.4.2. Right end of the molecules 
On the other hand, regarding the right end of the molecules (highlighted in 
greed in Figure 2.12), inspired by the SAR information of 
benzathiadiazole/isoquinoline derivatives, we selected three different groups: a 
para substituted aromatic ring, a cyclic aliphatic amine (piperidine) and a 
primary amine. These groups were introduced in an attempt to investigate the 
nature of the interaction exploited by the right end of the indole-based 
derivatives with the enzyme (highlighted in greed in Figure 2.12). 
As it is reported in SAR studies of  benzathiadiazole/isoquinoline derivatives 
(paragraph 1.4.5.1, pag. 40) this portion of the molecule has proven to be 
essential for PRMT3 inhibition activity, since prevents the formation of a 
catalytically competent state of PRMT3 through hydrophobic interactions with 
the dimerization arm of PRMT3.  
2.4.3. Central linkers 
The three series of compounds differ each others for the nature of the central 
linker between the indolic scaffold and the substituents at the right end. An 
aliphatic chain of 6 units was selected for all the derivatives, however the 
central spacer differs among the three series for the position of the ureidic 
moiety and for the presence of an amide function. 
Compounds of Series I show the same aliphatic linker of Uracandolates, in 
particular they are characterized by a methylene unit between an amide 
moiety, directly bound to the byciclic aromatic region, and the ureidic function 
that is asymmetrically substituted (Figure 2.15).  





Figure 2.15. Compounds of Series I 
 
Starting from compounds of Series I, the formal shift of the ureidic moiety to 
the indolic ring provided compounds of Series II (Figure 2.16). The aliphatic 
spacer of this set of compounds displays an arrangement similar to 
benzathiadiazolic derivatives. 
 
Figura 2.16 Design of the Series II 
Finally the replacement of the amide group of Series I derivatives with an 
amino group led to the derivatives of Series III (Figure 2.17). This 
modification was performed in order to assess the role of the carbonyl group 
of the amide function within the aliphatic spacer. The role of this function was 
not well elucidated by the SAR studies of  bezathaidiazole compounds, indeed 




it has been reported that derivatives bearing only the ureidic function without 
the amide group still showed a good inhibition activity against PRMT3 
(chapter 1, Figure 1.1.6).  
 































































3.1. Synthesis of CARM1 pyrrole inhibitors  
From a synthetic point of view, the pyrrolic compounds were divided into 3 
groups: 
1) Pyrrole analogue of lead compound I. 
2) N-phenyl pyrrole derivatives (Series II). 
3) N-benzyl pyrrole derivatives (Series III). 
The scaffold construction was the pivotal step for the preparation of the 
designed derivatives, indeed the different substitutions of the heterocycle 
required distinct methods for its construction. In Figure 3.1 are schematically 
reported the procedures used for the scaffolds synthesis, which differ between 
each other for the retrosynthetic dissections  
 
Figure 3.1. Three different synthetic approaches for the synthesis of the scaffolds: A) Intramolecular 
cyclization. B) van Leusen or Clauson-Kaas reaction. C) 1,3-dipolar cycloaddition reaction 




The 3-trifluoromethyl-1H-pyrrole, precursor of the pyrrolic analogue of lead 
compound I, was obtained exploiting an intramolecular cyclization of the 
aminocarbonyl intermediate (Figure 3.1. A).156 Whereas the ethyl 1H-pyrrole-
3-carboxylate was obtained via van Leusen reaction (Figure 3.1. B),157 in 
which tosylmethyl-isocyanide (TOSMIC) is cyclocondensed with the α,β-
unsaturated ester (ethyl acrylate) in presence of base.  
These procedures, unlike the others that are discussed below, did not afford to 
N-substituted pyrrole scaffolds, therefore a cross coupling reaction between 
the heterocycles and a proper aryl bromide was performed in order to obtain 
the derivatives N-Phenyl substituted. 
Conversely the Clauson-Kaas reaction as well as the 1,3-dipolar cycloaddition 
reaction,158 respectively used for the synthesis of the Series II and III 
compounds (Figure 3.1 B and C),  provided the pyrrolic scaffold N-Phenyl or 
N-Benzyl substituted. 
Starting from proper aniline and 2, 5 dimethoxytetrahydrofuran the N-Phenyl 
pyrrole derivatives of the Series II were prepared by Clauson-Kaas reaction 
(Figure 3.1. B). While, the 1, 3 dipolar cycloaddition reaction between 
ethylpropiolate and  1, 3 diacylic intermediate led to the synthesis of N-benzyl 
derivatives (Figure 3.1. C).    
Once obtained the pyrrolic central cores, the synthetic procedures used for the 
scaffolds decoration were common for all the designed derivatives and simple 















3.1.1. Synthesis of pyrrole analogue of lead compound I 
3.1.1.1. Synthesis of 3-trifluoromethyl-1H-pyrrole. 
The synthesis of the 3-trifluoromethyl-1H-pyrrole was accomplished 
following the synthetic procedure reported by Shaitanova et al. in 2008.156 
The reaction between ethyl vinyl ether (86) and trifluoroacetic anhydride in 
the presence of catalytic amount of DMAP yielded α, β unsaturated carbonylic 
compound (87), which after the addition of trimethylsilylcyanide (TMSCN) in 
presence of a catalytic amount of base, was converted to a silylated 
cyanohydrins compound (88). Finally, reduction of 88 with LiAlH4 led to the 
synthesis of the amino alcohol intermediate (89) in high yield, Scheme 3.1. 
  
 
Scheme 3.1.  Reagent and condition: (a) DMAP, trifluoroacetic anhydride, Ethyl vinyl ether, 
-10 °C, 30 min., then 0 °C, 10 h; 99%; (b) TMSCN, Et3N, 0 – 10 °C, 95%; (c) LiAlH4, diethyl 
ether, 0 °C, 88%. 
At this point, according to the reported procedure, the last step of the 3-
trifluoromethyl-1H-pyrrole synthesis should be the hydrolysis of the 
alkoxyvinyl group of 89 to aminocarbonyl compounds (90) using catalytic or 
stoichiometric amount of 5% aqueous hydrochloric acid. Intermediate 89 in 
turn, should cyclize to the pyrrole (92) via intramolecular Schiff base 
formation (91) with subsequent dehydration and proton migration (Scheme 
3.2). Following this procedure, any attempts to obtain the aforementioned 
scaffold (92) failed. In particular, we found that the intermolecular 
polymerizations of 89, after the hydrolysis of the alkoxyvinyl group, were 
favourited compared to the desired intramolecular cyclization. In addition, the 
3-trifluoromethyl-1H-pyrrole has a very low boiling point (< 35 °C), therefore 
its failure recovery, should be also due to its loss during the time of reaction (7 




days). Our hypotheses were then confirmed by the authors of this procedure, 
which revealed that the reaction suffers of scale-up problems too. 
The selective protection of the amino group of the intermediate 89 (Scheme 
3.2) (compound 93) with benzoyl chloride, followed by an intramolecular 
cyclization under acidic condition (mixture of DCM/TFA 7: 3), led to the 
pyrrole ring formation N-benzoyl protected (compound 94, Scheme 3.2), 
overcoming the intermolecular polymerization and the problem of product 
volatility.  
Final deprotection with LiOH in a mixture of dioxane/water  allowed us to 
obtain the desidered pyrrolic scaffold (92), which, considering the low boiling 





Scheme 3.2. Reagent and condition: (d)  HCl (0.1 eq. 5% aq.), CH3CN/H2O 2:1, t. a., 1 week 
or HCl (1 eq. 5% aq.), CH3CN/H2O 2:1, t. a., 1 week; (e) Benzoyl chloride, TEA, DCM, 0°C, 
5 min, r. t., overnight., 65%; (f) DCM/TFA 7:3, r. t., 24 h, 99%; (g) LiOH, dioxane/H2O 1: 1, 








3.1.1.2. Functionalization of the 3-trifluoromethyl-1H-pyrrole 
As it is previously reported the key step for the synthesis of the designed 
pyrrole derivatives was the central core construction. The synthetic procedures 
for the scaffolds decoration were common for all the pyrrolic derivatives and 
consisted of simple reactions. 
The C-2 functionalization of the pyrrole intermediate 92 with the benzylamide 
moiety was accomplished by Friedel-Crafts acylation with trichloroacetyl 
chloride (95), followed by nuclephilic substitution, employing benzylamine as 
reagent (derivative 96, Scheme 3.3). Notably, negative results were obtained 
in our attempt to acylate, under Friedel-Crafts conditions, the pyrrolic α-
position of 94 (Scheme 3.2), since the presence of the benzoyl protecting 
group strongly deactivated the aforementioned position. 
  
 
Scheme 3.3. Reagent and condition: (h) trichloroacetyl chloride, DCM, 70 °C, 36 h, 56 % 
over steps f and g; (i) benzylamine, K2CO3, DMF, MW, 80 °C, 30 min, 70% 
Afterwards, the N-arylation of 96 was accomplished exploiting an Ullmann-
type reaction (Scheme 3.4). 159 The microwave-assisted reaction between 3-
Bromobenzonitrile and 96, using CuI, N, N’-dimethylethylendiamine and 
K3PO4 at 130 °C in dioxane yielded the N-Phenyl substituted intermediate 97. 
The subsequently reduction of nitrile group with NaBH4 in the presence of 
catalytic amount of NiSO4•6 H2O (compound 98), followed by coupling 
reaction with L-Boc-Ala-OH led to the introduction of the aminoacidic portion 
on the phenyl ring (intermediate 99). Final removal of Boc protecting group 
provided the pyrrole analogue of the lead compound I (compound 100, 
Scheme 3.5). 





Scheme 3.4. Reagent and condition: (j) 3-Bromobenzonitrile, CuI, N,N′- 
Dimethylethylenediamine, K3PO4, dioxane dry, MW, 130 °C, 30 min, 80% ; (k) NaBH4, 
NiSO4•6 H2O, MeOH, 30 min., r. t.; (l) (L) - Boc - Ala - OH, DMAP, DCC, DCM, overnight, 
r.t., 75 % over steps j and k; (m) DCM/TFA 9: 1; r. t., 30 min, 99%. 
3.1.2. Synthesis of N-Phenyl pyrrole derivatives (Series II) 
Within this series of derivatives, two synthetic approaches were used for the 
preparation of the central core, since the different substitution of the pyrrole 
ring influenced its reactivity.  
3.1.2.1. Pyrrole scaffold synthesis  
Compounds 103a and 103b were obtained by Clauson-Kaas reaction,160 
starting from a proper substituted aniline (101a or 101b) and 2, 5 dimethoxy 
tetrahydrofuran (102a) heating at 80 °C in AcOH (Scheme 3.5). 
 
Scheme 3.5. Reagents and conditions: (a) 2,5-Dimethoxytetrahydrofuran, AcOH, 80 °C, 2 h, 
70 – 84%. 
 




The Clauson-Kaas reaction is a very advantageous procedure, because allow to 
obtain the N-Phenyl pyrrolic scaffold in one step with high yield. Therefore, 
we initially sought to use this approach for preparing all the derivatives of the 
Series II, including the 3-ethyl ester substituted N-Phenyl pyrroles (Scheme 
3.5, compounds 103c, d). Our initial attempts gave good results leading to the 
synthesis of 103c and 103d in good yield (Scheme 3.5) by reaction of 101a 
and 101b with ethyl 2,5-dimethoxytetrahydrofuran-3-carboxylate (102b), 
heating at 80°C in AcOH. Nevertheless, the following step of pyrrole 
electrophilic substitution of 103c, d with trichloroacetyl chloride afforded 
several problems. For the acylation step of the ester substituted derivatives 
were required strong conditions, since the steric hindrance as well as the 
electronic deactivation of the C-2 pyrrolic position, made it less susceptible to 
the electrophilic substitution. In particular our attempts to carry out this 
reaction with trichoroacetyl chloride in presence of aluminum chloride, under 
Friedel-Crafts acylation conditions, resulted in a mixture of positional isomers 
obtained in low yields (< 20 %) difficult to separate (Scheme 3.6). Whereas 
the reaction by 103a, b and trichloroacetyl chloride heating at 120 °C yielded 
the desired products in high yield (intermediates 104a – b, Scheme 3.6). 
 
Scheme 3.6. Reagents and conditions: (b) ClCOCCl3, neat, MW 120 °C, 1.5 h for 105b, c or 
ClCOCl3, AlCl3, DCM, r. t., 12h, > 20%. 




Therefore, taking into account these problems, we decided to employ the van 
Lausen reaction for obtaining the pyrrole scaffold bearing the ethyl ester 
moiety at the β position of the heterocycle. Ethyl 1H-pyrrole-3-carboxylate  
(107) was prepared starting from tosylmethyl-isocyanide (TOSMIC) which 
was cyclocondensed with ethyl acrylate in the presence of NaH in good yield 
(Scheme 3.7). 
 
Scheme 3.7. Reagents and conditions: (a’) Tosmic, NaH, DMSO dry, Et2O dry, 5 h, 60 %; 
3.1.2.2. Scaffold decoration 
Friedel-Crafts acylation with trichloroacety chloride, followed by nuclephilic 
substitution with benzylamine provided the introduction of the benzylamide 
moiety at pyrrole position C-2 of derivatives 108a, b and 110 (Schemes 3.8 
and 3.9). The N-Aryl derivatives 108c, d were prepared by reaction of Ullman 
employing intermediate 110 (Scheme 3.9), a proper aryl bromine, K3PO4 as a 
base and CuI, N, N’- Dimethylethylenediamine in dioxane heating at 130 °C 
for 30 minutes (Scheme 3.9).  
 
 
Scheme 3.8. Reagents and conditions:  (b) ClCOCCl3, neat, MW 120 °C, 1.5 h; (c) 
benzylamine, K2CO3, DMF, MW, 80 °C , 30 min, 65 – 70 %. 
 
 






Scheme 3.9. Reagent and condition: (b) ClCOCCl3, DCM dry, 80 °C, 5 h, 60 – 70 %; (c) 
benzylamine, K2CO3, DMF, MW, 80 °C , 30 min, 70 – 80 %; (d) 1-Bromo-3-nitrobenzene  or 
3-Bromobenzonitrile, CuI, N,N’- Dimethylethylenediamine, K3PO4, dioxane dry, MW, 130 
°C, 30 min, 75 – 80 % 
 
Reduction of nitro (108a, c) and cyano (108b, d) substituted derivatives, using 
Zn in AcOH and NaBH4 in presence of catalytically amount of NiSO4•6H2O 
respectively, followed by coupling reaction with L-Boc-Ala-OH or D-Boc-Ala-
OH provided the Boc-protected alanine-benzylamides 110 a - d and ent-110 a 
- d (Scheme 3.10), which then were deprotected with trifluoroacetic acid 
(compounds 111 a - d and ent-111 a - d). Hydrolisis of esters 110c, d; ent-
110c, 111c, d and ent-111c d with LiOH gave the corresponding acids 110 e - 
f, ent-110 e - f, 111 e - f and ent-111 e - f. 
 
 
Scheme 3.10. Reagent and condition: (d) Zn, AcOH, r. t. 1 h,  (for 108a, c) or NaBH4, 
NiSO4•6H2O, THF/iPrOH, r. t., 4 h (for 108c, d); (e) Boc-L-Ala-OH (for 109a-d) or Boc-D-
Ala-OH (for ent-109 a-d), DCC, DMAP, DCM, r. t., overnight, 50 – 70% (over step d and e); 
(f) LiOH, 40 °C, EtOH/H2O, overnight, 90 – 95%; (g) DCM/TFA (9:1), r. t., 30 min, 99%.  
 




3.1.3. Synthesis of N-Benzyl derivatives (Series III) 
3.1.3.1. Synthesis of  N-Benzyl pyrrolic scaffold 
The pyrrolic scaffold of Series III derivatives was obtained employing  a 
1, 3 dipolar cycloaddition reaction between ethylpropiolate and 1, 3 diacylic 
intermediates (115 a, b).194 Apparently, this procedure compared to the 
Clauson-Kaas reaction seems to be not convenient due to a greater number of 
synthetic steps. However, it allowed to obtain the desidered N-benzyl pyrrole 
building blocks (116a, b) with high yields and starting from not expensive 
reagents (Scheme 3.11). Moreover this procedure did not require intermediate 
steps of purification. 
The first reaction is a reductive amination, the reaction between a glycine ethyl 
ester and 3-nitro or 3-cyano benzaldheyde (112a or 112b)  led to the iminic 
intermediates, which in turns were reduced in situ with NaBH4 providing the 
amino derivatives (113a and 113b). Formylation of compounds 113a, b 
accomplished by formic acid and acetic anhydride, followed by hydrolysis of 
the esteric moiety with NaOH 2N led to the 1, 3 diacylic derivatives 115a and 
115b. The N-Benzyl pyrrolic scaffold (116a and 116b) was obtained by 
reaction of 1, 3 dipolar cycloaddition between ethylpropiolate and compounds 




Scheme 3.11. Reagent and condition: (a)  Gly-OEt•HCl, TEA, EtOH dry, r. t., overnight, 
NaBH4, 0 °C, 1 h, 70 – 80 %; (b) Ac2O,  formic acid, r.t., overnight 80 – 90 %; (c) NaOH 2 N, 
EtOH, r. t., 1 h, 80 – 90 %; (d) ethylpropiolate, Ac2O, 140 °C, 5 h, 60 – 70 %; 
 
 




3.1.3.2. N-Benzyl pyrrolic scaffold decoration 
The pyrrole scaffolds of derivatives 116a, b was then functionalized 
employing the same synthetic approaches used for pyrrole analogue of lead 
compound I and for derivatives of the Series II (paragraphs 3.1.1.2 and 
3.1.2.2). In particular the acylation with trochloroacetyl chloride (117a, b) 
followed by nuclephilic substitution with benzylamine provided the 
introduction of the benzylamide moiety at the C-2 position of the pyrrole ring 
(118a, b). Whereas the coupling reaction with L-Boc-Ala-OH or D-Boc-Ala-
OH, after the reduction of the nitro or cyano groups with Zn in AcOH (119a) 
or NaBH4 in presence of catalytically amount of NiSO4•6H2O (119b), led to 
the boc protected alanine-amides 120a, b and ent-120a, b. Removal of the 
tert-butyloxycabonyl protecting group with DCM/TFA 9:1 yielded the amino 
derivatives 121a-d and ent-121a-d, which in turn where hydrolysed with 
LiOH obtaining the corresponding acids 120c-d, ent-120c-d, 121c-d and ent-
121c-d  (Scheme  3.12). 
 
 






Scheme 3.12. Reagent and condition:(e) ClCOCCl3, MW 120 °C, 1.5 h, 60% (f) Zn, AcOH, 
r. t., 1 h (for 118a) or NaBH4, NiSO4•6 H2O, THF/iPrOH, r. t., 4 h (for 118b); (g) Boc-l-Ala-
OH (for 120a, b) or Boc-d-Ala-OH (for ent-120a, b), DCC, DMAP, DCM, r. t., overnight, 60 
–  70 % (over step c and d);  (h) LiOH, EtOH/H2O, 45 °C, 5 h, 90 – 95 %; (i) DCM/TFA 9:1, 





















3.2. Synthesis of bisubtrate inhibitors of CARM1 
From a synthetic point of view the assembly of the bisubstrate inhibitors 
required a convergent synthesis, based on the initial preparation of both 
peptides and Adenosine fragments. Subsequently, the obtained building blocks 
were coupled employing, on solid phase, a synthetic procedure reported by 
Martin N. I. and coworkers for the preparation of NG – substituted 
guanidines.161 
3.2.1. Synthesis of peptide sequences 
The peptide fragments (124 and 127) were obtained employing an acid 
sensitive resin (TentaGel® S RAM Resin) and using standard Fmoc SPPS 
techniques (Solid Phase Peptide Synthesis) (Scheme 3.13 A and B). The 
synthesis of the two sequences began respectively at the Proline (122) and 
Methionine (125) residues and an Alloc (allyloxycarbonyl) protected L-
Ornithine was incorporated instead of L-Arginine. Subsequently, the protecting 
group on the side chain of Ornhitine residue was selectively removed 162 with 
Pd(PPh3)4 and PhSiH3 in CH2Cl2 under argon atmosphere providing an 
attachment point for the adenosine portions. 
 





Scheme 3.13. Reagents and conditions: (a) Fmoc-Xaa-OH, BOP, DIPEA, DMF; (b) 
Pd(PPh3)4, PhSiH3, CH2Cl2. 
3.2.2. Synthesis of Adenosine building blocks  
The synthetic routes used for the preparation of the Adenosine Pbf-protected 
thioureas 131, 137 and 138 all started from the commercially available 2,3-O-
isopropylideneadenosine building block 128. 
The synthesis of 131 (Scheme 3.14) began with the one carbon homologation 
of 128 via a Mitsunobu reaction employing PPh3, DEAD, and 
acetonecyanohydrin to yield the nitrile 129.  Subsequent reduction to the 
amine (130) followed by treatment with Pbf-NCS provided the Pbf-protected 
thiourea species (compound 131, Scheme 3.14).  
 
Scheme 3.14. Reagents and conditions: (a) acetone cyanohydrin, PPh3, DEAD, THF, 90%; 
(b) PtO2, AcOH, H2, quant.; (c) PbfNCS, Et3N, CH2Cl2, 50%. 




On the other hand the synthesis of 137 and 138 (Scheme 3.15) began with a 
one pot IBX oxidation of 128 to yield the intermediate aldehyde which was 
directly converted to alkene 132 via a Wittig reaction with 
triphenylcarbethoxymethylenephosphorane. Reduction of 132 with DIBAL 
yielded an alcohol which was transformed into intermediate 134 by a 
Mitsunobu reaction employing PPh3, DEAD, and phthalimide.
142 Removal of 
the phthalimide group with methylamine provided amino compound 135, 
which was converted into Pbf-protected thiourea species 137 by treatment 
with Pbf-NCS. Hydrogenation of 135163  followed by reaction with Pbf-NCS 
using the procedure described above for 131 and 137 yielded compound 138. 
 
 
Scheme 3.15. Reagents and conditions: (a) IBX, Ph3P=CHCO2Et, DMSO, 79%; (b) DIBAL-
H, hexane, CH2Cl2, 78%; (c) phthalimide, PPh3, DEAD, THF, 83%; (d) MeNH2, EtOH, 94%; 
(e) 10 % Pd/C, H2EtOH, quant.; (f) PbfNCS, Et3N, CH2Cl2, 50 – 60%. 
3.2.3. Synthesis of bisubstrate inhibitors 
The obtained fragments (adenosine and peptide building blocks) were coupled 
through guanidine moiety, using a synthetic methodology previously described 
by Martin N. I. and co-workers.161 This procedure, reported for the synthesis 




of NG-substituted guanidines, proved to be suitable also for the solid phase 
techniques. The coupling reaction between the proper ornithine containing 
peptide on resin (124 or 127) and Pbf-protected adenosine thiourea species 
(131, 137 and 138), was performed using EDCI as a coupling reagent 
(Schemes 3.16). Final deprotection/cleavage and purification by using RP-
HPLC allowed us to obtain all of the designed compounds (80 – 85). 
 
 Scheme 3.16. Reagents and conditions: (a) EDCI, proper Pbf-protected adenosine thiourea 
(131, 137 or 138), CH2Cl2; (b) TFA–TIS–H2O. 
3.2.4. Synthesis of control compounds 
Moreover, we decided to synthesize the two selected peptide sequences 
bearing an unmethylated (compounds 139 and 142, Scheme 3.17), singly 
methylated (compounds 140 and 143, Scheme 3.18) or asymmetric 
dimethylated (compounds 141 and 144, Scheme 3.17) arginine residues.  




Peptides 139 – 144 were obtained employing a standard Fmoc SPPS technique 
(Solid Phase Peptide Synthesis) using the procedure described above for 124 
and 127 (Scheme 3.13).  
 
Scheme 3.17. Reagents and conditions: (a) Fmoc-Xaa-OH, BOP, DIPEA, DMF; (b) TFA–
TIS–H2O. 
The modified Arginine building block used for the peptide synthesis was 
obtained employing a synthetic procedure previously describes by the group of 
Martin and coll. (Scheme 3.18).161 The Pbf/Fmoc-protected thiourea precursor 
(146) was obtained after treatment of deprotected L-ornithine (145) with 
PbfNCS in the presence of TEA. The reaction between 146 and methylamine 
or dimethylammine with EDCI yielded the expected modified- L-arginine 
(147 - 148). 
 
Scheme 3.18. Reagents and conditions: (a) TFA/CH2Cl2 3: 7, r. t. 30 min; (b) PbfNCS, 
CH2Cl2, TEA, r. t., 30 min.; (c) EDCI, methylamine or dimethylamine, CH2Cl2, r. t.; 1h. 




3.3. Indole inhibitors of PRMT3 
 
The indole inhibitors of PRMT3 have been structurally categorized in three 
Series according to the nature of the central linker (Figure 3.2) 
 
Figure 3.2. Three Series of indole based derivatives 
 
3.3.1. Indole scaffold synthesis 
Derivatives of Series I, II and III were prepared starting from 5-nitro-1H-
indole (149a), ethyl 5-nitro-1H-indole-3-carboxylate (149b) and ethyl 5-nitro-
1H-indole-2-carboxylate (149c) scaffolds (Scheme 3.19 and 3.20). Compound 
149a is commercially available, whereas the 3,5 and 2,5 substituted indole 
scaffolds were synthesized following the previously described procedures.126 
Ethyl 5-nitro-1H-indole-3-carboxylate (149b) was prepared according to the 
synthetic approach reported in Scheme 3.19. The first step was a 
regioselective Friedel-Crafts acylation of 5-nitroindole (149a) with oxalyl 
chloride (150) followed by alkaline hydrolysis (151). Oxidative 
decarboxylation (152) and final etherification yielded the 3, 5 substituted 
indole scaffold (149b).  
On the other hand, the 2,5-substituted analogue (149c) was obtained 
employing one of the best method for preparing indoles: the Fischer indole 
synthesis (Scheme 3.20).164 The reaction by 4-nitrophenylhydrazine with 




ethyl-piruvate led to the formation of the phenylhydrazone (154), which in 
turn was converted to ethyl 5-nitro-1H-indole-2-carboxylate (149c)  under acid 
condition with polyphosphoric acid. 
 
Scheme 3.19. A. Reagents and conditions: (a) (COCl)2, Et2O, 0 °C, overnight; (b) KOH, 
H2O, reflux, 2 h; (c) H2O2 (10 % wt in H2O), reflux, 4 h; (d) H2SO4, MeOH, reflux, 6 h. 
Scheme 3.20. B. Reagents and conditions: (a) AcOH/EtOH 1:2, 55°C, 1 h; ethyl-piruvate, r. 
t., overnight; (b) PPA, toluene, 120°C, 5 h. 
3.3.2. Aromatic nitro reduction 
Reduction of nitro compounds 149a – c to the corresponding 5-amino 
derivative 155a – c (Scheme 3.21), under continuous-flow catalytic 
hydrogenation conditions, provided an attachment point for the scaffold 
decoration. The continuous flow aromatic nitro reduction was preferred over 
traditional metal mediated non-catalytic reduction procedures, due to its 
efficiency, high yielding and ease in scale up. Moreover, since the products 
were delivered in high intrinsic purities, no purification steps were required. 
 
 





Scheme 3.21. Reagents and conditions: (a) H2,  10% Pd/C, EtOH/AcOEt 1:1, 30 °C, 10 bar, 
1mL/min, H-Cube™ (ThalesNano©). 
 
3.3.3. Synthesis of Series I derivatives 
Once obtained the 5-amino indolic scaffolds (155a – c ), compounds of Series 
I were prepared according to the previously synthetic procedures reported by 
us for the synthesis of Uracandolates (Chapter 2 Aim of the work)126. 
Coupling reaction followed by deprotection and ureidic moiety formation 
allow us to obtaine the designed derivatives of Series I. 
3.3.3.1. Coupling reaction and removal of protecting group  
The reaction of 155a - c with Fmoc-Gly-OH or Boc-Gly-OH in the presence 
of the peptide coupling reagents hydroxybenzotriazole (HOBt) and O-
benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexa-fluoro-phosphate (HBTU) 
and N,N-diisopropylethylamine, DIEA yielded the Fmoc or Boc protected 
glycinamides (156 a – c), which were deprotected with piperidine or  
trifluoroacetic acid yielding the corresponding amino derivatives (157a – c), 
Scheme 3.22. 
 
Scheme 3.22. Reagents and conditions: (b)  Fmoc-Gly-OH or Boc-Gly-OH, DIPEA, HOBt, 
HBTU, THF/DMF 4:1, r.t., overnight; (c) CH2Cl2/piperidine 8:2, r.t., 30 min or CH2Cl2/TFA 
8:2, r.t., 30 min. 




Notably, it was not possible to couple compound 155a with Boc-Gly-OH, 
since the traditional acidic conditions used for removing the Boc protecting 
group led to the degradation of the 5-substituted indole scaffold (155a), which 
conversely resulted to be stable in basic condition. Therefore we used two 
different protecting groups, Fmoc (156a) or Boc (156b, c) for the glycinamide 
moieties.  
3.3.3.2. Ureidic moiety formation 
Derivatives 157a – c by reaction with commercially available 4-methyl 
phenylisocyanate (158) in the presence of triethylamine yielded final 
compounds 159a – c bearing an aromatic moiety at the right end of the 
molecules (Scheme 3.23).  
 
Scheme 3.23. Reagents and conditions: (d) TEA, THF, r. t., 8 h. 
Instead, the formation of the ureidic moieties of compounds 161a – c and 163a 
– c was accomplished by reaction of 157 a – d with a proper amine (1-(2-
Aminoethyl)-piperidine 160 or protected ethylendiamines (162a, b) in the 




presence of CDI and TEA (Schemes 3.24 and 3.25).  Removal of Boc 
protecting group of 163b, c with TFA led to the corresponding amino 
compounds 164b, c (Scheme 3.25). On the other hand, being the 5 substituted 
scaffold (157a) unstable under acidic conditions, the N-Boc ethylenediamine 
moiety (162b), used for compounds 163b, c, was replaced with 2-
azidoethylamine (162a), which by reaction with 157a in the presence of CDI 
and TEA, followed by continuous-flow catalytic hydrogenation yielded the 
final compound 164a. 
 
Scheme 3.24. Reagents and conditions: (e) CDI, TEA, 0 °C, 5 min, 9a, 9b o 9c THF, 2 die 





Scheme 3.25. Reagents and conditions: (f) CDI, TEA, 0 °C, 5 min, THF, 2 die; (g) H2,  10% 
Pd/C, MeOH, 30 °C, 1 bar, 1mL/min, H-Cube™ (ThalesNano©); (h) DCM/TFA 8:2, r. t., 30 
min. 
3.3.4. Synthesis of Series II derivatives 
The synthesis of Series II compounds required the initial formation of the 
ureidic function on the heterocycles, followed by coupling reactions for 
introducing aliphatic or aromatic substituents at the right end of the molecule. 
3.3.4.1. Urea formation and deprotection 
The ureidic derivatives (165 a – c, Scheme 3.26) were easily prepared by 
reaction between 5-amino indolic derivatives (158 a - c) and glycine tert-butyl 
or ethyl esters in the presence of CDI and TEA. The corresponding acids (166 
a – c) were then obtained by hydrolysis under basic (for 165a) or acidic 
conditions (for 165b, c) of the esters. Also in this case were used two different 
protecting groups for the aliphatic carboxylic acid of the indole derivatives 
(165a – c). The instability of 155a under acidic conditions didn’t allow us to 
protect the aliphatic carboxylic moiety with an acid labile tert-butyl ester. In 
addition could not be used the glycine ethyl ester for 3, 5 and 2, 5 disubstituted 




indole scaffolds (155b and 155c), since the presence of an aromatic ethyl ester 
group limited the selective hydrolysis of the aliphatic ester.  
 
Scheme 3.26. Reagents e conditions: (a) CDI, TEA, glicyne ethyl ester o glycine tert-butyl 
ester, THF, overnight; (b) NaOH 2N, EtOH, r. t., 2 h or DCM/TFA 8:2, r. t., 30 min. 
3.3.4.2. Coupling reactions 
Final coupling reaction between compounds 166a – c and a proper amine, p-
toluidine (Scheme 3.27, compounds 168 a – c), 1-(2-Aminoethyl)-piperidine 
(Scheme 3.28, compounds 169 a – c) and 162a, b (Scheme 3.29, compounds 
170 a – c) respectively, in the presence of coupling reagent TBTU 
accomplished the derivatization of the aliphatic carboxylic moieties. 
Compounds 170 b – c were converted to the corresponding amino compounds 
(171 b – c) by removal Boc protecting group with TFA (Scheme 3.29), 
whereas derivative 171a was obtained after catalytic hydrogenation of the 
azido intermediate  170a (Scheme 3.29). 









Scheme 3.28. Reagents e conditions: (d) TBTU, TEA, DMF, r. t., overnight. 





Scheme 3.29. Reagents e conditions: (e) TBTU, TEA, DMF, r. t., overnight; (f) H2,  10% 
Pd/C, MeOH, 30 °C, 1 bar, 1mL/min, H-Cube™ (ThalesNano©); (g) DCM/TFA 8:2, r. t., 30 
min. 
3.3.5. Synthesis of Series III derivatives 
Compounds of Series III were prepared by alkylation of 5 amino-indoles 155a 
– c with methanesulfonates ureidic intermediates (174 a – c), previously 
synthesized.  
3.3.5.1. Synthesis of 174a - c building blocks 
The mesyl activated ureidic intermediates were synthesized according to the 
synthetic route depicted below (Scheme 3.30). Compound 174a was prepared 
by reaction of 4-methy-phenylisocyanate (158) with 2-aminoethanol, followed 
by OH-activation with mesyl chloride. While the synthesis of compounds 
174b, c required one more step. Initially, the amino building blocks 162a, b 
were treated with phenyl-chloroformate in order to obtain the carbamate 
intermediates (172a, b), which were converted into the corresponding ureidic 
compounds by reaction with 2-aminoethanol in 1,2-dichloroetane at 120 °C for 




8 h. Finally the methanesulfonates ureidic intermediates 174b, c were prepared 
by reaction with mesyl chloride. 
 
Scheme 3.30. Reagents e conditions: (a) phenyl-chloroformate, TEA, AcOEt, 0 °C, 4 h, 
70%; (b) for 173a , 2-aminoethanol, TEA, THF dry, 0 °C, 8 h, 70%; for 173b, c, 2-
aminoethanol, TEA, 1,2-dichloroetane, 120 °C, 8 h, 80%; (c) MsCl, TEA, THF dry, 0°C, 1 h, 
100%. 
3.3.5.2. Alkylation steps 
Final compounds (175a – c, 176a – c, 178b, c) were obtained after treatment 
of 5-amino indole derivatives 155a – c with methanesulfonates ureidic 
intermediates (174a – c), Schemes 3.31, 3.32, 3.33. 
 




Scheme 3.31. Reagents e conditions: (d) TEA, THF dry, 50 °C, 2 h, 50-70 %. 
 
Scheme 3.32. Reagents e conditions: (e) TEA, THF dry, 50 °C, 2 h, 50-70 %. 





 Scheme 3.33. Reagents e conditions: (f) TEA, THF dry, 50 °C, 2 h, 50-70 %; (g) H2,  10% 
Pd/C, MeOH, 30 °C, 1 bar, 1mL/min, H-Cube™ (ThalesNano©); 
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4.1. Biological evaluation of pyrrole derivatives 
Pyrrole derivatives were preliminarily tested at fixed dose (50 µM) in 
duplicate by Scintillation proximity assay against human CARM1, using as 
substrates histone H3 at 5 μM and 3H-SAM at 1 μM. The inhibition (%) at 
fixed dose was first determined, and then the IC50 values for the most active 
compounds were established. Pyrazole inhibitor (compound 54) was used as 
our internal reference compound. All the enzymatic assays were performed by 
Reaction Biology corporation. 
4.1.1. Results 
In Figure 4.1 are reported the results of CARM1 enzymatic inhibition assay at 
fixed dose by pyrrole compounds; whereas in Table 4.1 are reported the 
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In Table 4.2 are reported the IC50 values of compounds that showed a CARM1 
















Table 4.2. IC50 values of selected compounds. Compounds were tested in a 10 dose IC50 
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4.1.2. SAR of pyrrole inhibitors of CARM1 
These preliminary studies allowed us to delineate the structure-activity 
relationships of CARM1 pyrrole inhibitors. 
The most important result that emerge from this preliminary screening is that 
the structure-activity relationships of pyrrole derivatives and pyrazolic 
inhibitors are not overlapping, suggesting that has been developed and 
identified a new class of CARM1 inhibitors, which, due to the high synthetic 
versatility of the pyrrole ring, showed several possibilities for further structural 
optimizations, whom are precluded for pyrazole compounds.  
The activity revealed by the pyrrolic analogue of lead compound I (EML 568) 
confirmed our assumptions that the isosteric replacement of the pyrazolic ring 
with the pyrrole one could be also considered as a bioisosteric substitution. 
Indeed the aforementioned pyrrole derivative shows a good enzymatic 
inhibition against CARM1 (EML 568, IC50 = 7.23 µM, Table 4.2), however 
the pyrazole compound remains the most potent inhibitors of CARM1 (Lead 
IC50 = 0.5 µM) Figure 4.2. 
 
 
Figure 4.2. Effect of the substitution of the heterocycle central core of pyrazolic inhibitor 
The only thing in common between the SAR of pyrrole and pyrazole 
derivatives is the stereospecific activity of compounds. Indeed considering the 
enantiomeric couples of Series II and III derivatives, the CARM1 inhibition is 
achieved by compounds bearing the (S)-alanine moiety at the south end of the 
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molecules, its replacement with the optical isomer (R)-alanine leads to a loss 
of activity (Figure 4.3). [71.6 % of enzymatic inhibition (EML428) vs 2.89 % 
of enzymatic inhibition (EML429); IC50 = 2.42μM (EML438) vs IC50 = 
25.2μM (EML439), 80.5 % of enzymatic inhibition (EML446) vs 27.0 % of 
enzymatic inhibition (EML447)]. 
 
 
Figure 4.3. Comparison between the enantiomeric couples of derivatives  
 
Regarding the effect of the different functionalization of the pyrrolic C-4 
position emerge that the replacement of the trifluoromethyl group, present in 
analogue of lead compound I (EML568), with the ethyl ester moiety leads to 
an improvement of the inhibition activity [IC50 = 7.23 μM (EML568) vs IC50 
= 4.83 μM (EML446)] (Figure 4.4), whereas its elimination determines a 
slight decrease of potency [IC50 = 7.23 μM (EML568) vs IC50 = 9.72 μM 
(EML432)] (Figure 4.4). Interestingly, the hydrolysis of the ester derivatives 
to the corresponding acid results in a total loss of activity. The carboxylic 
derivative (EML448) show the lowest inhibitory potency compared to the 
unsubstituted pyrrole derivative (EML432) as well as to the 4- trifluoro  
(EML568) and 4-ethyl ester (EML446) substituted inhibitors (Figure 4.4). 




Figura 4.4 Effect of different substitution at pyrrole position 4 on the activity 
 
Next the role of the central core was investigated. The replacement of the N-
phenyl pyrrole scaffold of Series II derivatives with N-benzyl pyrrole one 
(Series III) negatively influences the activity of compounds. Comparing the 
IC50 values reported in Table 4.2, the N-benzyl pyrrole derivatives are less 
active than N-phenyl pyrroles [IC50 = 4.83 μM (EML446) vs IC50 = 11.5 μM 
(EML462) and IC50 = 2.42 μM (EML438) vs IC50 = 4.83 μM (EML454)] 
(Figure 4.5 A and B). 
 
Figure 4.5. N-phenyl derivatives vs N-benzyl derivatives 
In addition, regarding the different linkages between the aminoacidic moiety 
and the aromatic ring at the south end of the molecules, it has been assessed 
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that the elimination of the methylene group between the aforementioned 
groups provides an improvement of the activity in both the Series II and III of 
pyrrole derivatives [IC50 = 4.83 μM (EML446) vs IC50 = 2.42 μM (EML438) 




Figura 4.6 Effect of different linkages between the aminoacidic moiety ant the aromatic 
group at the south end of the molecules 
 
Summarizing all the information reported above the most potent pyrrole 
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4.1.3. Evaluation of cellular activity of pyrrole derivatives  
To determine whether the pyrrole inhibitors were able to inhibit CARM1 
within a cellular context, in collaboration with Professor Wei Xu from the 
University of Wisconsin, a homogenous cellular assay (LanthaScreen), that 
uses time-resolved (TR) FRET technology for monitoring CARM1 activity 
after treatment with pyrrole inhibitors, has been performed. 
4.1.3.1. General principles of FRET 
FRET (Fluorescence Resonance Energy Transfer) is based on the transfer of 
energy between two fluorophores, a donor and an acceptor, when in close 
proximity. Molecular interactions between biomolecules can be assessed by 
coupling each partner with a fluorescent label and by detecting the level of 
energy transfer. When two entities come close enough to each other, excitation 
of the donor by an energy source (e.g. a flash lamp or a laser) triggers an 
energy transfer towards the acceptor, which in turn emits specific fluorescence 
at a given wavelength (Figure 4.7). The donor and acceptor can be grafted 
covalently onto multiple partners that can associate, among others, two 
dimerizing proteins, two DNA strands, an antigen and an antibody, or a ligand 
and its receptor. Because of these spectral properties, FRET, a donor-acceptor 
complex, can be detected without the need for physical separation from the 
unbound partners. Fully homogeneous assays do not require separation steps 
such as centrifuging, washing, filtration, or magnetic partitioning. Traditional 
FRET chemistries are hampered by background fluorescence from sample 
components such as buffers, proteins, chemical compounds and cell lysate. 
This type of background fluorescence is extremely transient (with a lifetime in 
the nanosecond range) and can therefore be eliminated using time-resolved 
methodologies. 




Figure 4.7. Exciting the donor (Tb-2nd Ab) at 340 nm led to FRET-mediated light emission 
of the acceptors (GFP-fused protein), which in turn emits specific fluorescence at 520 nm 
 
4.1.3.2. TR-FRET cell-based assay and results 
Time-resolved Fluorescence resonance energy transfer (TR-FRET) 
LanthaScreen® cellular assay has been performed for the interrogation of 
CARM1 cellular inhibition by pyrrole derivatives EML426 – 466 (Figure 
4.8), using Tb-labeled antibody as a donor fluorophore and GFP-BAF155 
(Chromatin Remodeling Factor) as acceptor fuorophore. 
 BAF 155 is one of the non histonic substrates of CARM1 and the methylation 
occurs at R1064 residue. 
HEK 293 cells, stably expressing the fusion protein GFP-BAF155, were 
treated with 20 µM of each pyrrole compounds for 24h, using DMSO and 
Adox (20 µM) as negative and positive controls respectively. After cellular 
lysis, the buffer was supplemented with Me-BAF155 Ab and Tb-2nd Ab and 
incubated for 1 h. The ternary complex (Me-GFP-BAF155, Me-BAF155 Ab, 
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and Tb-2nd Ab) was detected by FRET between the Tb donor and the GFP 
acceptor. The TR-FRET ratio of the GFP-specific signal (measured at 520 nm) 
to the Tb-specific signal (measured at 495 nm) reflects the level of Me-GFP-
BAF155.  
The data emerging from this assay were not exciting (Figure 4.8). Due to their 
poor lipophilicity, pyrrolic derivatives (EML426 – 466) didn’t show any 
cellular activity in the tr-FRET cell-based assay as well as the pyrazolic lead 
(EML327). EML458 and 459 showed cytotoxic properties.  
The hypothesis of low cytopermeability of pyrrole derivatives was then 
confirmed by PAMPA assay (Parallel Artificial Membrane Permeation 
Assay). This non-cell based assay is designed to predict passive transcellular 
permeability through an artificial membrane of drugs in early drug discovery 
(Figure 4.9 A). As it is possible to see in Figure 4.9 B, the pyrrolic 
derivatives, although more lipophilic than pyrazolic lead, didn’t show a good 
transcellular permeability [Pa (x 10
-6 cm/s) = 0.15 (Lead) vs Pa (x 10
-6 cm/s) = 





























Figure 4.9. A) Individual Donor/Acceptor Well Assembly Before and After Incubation. B) All compound were tested at 500 µM (5% DMSO/PBS) 
except for EML 438 which was tested at 250 µM 5% DMSO/PBS.  EML 462 which was not soluble. Propanolol and Furosemide were used as 
positive and negative control respectively  
Compound  
Pa (x 10-6 cm/s) at 
pH 7.4  
Propranolol  7.13 ± 0.20 
Furosemide  0.10 ± 0.01 
EML568  0.35 ± 0.08  
EML428  0.15 ± 0.03  
EML432  0.05 ± 0.06  
EML438  0.76 ± 0.03  
EML446  0.48 ± 0.05  
EML454  0.30 ± 0.10  
EML462  -  
Lead 0.15 ± 0.03  
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4.1.3.3. Future plans 
Taking into account the good activity of pyrrolic inhibitors and the greater 
lipophilicity and versatility compared to the pyrazolic modulator, supported by 
computational studies performed by the group of Professor Giuseppe Bifulco 
of the University of Salerno, we operated structural optimization of the pyrrole 
derivatives, in order to obtain new derivatives, more permeable and potent 
than the molecules here described (see chapter 5). The synthesis of novel 
pyrrole inhibitors is still ongoing, and then their activity toward CARM1 will 
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4.2. Biological evaluation of bisubstrate inhibitors of CARM1 
Bisubstrate inhibitors and asymmetric dimetilated peptide 141 and 144 
(ADMA) (Figure 4.11) were evaluated as inhibitors of PRMT1 and 4. 
Enzyme activity was measured using an established chemiluminescence-based 
assay wherein a substrate peptide derived from histone H3 tail is treated with 
AdoMet (1 µM) and the methyltransferase of interest (PRMT1 80 ng per 
reaction, PRMT4 200 ng per reaction). After incubation, a primary antibody is 
then added to specifically bind the methylated arginine residue followed by 
washing and treatment with a horseradish peroxidase (HRP) conjugated 
secondary antibody. In the final step, an HRP substrate is added to generate a 
chemiluminescent signal that is measured using a standard microplate reader. 
Inclusion of potential inhibitors in the first step of this process in turn allows 
for the convenient detection and quantization of enzyme inhibition (Figure 
4.10). 
 
Figure 4.10. Chemiluminescent Assay 
Bisubstrate inhibitors and the asymmetrically dimethylated peptide (Figure 
4.11), were initially screened against PRMT1 and PRMT4 at a threshold 
concentration of 50 μM, in order to assess the biological activity. The known 
methyltransferase inhibitor S-adenosyl-L-homocysteine (AdoHcy), a by-
product of the AdoMet cofactor resulting from methylation, was also included 
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as a reference compound. Blanks and substrate controls were done in the 
absence of the enzyme and AdoMet respectively. 
 
 
Figure 4.11. Structures of tested compounds 
As shown in Figure 4.12 A and B, the bisubstrates inhibitors P1-C2, C3-sat, 
C3-unsat and P2-C2, C3-sat, C3-unsat displayed more than 50% inhibition 
of the PRMTs tested, whereas the asymmetrically dimethylated peptides (P1 
and P2 ADMA) did not show any inhibitory activity against PRMT1 or 
PRMT4. In cases where no appreciable inhibition was observed at 50 μM 
further inhibition studies were not performed. Conversely, in cases where 
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>50% inhibition was observed at the threshold inhibitor concentration of 50 
μM, complete IC50 curves were generated from at least seven unique inhibitor 






Figure 4.12. A) PRMT1 enzymatic inhibition assays at fixed dose 50µM. B) PRMT4 





























    
AdoHcy 8.0 0.24 33 
    
P1-C2 25 1.8 13 
    
P2-C2 26 3.2 8 
    
P1-C3-sat 24 0.078 307 
    
P2-C3-sat 26 0.070 370 
    
P1-C3-unsat 3.7 0.037 100 
    
P2-C3-unsat 39 0.043 906 
    
aIC50 values (µM) based on the best fit of dose-response curves generated from at least seven 
unique inhibitor concentrations (from 250 µM to 1 nM). Curve fitting performed with 
GraphPad Prism 5.0 
Table 4.3. IC50 values of tested compounds 
 
Our preliminary screening confirms our hypothesis that selective and potent 
inhibition of PRMT4 is achieved by compound characterized by structural 
features able to bind both the substrate binding sites (Table 4.3). The 
bisubstrate inhibitors generally display a potent and selective inhibition of 
PRMT4 with IC50 values between 3.2 µM and 43 nM. Based on these 
preliminary results it is possible to speculate that the linkers between the 
adenosine ring and the guanidine function of the peptide fragments [2 carbons 
spacer (P1-C2 and P2-C2 compouds), saturated or unsaturated 3 carbons 
spacer (P1-C3-sat, P2-C3-sat, P1-C3-unsat and P2-C3-unsat compounds)] 
play a pivotal role for the correct positioning of the inhibitors warheads, 
influencing the potency of compounds. On the other hand the selectivity of 
compounds seems to be regulated by the peptide sequences,  
(P1 =Ac-Phe-Gln-Asn-Met-Pro-Ala-Ile-Arg-Pro-Ala-Ala-Pro-NH2; P2 = Pro-
Ala-Ala-Pro-Arg-Pro-Pro-Phe-Ser-Thr-Met). As it is reported in Chapter 2 
(paragraph 2.3, pag. 66) these peptide fragments have been taken from PABP1 
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and contain respectively the residues of R455 and R460, which are recognized 
and methylated by PRMT4.  
Exception to this trend is represented by compounds P1-C2 and P2-C2, 
characterized by a two carbon spacer between the guanidine moiety and the 
adenosine ring. Indeed, they display the lowest potency and selectivity against 
PRMT4 (P1-C2 IC50 = 1.8 µM, P2-C2 IC50 = 3.2 µM), suggesting that their 
shorter linker between the two fragments is not optimal for mimicking the 
transitional state of the methyl transfer reaction. The two carbon spacer of 
compounds P1-C2 and P2-C2 probably does not allow to a correct positioning 
of the adenosine and peptidic fragments within the substrate binding pockets. 
This could also explain their lower selectivity toward PRMT4 vs PRMT1 and 
their lower potency compared to the shorter analogue 17a, a partial bisubstrate 
inhibitor developed by Martin et al.142 (Figure 4.13). 
 
Figure 4.13. Comparison of bisubstrate inhibitors P1-C2 and P2-C2 with their shorter 
analogue compound 17a. 
 
Conversely bisubstrate inhibitors bearing the saturated and unsaturated 3-
carbons linkers seem to be able to most closely approximate the PRMT4 
transition state. Indeed P1-C3-sat, P2-C3-sat, P1-C3-unsat and P2-C3-unsat 
show a nanomolar inhibition of CARM1 with IC50 values of 78, 70, 37, 43 nM 
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respectively (Table 4.3). These compounds are largely more potent and 
selective than their shorter analogues 17b and 17c142 (Figure 4.14), which are 
characterized by an adenosine ring linked to a guanidine moiety through a 
saturated or unsaturated three carbons linkers (Figure 4.14 and 4.15).  In these 
cases the presence of the peptide fragment leads to a net improvement of 
activity [IC50 = 0.078 µM and 0.070 µM (P1-C3-sat and P2-C3-sat) vs IC50 = 
0.15 µM (17c); IC50 = 0.037 µM and 0.043 µM (P1-C3-unsat and P2-C3-
unsat) vs IC50 = 0.56 µM (17b)]. 
 
Figure 4.14. Comparison between bisubstrate inhibitors P1-C3-sat and P2-C3-sat with the 
partial bisubstrate inhibitor 17c 




Figure 4.15. Comparison between bisubstrate inhibitors P1-C3-unsat and P2-C3-unsat with 
the partial bisubstrate inhibitor 17b 
 
Comparing the bisubstrate inhibitors bearing the three carbons linkers, the 
results of the inhibition studies revealed that compounds P1-C3-unsat and P2-
C3-unsat which show a double bond in their alkyl spacer are more potent 
PRMT4 inhibitors than compounds P1-C3-sat and P2-C3-sat which contain a 
fully saturated spacer [(IC50 = 37 nM (P1-C3-unsat) vs IC50 = 78 nM (P1-C3-
sat); IC50 = 43 nM (P2-C3-unsat) vs IC50 = 70 nM (P2-C3-sat)] (Figure 
4.16).  




Figure 4.16. Derivatives P1-C3-unsat and P2-C3-unsat are more PRMT4 inhibitors than 
their saturated analogues P1-C3-sat and P2-C3-sat 
 
Interestingly, the peptide sequences seem to influence the selectivity of 
compounds toward PRMT4 vs PRMT1 without affecting dramatically the 
potency. In particular compounds bearing the shorter peptide sequence (P2-
C3-sat and P2-C3-unsat) showed the highest selectivity (Figure 4.17). 
Compound P2-C3-unsat shows a near 900 fold selective inhibition towards 
CARM1 over PRMT1, whereas its analogue with a longer peptide sequence 
P1-C3-unsat displays a similar potency, but less selectivity toward CARM1 
vs PRMT1(PRMT1/PRMT4 IC50 ratio = 100) (Figure 4.17). Although to a 
lesser extent, also for compounds bearing a fully saturated spacer (P1-C3-sat 
and P2-C3-sat) is possible to verify a difference of selectivity 
[PRMT1/PRMT4 IC50 ratio = 370 (P2-C3-sat) vs PRMT1/PRMT4 IC50 ratio = 
307 (P1-C3-sat)] (Figure 4.17). 
 
 




Figure 4.17. Effect of the peptide sequences on the selectivity against PRMT4 over PRMT1 
 
The potent and selective CARM1 inhibition activities displayed by compounds 
P1-C3-sat, P2-C3-sat, P1-C3-unsat and P2-C3-unsat in vitro assay, place 
them amongst the most active PRMT4 inhibitors reported to date. Further 
biochemical and biophysical assays are necessary in order to better 
characterize their activity and their inhibition mechanism.  
Crystal structures of CARM1 and bisubstrate inhibitors will be also solved in 
order to elucidate the accommodation of these molecules within the CARM1 
binding sites. The information obtained from these studies could provide 
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4.3. Biological evaluation of PRMT3 indole inhibitors  
The indole derivatives of Series I and II (reported in Figure 4.13) were 
preliminarily tested at fixed dose (100 µM) in duplicate against PRMT1 and 
PRMT3 using biotinylated histone H4 as substrate and SAM as cofactor, 
employing Alphascreen technology.  
4.3.1 General principles of Alphascreen technology 
AlphaScreen is a bead-based, non-radioactive Amplified Luminescent 
Proximity Homogeneous Assay. When a biological interaction brings the 
beads together, a cascade of chemical reactions acts to produce a greatly 
amplified signal. On laser excitation, a photosensitizer in the “Donor” bead 
converts ambient oxygen to a more excited singlet state. The singlet state 
oxygen molecules diffuse across to react with a thioxene derivative in the 
Acceptor bead generating chemiluminescence at 370 nm that further activates 
fluorophores contained in the same bead. The fluorophores subsequently emit 
light at 520-620 nm (Figure 4.18). In the absence of a specific biological 
interaction, the singlet state oxygen molecules produced by the Donor bead go 
undetected without the close proximity of the Acceptor bead. As a result, only 
a very low background signal is produced.  
 
Figure 1.18. When biological interactions bring the Donor and Acceptor beads into close 
proximity, a highly amplified signal with output in the 520-620 nm range is generated. 
 




Indole compounds of Series I and II (Figure 1.19) were tested as inhibitors at 
100 µM against PRMT1 and PRMT3 using a biotinylated histone H4-derived 
peptide (1-21) as substrate, SAM as cofactor and AMI-1 as reference inhibitor. 
Detection of the histone H4 arginine 3 methylated product is achieved through 
the addition of Streptavidin (SA) Alpha Donor beads and AlphaLISA 
Acceptor beads conjugated to an antibody (Ab) directed against the mark of 
interest. Upon laser irradiation of the beads-target complexes at 680 nm, short-
lived singlet oxygen molecules produced by the Donor beads can reach the 
Acceptor beads in proximity to generate an amplified chemiluminescent signal 
at 615 nm. The intensity of the light emission is proportional to the 







Figure 4.19. Structures of tested compounds 
Compounds of Series I and II bearing the aromatic moiety at the right end of 
the molecule (Figure 4.20) were not tested for problems of solubility. Also the 
amino derivatives 164a and 171a were not tested since they showed high 
instability (Figure 4.20).  




Figure 4.20. Indole compounds bearing the aromatic moiety at the right and of the molecules 
as well as amino derivatives 164a and 171a were not tested against PRMT1and PRMT3 for 
problems of solubility or instability. 
In Figure 4.21 are reported the results of PRMT1 and PRMT3 enzymatic 
assays. EML598 and 599 show an appreciable inhibition of PRMT3 at 100 
µM, without affecting the activity of PRMT1. To date is ongoing the screening 
of the biological activity of Series III compounds against PRMT1 and 
PRMT3. 
 
Figure 4.15. Enzymatic in vitro inhibion assay against PRMT1 and PRMT3, using a 
biotinylated histone H4-derived peptide (1-21) as substrate, SAM as cofactor and AMI-1 as 
reference inhibitor 
 
                                                                                               Chapter 4: Biology 
136 
 
In addition, considering that these derivative have been developed starting 
from activators of PRMT4 (Uracandolates), we decided to assess the activity 
of some selected indole compounds against CARM1 through enzymatic 
inhibition assay at fixed dose (50 µM), in order to verify the presence of 
possible interferences. As it is shown in Figure 4.16, indole derivatives didn’t 
show any activity against CARM1. 
 
Figure 4.16. CARM1 in vitro inhibition assay at fixed dose (50 µM) 
 
Once assessed the activity of all the synthesized indole derivatives through 
enzymatic assay at fixed dose (100 µM), the IC50 values of the most potent 
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As it is discussed in Chapter 4, pyrrole derivatives, designed as inhibitors of 
CARM1, didn’t prove any effects against the enzyme target in cell-based 
assay, due to their poor cell permeability. On these basis, being interested on 
developing more potent and cell permeable derivatives, supported by 
computational studied performed by Professor Giuseppe Bifulco from the 
University of Salerno, we decided to start a structural optimization process of 
the synthesized pyrrole inhibitors. In fact, the high synthetic versatility of the 
pyrrolic ring could allow us to do different structural modifications of the 
compounds here described (Chapters 2, 3 and 4), in order to enhance 
enzymatic inhibition and cell permeability.  
First of all the binding modes of pyrrolic derivatives were investigated then 
novel derivatives with different substitution patterns were designed.  
 
5.2.  Binding mode of EML438 and design of new derivatives 
The computational studies were performed by molecular docking (Glide 
software version 6.1, standard and extra precision level) using as a model the 
X–ray structures of human CARM1 co-crystallized with indole CMPD1 or 
pyrazole CMPD2 inhibitors in complex with cofactors [SAH (S-adenosyl- L-
homocysteine) or SNF (sinefungin)] (Figure 5.1). 152 Comparison of the 
binding mode of CMPD-1 and CMPD-2 reveals that the two inhibitors, since 
use different regions of the binding pocket that exists at the interface between 
the two domains of CARM1 (Figures 5.1), both exploit the arginine-binding 
cavity; site where the transfer of methyl group from the cofactor to the 
peptidic substrate takes place. Here they make polar interactions (H-bond) 
with Met260, Glu266 and Glu257, residues known to be critical for substrate 
recognition; π- π interaction with His414 and van der Waals interaction with 
Phe153, indicative of a good accommodation within the CARM1 binding site. 
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These interactions play a major role in influencing CARM1 functionality, 






Figure 5.1. Superpositions of the CARM1−H3 R17(Me) complex (green/yellow) with 
CMPD1 (purple) and CMP2 (gray) inhibitors.. 
 
In light of the elucidated structural insights, we evaluated the binding mode of 
our best pyrrole inhibitors, EML438, by molecular docking experiments. 
These studies revealed that the pyrrole compound, although maintains a 
similar contact patterns of CMPD1 and CMPD2 within the arginine-binding 
cavity, is not able to completely exploit the binding pocket that exists at the 
interface between the two domains of CARM1. This is clearly demonstrated 
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by the structures superimposition of CMPD1, CMPD2, pyrazole inhibitor 54  
and EML438 docked into PRMT4 binding site (Figure 5.2).  
 
 
Figure 5.2. Overlay of CMPD1 (blue), CMPD2 (pink salmon), pyrazole inhibitor 54 (purple)  
and EML438 (green) structures within  the CARM1 binding pocket 
 
This data suggests the possibility of decorating the pyrrole scaffold with 
additional substituents, in order to improve the binding properties of pyrrole 
derivatives. To this end, the selection of bulky moieties will also ensure an 
improvement of the lipophilicity of the molecules, guaranteeing the 
development of new derivatives suitable for cell-based assays. 
Therefore, we focused on designing three class of related analogues of 
EML438 and EML446, preserving the N-phenyl-pyrrole scaffold, because of 
its good shape complementarity with the enzyme, and the S-alanine moiety, 
essential for the CARM1 inhibition, since it is interested in key interactions 
within the arginine binding cavity.  
More than 100 compounds were designed making precise and accurate 
modifications. All compounds were divided in three classes (A, B and C) 
according to the different substitution patterns (Figure 5.3).  
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Figure 5.3. Structural optimization of EML438 and 446. 
 
As it is highlighted in Figure 5.3 compound of series A are characterized by 
the functionalization of the benzylamidic aromatic ring (highlight in violet), 
whereas the addition of a second heterocycle at the right or left side of the N-
phenyl-pyrrolic scaffold led to the design of Series B and C derivatives. 
Then, the ability of these novel derivatives to bind the targets, expressed by a 
Glide score (kcal/mol) and by the number of key interactions established with 
the arginine binding cavity of CARM1, were considered. For the calculated 
binding mode the interactions with the following amino acids were considered 
discriminant: (a) H-bond with Met 260, Glu266 and Glu257; (b) π- π 
interaction with His414; (c) van der Waals interaction with Phe153.  
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Furthermore, employing the QuikProp program, the prediction of apparent 
Caco-2 cell permeability (QikProp program) was calculated for all the 
designed derivatives. 
According to the score of the aforementioned properties, were selected 
derivatives with: (a) Glide score ≥ 8 kcal/mol, (b) number of interaction with 
key residues of the arginine binding cavity ≥ 3 and (c) apparent Caco-2 
permeability ≥ 2 nm/sec.  
Notably, a first set of molecules (Table 5.1), structural related to EML438 and 
EML446, has been selected in order to validate the computational model. 
These compounds, although not suitable for cellular assays due to their low 
predicted apparent permeability, display the highest binding properties and, 
compared to compounds of Series B and C, a greater ease of synthesis.  
In accordance with the computational outcomes, the selected molecules of 
Series A should have the best in vitro potency. If biological evaluation of these 
molecules confirm our hypothesis, furher efforts will be focused on the 
synthesis of series B and C compounds, which, although less simple from a 
synthetic point of view, display interesting properties of binding mode as well 
as good values of predicted apparent permeability (Table 5.2). 































































































































Table 5.1. Most promising pyrrole derivatives. 
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The present PhD project was focused on design, synthesis and biological 
evaluation of new small-molecule modulators of Protein Methyltransferases, 
with particular interest for PRMT3 and CARM1 (Coactivator associated 
Arginine Methyltransferase 1), also known as PRMT4. 
The first objective of my PhD project was the design, synthesis and biological 
evaluation of a small set of novel pyrrole-based CARM1 inhibitors. These 
compounds were designed taking into account the information obtained from 
the structure-activity relationships (SAR) of pyrazole and indole compounds, 
the most potent PRMT4 inhibitor, which, however, lack activity in cell-based 
assays. We hypothesized that the pyrrole ring, considered as a result of 
isosteric substitution of pyrazole together with opening and simplifation of the 
indole ring, would be a good scaffold for targeting CARM1. Indeed, a potent 
inhibition was observed when testing pyrrole derivatives against CARM1 (i.e. 
EML 438, IC50 = 2.42 µM), nevertheless they didn’t prove a significant 
cellular activity, due to their poor transcellular permeability. Docking studies 
were also performed with pyrrole compounds and PRMT4, in collaboration 
with the group of Professor Giuseppe Bifulco from the University of Salerno. 
These studies suggest many possibilities for further improving the inhibitor 
affinity and the cell permeability of the pyrrole modulators by structural 
optimization. To this end, facilited by the high synthetic versatility of the 
pyrrole ring and considering the structure-activity relationships of the 
inhibitors, further pyrrole derivatives have been designed and identified. To 
date the synthesis and biological evaluation of the new selected compounds 
are still ongoing. 
Furthermore, in collaboration with Professor Nathaniel Martin from the 
University of Utrecht, we have successfully synthesized a set of novel 
potential PRMT4 bisubstrate inhibitors, providing a convenient synthetic route 
to link SAM analogues with peptide substrate portions, through variable 
guanidine linkers. Preliminary screening of their biological activity revealed a 
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nanomolar inhibition of PRMT4 (P2-C3-unsat, IC50 = 43 nM) with about 
900-fold selectivity for CARM1 over PRMT1. These results confirm our 
hypothesis that selective and potent inhibition is achieved by compounds 
characterized by structural features able to bind both the substrate binding sites 
and mimic the transition state. The potency and the selectivity displayed by 
bisubstrate inhibitors against PRMT4 place them as one of the most interesting 
set of chemical tools for studying the enzyme target. Further biological and 
biophysical assays are ongoing in order to better asses the selectivity, the 
binding mechanism and the pharmacokinetic properties of these compounds. 
Moreover crystal structures of bisubstrate inhibitors with PRMT4 will be 
solved.  These christallografic structures may provide a meaningful guidance 
in designing novel CARM1 inhibitors. 
We also started a program aiming at developing inhibitors of PRMT3. In 2012 
we discovered a class of indole derivatives, with aryl ureido acetamido indole 
carboxylate structures (dubbed Uracandolates), characterized by a peculiar 
activity against the PRMTs. They were able to enhance the activity of CARM1 
both in vitro and cellular setting, providing, at the same time, an inhibitory 
activity, although low, against PRMT3. Therefore with the aim to develop 
novel inhibitors of PRMT3, we decided to properly modify the structure of 
Uracandolate compounds. Ispired by the SAR information of benzothiadiazole 
and isoquinoline allosteric inhibitors developed by Jin and coll., we designed 
and synthesized three series of indole-based compounds. Their inhibitory 
activities were assessed against a panel of PRMTs (PRMT1, PRMT3 and 
PRMT4), testing compounds at fixed dose (100 µM) in duplicate. EML598 
and EML599 display a selective inhibition of PRMT3 (70 % of PRMT3 
inhibition at 100 µM). To date, further biochemical assays are ongoing in 
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7.1. General information 
All chemicals were purchased from Aldrich Chimica (Milan, Italy) and were 
of the highest purity. All solvents were reagent grade. Reactions were 
routinely monitored by TLC performed on aluminum-backed silica gel plates 
(Merck DC, Alufolien Kieselgel 60 F254) with spots visualized by UV light (l 
¼ 254, 365 nm). Solvents were removed using a rotary evaporator operating at 
a reduced pressure of _10 Torr. Organic solutions were dried  over anhydrous 
Na2SO4. Chromatographic purifications were done on an automated flash-
chromatography system (Isolera ™One, Biotage) using cartridges packed with 
KP-SIL, 60 °A (40–63 mm particle size). High performance liquid 
chromatography (HPLC) was performed on a Shimadzu SPD 20A UV/VIS 
detector (l ¼ 215 nm) using C-18 column Phenomenex Synergi Fusion – RP 
80A (75 _ 4.60 mm; 4 mm) at 25 _C using a mobile phase A (water + 0.1% 
trifluoracetic acid (TFA)) and B (MeCN + 0.1% TFA) at a flow rate of 1 mL 
min_1. The following gradient was applied: isocratic elution for 1 min at 10% 
of solvent B, linear increase from 10% to 95% of solvent B over 10 min, hold 
at 95% solvent B for 3 min.   
Melting points were determined on a Stuart SMP30 melting point apparatus in 
open capillary tubes and are uncorrected. 1H spectra were recorded at 300 
MHz with a Bruker Avance 300 spectrometer. Chemical shifts are reported in 
δ (ppm) relative to the internal reference tetramethylsilane (TMS). When the 
NMR analysis is not included, compounds were used in the next step without 
further purification. Mass spectra were recorded on a Finnigan LCQ DECA 
TermoQuest (San Jose, CA) mass spectrometer in electrospray positive and 
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7.2. Pyrrole derivatives 
Synthesis of Synthesis of (E)-4-ethoxy-1,1,1-trifluorobut-3-en-2-one (87)156 
 
To a stirred solution of 4-dimethylaminopyridine (12.0 mg, 0.10 mmol) and 
trifuoro acetic anhydride (3.28 gm, 15.62 mmol) in dichloromethane (20.00 
ml), ethyl vinyl ether (1.06 g, 14.70 mmol) was added dropwise at -10 °C. 
The reaction mixture was stirred for 19 h at 0°C, allowed to warm to room 
temperature and the solvent was evaporated in vacuo. The reaction mixture 
was poured into sodium bicarbonate solution (the deep violet colour changed 
to a yellow colour), the two phases were separated and the organic phase was 
washed with water, dried over anhydrous sodium sulfate and the solvent was 
evaporated in vacuo to give the crude title compound (87) as a yellow oil (2.00 
gm, 81%). The crude product was used directly in subsequent step without 
further purification. 1H NMR (300 MHz, CDCl3): δ 7.89 (d, J = 12.3 Hz, 1H), 
5.85 (d, J = 12.3 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H). 
ESI-MS m/z: 169.3 (M + 1)+. 
Synthesis of  (E)-4-ethoxy-2-(trifluoromethyl)-2-((trimethylsilyl)oxy)but-
3-enenitrile (88)156 
 
To a mixture (0.5 mmol, 50 mg) Et3N and TMSCN (13 mmol, 1.29 g) was 
added 10 mmol of ketone 85 at 0-5 C under stirring. Then the mixture was 
stirred for 12h at RT, and the product was isolated by vacuum distillation 
(80%).  
1H NMR (300 MHz, CDCl3) 5:0.26 (s, 9 H), 1.32 (t, 3 H, J = 7.1 Hz), 3.85 (q, 
2 H, J=7.1 Hz), 4.83 (d, 1 H, J = 12.5 Hz), 6.98 (d, 1 H, J = 12.5 Hz). ESI-MS 
m/z: 268.0 (M + 1)+. 




Synthesis of  (E)-2-(aminomethyl)-4-ethoxy-1,1,1-trifluorobut-3-en-2-ol 
(89)156 
 
To a suspension of LiAlH4 (2.03 g, 53.5 mmol) in dry ether (50 mL) 88 (12.99 
g, 48.6 mmol) was added dropwise with stirring for 30 min at 0–5 °C. The 
mixture was stirred overnight at room temperature. Excess LiAlH4 was 
decomposed with 30% aq NaOH (10 mL) with stirring at 0° C, then 
precipitated alumina was filtered and washed thoroughly with ether (3 x 50 
mL). The filtrate was dried (Na2SO4) and concentrated under reduced pressure 
to give a brown oil (5.8 g, 60%). The productwas used directly in subsequent 
step without further purification. 1H NMR (300 MHz, CDCl3): δ 6.75 (d, J = 
12.6 Hz, 1H), 5.32 (m, 2H, exchangeable with D2O) 4.71 (d, J = 12.6 Hz, 1H), 
3.77 (q, J = 7.0 Hz, 2H), 3.13 (s, 1H, exchangeable with D2O), 2.69 (d, J = 





To a mixture of amino alcohols 88 (0.8 g, 4 mmol) and Et3N (0.404 g, 4 
mmol) in dry DCM (30 mL), benzoyl chloride (0.562 g, 4 mmol) was added at 
0 C. The mixture was stirred for 2 h at room temperature and water (15 mL) 
was added. The organic phase was washed with saturated aqueous solution of 
NaHCO3 (3 x 20 mL) and water (3 x  25 mL). The aqueous layer was extracted 
                                                                        Chapter 7: Experimental section  
156 
 
with DCM (3 x 25 mL) and the combined organic layers were dried (NaSO4) 
and then evaporated. Compound 93 was obtained as a yellow oil after 
purification by column chromatography on silica gel (eluent EtOAc/hexane 
1:6). 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 7.2 Hz, 2H), 7.59 – 7.50 (m, 
1H), 7.44 (t, J = 7.4 Hz, 1H), 6.80 (d, J = 12.4 Hz, 1H), 6.64 (bs, 1H), 5.10 
(bs, 1H), 4.73 (d, J = 12.4 Hz, 1H), 3.99 – 3.86 (m, 1H), 3.76 (q, J = 7.0 Hz, 
2H), 3.69 – 3.53 (m, 2H), 1.25 (t, J = 7.0 Hz, 3H). ESI-MS m/z: 304 (M + 1)+. 
Synthesis of phenyl(3-(trifluoromethyl)-1H-pyrrol-1-yl)methanone (94).  
 
A mixture of DCM/TFA  7:3 (2mL) was added to compound 93 (0.191 g, 0.63 
mmol). The reaction  was stirred at room temperature overnight  and then 
concentrated in vacuo to give the title compound as a yellow oil (0.150 g, 
99%).  1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 7.1 Hz, 2H), 7.71 – 7.63 (m, 
1H), 7.63 – 7.51 (m, 3H), 7.37 – 7.31 (m, 1H), 6.56 – 6.49 (m, 1H). ESI-MS 
m/z: 478.8 [(M x 2) + 1] +. 
Synthesis of 2,2,2-trichloro-1-(4-(trifluoromethyl)-1H-pyrrol-2-
yl)ethanone (95).  
 
To a solution of 94 (0.500 g, 2.1 mmol) in Dioxane/H2O 1: 1 (3 mL) was 
added LiOH (0.050 g, 2.1 mmol). The reaction was sealed and left to stirr at 
room temperature for 4h. Water was added and the aqueous layer was 
extracted with DCM (3 x 3 mL). The combined  organic layers were dried 
(Na2SO4) , filtered and placed into the vessel. Then trichloroacetyl chloride 
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was added  (3.81 g ,21 mmol was stirred at 70 °C for 36 h. The mixture was 
diluted with DCM (100 mL) and washed with  satured aqueous solution of 
NaHCO3 (5 x 30 mL), Brine (1 x 10 mL), dried (Na2SO4), filtered and 
evaporated under vacuum. The residue was purified by silica gel 
chromatography (ethyl acetate : petroleum ether, 5 : 95 ) to give the title 
compound as a yellow solid (0.329 g, 56 %); m.p. 107 - 109 °C. 1H NMR (300 
MHz, CDCl3) δ 9.61 (bs, 1H, exchangeable with D2O), 7.53 – 7.48 (m, 1H), 
7.47 – 7.42 (m, 1H). ESI-MS m/z : 277.85 (M – 1)-.  




95 (0.100 g, 0.36 mmol), K2CO3 (0.148 g, 1.8 mmol) and benzylamine (0.148 
g, 1.08 mmol) were dissolved in DMF (5 mL) at room temperature in a 35 mL 
CEM pressure vessel equipped with a stirrer bar. The vial was sealed and 
heated in a CEM Discover microwave synthesizer (max power 300W, max 
internal pressure 250 psi) to 80 °C (measured by the vertically focused IR 
temperature sensor) for 30 min. The cold reaction mixture was diluted with 
H2O (100 mL) and extracted with AcOEt (3 x 30 mL). The combined organic 
layers were washed with 0.5 N HCl (3 × 30 mL), NaHCO3 saturated aqueous 
solution and brine. The organic phase was dried (Na2SO4), filtered, and 
concentrated in vacuo. The residue was purified by silica gel chromatography 
(ethyl acetate : petroleum ether, 1:9 to 2:8) to give the title compound as a 
yellow solid (0.066 g, 68%), mp 128 – 130 °C. 1H NMR (300 MHz, CDCl3): δ 
10.18 (bs, 1H, exchangeable with deuterium oxide), 7.42 – 7.29 (m, 5H), 7.23 
– 7.15 (m, 1H), 6.77 – 6.67 (m, 1H), 6.22 (t, J = 5.8 Hz, 1H, exchangeable 
with deuterium oxide), 4.62 (d, J = 5.8 Hz, 2H). ESI-MS m/z : 267.8 (M + 1)+. 




2-carboxamide (97).  
 
3-bromobenzonitrile (0.156 g, 0.82 mmol) and CuI (0.156  g, 0.82 mmol ) 
were suspended in Dioxane dry (1.2 mL) at room temperature in a 10 mL 
CEM pressure vessel equipped with a stirrer bar. The vial was degassed and 
N1,N2-dimethylethane-1,2-diamine (1.65 mmol, 0.145 g) was added to a 
mixture. The reaction was stirred at room temperature for 5 minutes and then 
compound 96 (0.200 g, 0.75 mmol) and K3PO4 (0.316 g, 1.49 mmol) were 
added. The reaction was degassed and heated in a CEM Discover microwave 
synthesizer (max power 300W, max pressure 250 psi) to 130 °C for 30 min, 
then water (10 ml) was added and the mixture was extracted with ethyl acetate 
(3 x 10 mL). The combined organic layers were washed with brine, dried 
(Na2SO4), filtered and concentrated in vacuum. The residue was purified by 
silica gel chromatography (ethyl acetate : petroleum ether, 1:1) to give the title 
compound as a white solid (0.221 g, 80%); m. p. 162 – 164 °C. 1H NMR (300 
MHz, CDCl3): δ 7.72 (d, J = 6.3 Hz, 1H), 7.67 – 7.49 (m, 3H), 7.44 – 7.27 (m, 
5H), 7.20 (s, 1H), 6.87 (s, 1H), 6.22 (s, 1H,exchangeable with D2O), 4.49 (d, J 
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 NaBH4 (0.090g, 2.6 mmol) was added over 30 min to a solution of 
NiSO4•6H2O (0.012 g, 0.049 mmol), and Compound 97 (0.180 g, 0.49 mmol) 
in MeOH (15 ml) at 0°C. The mixture was stirred, at room temperature, for 3 h 
and then was added NaHCO3 saturated aqueous solution (3 x 30 mL). The 
aqueous layer was extracted with EtOAc (3 x 10 m), the combined layers were 
washed with brine (3 x 10 mL), dried (Na2SO4), filtered and concentrated in 
vacuo. The residue was purified by silica gel chromatography (ethyl acetate : 
petroleum ether, 1:1) to give the title compound as a white gel (0.115 g, 63%). 
1H NMR (300 MHz, DMSO): δ 8.95 (t, J = 5.6 Hz, 1H, exchangeable with 
deuterium oxide), 7.74 – 7.58 (m, 1H), 7.41 – 7.23 (m, 8H), 7.21 – 7.13 (m, 
2H), 4.33 (d, J = 5.6 Hz, 2H), 3.89 – 3.68 (m, 2H), 3.53 – 3.31 (m, 2H, 
exchangeable with deuterium oxide). ESI-MS m/z :  374 (M + 1) +. 
Synthesis of (S)-tert-butyl (1-((3-(2-((2-methoxybenzyl)carbamoyl)-4-
(trifluoromethyl)-1H-pyrrol-1-yl)benzyl)amino)-1-oxopropan-2-
yl)carbamate (99).  
 
To a solution of 98 (0.115 g, 0.31 mmol), DMAP (0.004 g, 0.031 mmol) and 
Boc-L-Ala-OH (0.087 g, 0.46 mmol) in DCM dry (6.5 mL) was added DCC 
(0.095 g, 0.46 mmol). The mixture was left to stir at room remperature 
overnight, and then was filtered and concentrated under vacuum. The residue 
was dissolved with DCM (100 mL) and washed with saturated aqueous 
solution  of NaHCO3 (3 x 30 mL) and brine. The organic phase was dried over 
Na2SO4, filtered and concentrated under vacuum. The title compound 99 was 
obtained as white solid  (0.147 g, yield 87 %) after purification by silica gel 
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chromatography (ethyl acetate : petroleum ether, 1:1); mp 165 – 166  °C. [α]D  
-2.6  (c 0.3, MeOH). 1H NMR (300 MHz, DMSO): δ 8.91 (t, J = 5.4 Hz, 1H, 
exchangeable with deuterium oxide ), 8.44 – 8.27 (m, 1H, exchangeable with 
deuterium oxide), 7.72 – 7.55 (m, 1H), 7.38 – 7.14 (m, 10H), 7.04 – 6.90 (m, 
1H, exchangeable with deuterium oxide), 4.40 – 4.20 (m, 4H), 4.04 – 3.85 (m, 
1H), 1.34 (s, 9H), 1.19 (d, J = 7.0 Hz, 3H). ESI-MS m/z:  544.8 (M + 1) +.  
 
Synthesis of (S)-1-((3-(2-(benzylcarbamoyl)-4-(trifluoromethyl)-1H-
pyrrol-1-yl)benzyl)amino)-1-oxopropan-2-aminium (100).  
 
Compound 99 was dissolved with a mixture of DCM/TFA (9:1, 4 mL) and 
lefto to stir at room temperature for 30 min. The desidered product 100 was 
obtained as white solid after evaporation of the mixture of reaction under 
vacuum; mp 110 - 113  °C. [α]D  + 8.9  (c 0.3, MeOH). 
1H NMR (300 MHz, 
DMSO):δ 9.00 – 8.85 (m, 2H, exchangeable with deuterium oxide), 8.17 – 
8.03 (m, 3H, exchangeable with deuterium oxide), 7.71 – 7.63 (m, 1H), 7.45 – 
7.35 (m, 2H), 7.33 – 7.13 (m, 8H), 4.42 – 4.36 (m, 2H), 4.33 (d, J = 5.6 Hz, 
2H), 3.93 – 3.84 (m, 1H), 1.38 (d, J = 6.8 Hz, 3H). ESI-MS m/z:  445.11 (M + 
1)+. 
Synthesis of 1-(3-nitrophenyl)1H-pyrrole (103a) 165.  
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A solution of 3-nitroaniline (1.9 g, 13.7 mmol) and 2,5-
dimethoxytetrahydrofuran (15.1 mmol, 2.0 g) in glacial acetic acid (10 mL) 
was heated at 80 °C for 2 h. After cooling, the solvent was evaporated under 
vacuo. The residue was made basic with a saturated aqueous solution of 
NaHCO3 (150 mL) and extracted with ethyl acetate (3 x 50 mL). The organic 
layer was washed with brine (20 mL), dried over Na2SO4 and filtered. After 
evaporation of the solvent, the crude mixture was purified by flash silica gel 
chromatography (ethyl acetate: n-hexane = 1:9 as eluent) to furnish 103a (2.26 
g, 84%) as yellow solid, mp 73 – 74 °C. 1H-NMR (300 MHz, CDCl3): δ= 8.44 
(t, 1H, J = 2.26 Hz), 8.30 (d, 1H, J = 8.30 Hz), 7.93-7.90 (m, 1H), 7.82-7.75 
(m, 1H), 7.35 (t, 2H, J = 2.26 Hz), 6.60 (t, 2H, J = 2.26 Hz). ESI-MS m/z: 
189.1 (M + 1)+. 
Synthesis of 3-(1H-pyrrol-yl)benzonitrile (103b) 166.  
 
 Compound 103b was obtained as a yellow solid (2.3 g, 80%) from compound 
101b (1.6 g, 13.7 mmol) and 102a (2.0 g, 15.1 mmol), according to the 
procedure used for 103a. 1H NMR (CDCl3) δ: 6.41 (t, J ) 2.2 Hz, 2H), 7.09 (t, 
J ) 2.2 Hz, 2H), 7.51-7.55 (m, 2H), 7.60-7.66 (m, 2H). ESI-MS m/z: 169 (M + 
H) 
 
Synthesis of  2,2,2-trichloro-1-(1-(3-nitrophenyl)-1H-pyrrol-2-yl)ethanone 
(104a).  
 
A mixture of trichloroacetyl chloride (5.4 g, 29.7 mmol) and 103a (1.0 g, 2.97 
mmol) ) were placed into CEM pressure vessel equipped with a stirrer bar. 
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The vial was sealed and heated in a CEM Discover microwave synthesizer 
(max power 300W, max internal pressure 250 psi) to 140 °C (measured by the 
vertically focused IR temperature sensor) for 1.5 h. The cold reaction mixture 
was diluted with CHCl3 (100 mL) and washed with a saturated aqueous 
solution of NaHCO3 (3 x 20 mL) and Brine. The organic layer was dried, and 
filtered. Removal of a solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate: petroleum ether 1:9 as eluent) to 
give 104a (1.40 g, 60%) as a yellow solid;  mp 100 – 101°C. 1H NMR (300 
MHz, CDCl3): δ 8.35 – 8.29 (m, 1H), 8.21 – 8.14 (m, 1H), 7.73 – 7.68 (m, 
1H), 7.68 – 7.63 (m, 2H), 7.15 – 7.10 (m, 1H), 6.52 – 6.45 (m, 1H). ESI-MS 
m/z:  355.04 (M + Na)+ 
 
Synthesis of 3-(2-(2,2,2-trichloroacetyl)-1H-pyrrol-1-yl)benzonitrile 
(104b).  
 
Compound 104b was obtained as a yellow solid (0.56 g, 60 %) from 
compound 103b (0.50 g, 2.97 mmol), according to the procedure used for 4a; 
mp 120-123 °C. 1H NMR (300 MHz, CDCl3) δ 7.78 – 7.71 (m, 1H), 7.71 – 
7.66 (m, 1H), 7.65 – 7.51 (m, 3H), 7.12 – 7.03 (m, 1H), 6.50 – 6.40 (m, 1H). 
ESI-MS m/z:  314.7(M + 1)+ 
 
Synthesis of ethyl 1H-pyrrole-3-carboxylate (107). 
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A suspension of TosMIC (10.5 g, 0.053 mol) and ethyl acrylates (0.056 mol) 
in dry ethyl ether/DMSO (100 mL/50 mL) was added dropwise under nitrogen 
to a suspension of NaH (3.75 g, 0.094 mol) in diethyl ether (50 mL) at room 
temperature. Then the mixture was stirred for 4–5 h. Ice water (200 mL) was 
added into the mixture. The aqueous phase was extracted with ethyl ether (3 × 
100 mL). The organic phase was dried with anhydrous Na2SO4, concentrated 
under vacuum to get light brown liquid compounds which was purified by 
flash chromatography ( AcOEt/hexane 2:8). Yellow oil (6.5 g, 88%); 1H-
NMR (CDCl3): δ 9.86 (s, 1H, exchangeable with D2O), 7.45–7.46 (m, 1H), 
6.76–6.79 (m, 1H), 6.65–6.67 (m, 1H), 4.31 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 
7.1 Hz, 3H). 
Synthesis of  N-benzyl-1-(3-nitrophenyl)-1H-pyrrole-2-carboxamide 
(108a).  
 
Compound 104a (1.5 g, 4.37 mmol), benzylamine (1.4 g,13.1 mmol) and 
K2CO3 (21.8 mmol) were suspended in dry DMF (28 mL) under N2 
atmosphere. The vessel was sealed and the reaction was stirred at 120 °C for 
2h, and then H2O (50 mL) was added. The aqueous layer was extracted with 
EtOAc (3 × 50 mL), and the combined organic layers were washed with 
saturated aqueous solution of NaHCO3 (3 x 30 mL), HCl 1N (3 x 30 mL),  
brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue 
was purified by silica gel chromatography (ethyl acetate : petroleum ether, 
3:7) to give the title compound as a yellow solid (0.870 g, 62%), mp 98 – 100 
°C. 1H NMR (300 MHz, CDCl3) δ 8.30 – 8.24 (m, 1H), 8.26 – 8.17 (m, 1H), 
7.75 – 7.67 (m, 1H), 7.65 – 7.54 (m, 1H), 7.46 – 7.23 (m, 5H), 7.01 – 6.96 (m, 
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1H), 6.81 – 6.73 (m, 1H), 6.40 – 6.30 (m, 2H, 1H exchangeable with D2O), 
4.52 (d, J = 5.7 Hz, 2H). ESI-MS m/z:  322.20 (M + 1) +. 
 




Compound 108b was obtained as a yellow solid (0.36 g, 42 %) from 
compound 104b ( 0.9 g, 2.8 mmol), according to the procedure used for 108a, 
98 – 100 °C.  1H NMR (300 MHz, CDCl3): δ 7.70 – 7.47 (m, 4H), 7.44 – 7.23 
(m, 5H), 6.89 (dd, J = 2.7, 1.6 Hz, 1H), 6.72 (dd, J = 3.8, 1.6 Hz, 1H), 6.29 
(dd, J = 3.8, 2.7 Hz, 1H), 6.19 (t, J = 5.8 Hz, 1H, exchangeable with D2O), 
4.50 (d, J = 5.8 Hz, 1H). ESI-MS m/z:   301.97 (M + 1)+ 
Synthesis of ethyl 5-(2,2,2-trichloroacetyl)-1H-pyrrole-3-carboxylate 
(109). 
 
To a solution of 107 (2.15 mmol, 0.300 g) in dry DCM (3 mL) in sealed vessel 
was added dropwise ClCOCCl3 (21.5 mmol, 3.9 g).  The reaction was left to 
stir heating at 80°C for 36 h. The mixture of reaction was diluted with DCM 
(50 mL) and washed with saturated aqueous solution of NaHCO3 (3 x 30 mL), 
brine and dried over Na2SO4. The organic layer was filtered and evaporated 
under reduced pressure. The title compound was obtained as yellow solid 
(1.13 g, 50%) after chromatographyc purification (AcOEt/hexane 2:8); mp 
115-118 °C. 1H NMR (300 MHz, CDCl3): 
1H NMR (300 MHz, CDCl3) δ 9.68 
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(bs, 1H, exchangeable with D2O), 7.76 – 7.72 (m, J = 2.5 Hz, 1H), 7.72 – 7.69 
(m, J = 3.3 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H). ESI-MS 
m/z:   285.1 (M + 1)+. 
 
Synthesis of  ethyl 5-(benzylcarbamoyl)-1H-pyrrole-3-carboxylate (110) 
 
To a solution of 109 (3.20 mmol, 0.860 g) in DCM dry (16 mL) was added 
benzylamine (3.52 mmol, 0.377 g). The reaction was left to stir at room 
temperature for 12h and evaporated under under reduced pressure. The residue 
was purified by silica gel chromatography (ethyl acetate : petroleum ether, 
3:7) to afford the desired product as white solid (0.740 g, 85%), mp 140 – 142 
°C. 1H NMR (300 MHz, CDCl3): δ 10.00 (bs, 1H, exchangeable with D2O), 
7.53 – 7.46 (m, 1H), 7.41 – 7.29 (m, 5H), 7.07 – 6.92 (m, 1H), 6.29 (t, J = 5.8 
Hz, 1H, exchangeable with D2O), 4.61 (d, J = 5.8 Hz, 2H), 4.27 (q, J = 7.1 Hz, 
2H), 1.33 (t, J = 7.1 Hz, 3H). ESI-MS m/z:   273.42 (M + 1)+. 
 
Synthesis of ethyl 5-(benzylcarbamoyl)-1-(3-nitrophenyl)-1H-pyrrole-3-
carboxylate (108c). 
 
Compound 108c was obtained as yellow solid (0.346 g, 80%), from compound 
110 (1.10 mmol, 0.300 g) and 3-bromonitrobenzene (2.64 mmol, 0.53 g), 
according to the procedure used for 97; mp 156 – 157 °C. 1H NMR (300 MHz, 
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CDCl3) δ 8.32 – 8.26 (m, , 1H), 8.23 – 8.19 (m, 1H), 7.74 – 7.59 (m, , 8.0 Hz, 
2H), 7.54 – 7.51 (m, 1H), 7.40 – 7.25 (m, 5H), 7.17 – 7.13 (m, 1H), 6.23 (t, J 
= 5.8 Hz, 1H, exchangeable with D2O), 4.49 (d, J = 5.8 Hz, 2H), 4.31 (q, J = 
7.1 Hz, 2H), 1.35 (t, J = 7.1 Hz, 3H). ESI-MS m/z:  393.99 (M + 1) +. 
Synthesis of ethyl 5-(benzylcarbamoyl)-1-(3-cyanophenyl)-1H-pyrrole-3-
carboxylate (108 d) 
 
Compound 108c was obtained as yellow solid (0.231 g, 85%), from compound 
110 (0.73 mmol, 0.200 g) and 3-bromonitrobenzene (1.61mmol, 0.30 g), 
according to the procedure used for 97, mp164 – 165 °C. 1H NMR (300 MHz, 
CDCl3) δ 7.73 – 7.64 (m, 1H), 7.63 – 7.52 (m, 5H), 7.50 – 7.46 (m, 1H), 7.43 
– 7.37 (m, 2H), 7.26 – 7.22 (m, 1H), 7.17 (m, 1H), 6.41 (t, J = 5.9 Hz, 1H, 
exchangeable with D2O), 4.54 (d, J = 5.9 Hz, 2H), 4.28 (q, J = 7.1 Hz, 2H), 
1.33 (t, J = 7.1 Hz, 3H). ESI-MS m/z: 374.04 (M + 1) +. 
 
General Procedure for reduction of nitro group 109a and 109c.  
Example: Synthesis of  1-(3-aminophenyl)-N-benzyl-1H-pyrrole-2-
carboxamide (109a).  
 
To a solution of 108a (0.517 g, 17.20 mmol) in acetic acid (26 mL) was added 
a powder of Zn (1.12 g, 17.20 mmol). The reaction was stirred for 1 h at room 
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temperature, filtered, and concentrated in vacuo. The residue was dissolved in 
saturated aqueous solution of NaHCO3 (100 mL) and extracted with EtOAc (3 
× 50 mL). The combined organic layers were washed with brine, dried 
(Na2SO4), and filtered. Vacuum evaporation of the solvents gave the title 
compound  (0.300 g, 65%) as a yellow solid which was directly used in the 
next step without further step of purification. 1H NMR (300 MHz, CDCl3): δ 
8.55 (t, J = 5.7 Hz, 1H, exchangeable with deuterium oxide), 7.40 – 7.16 (m, 
5H), 7.05 – 6.92 (m, 2H), 6.85 – 6.77 (m, 1H), 6.54 – 6.48 (m, 1H), 6.47 – 
6.42 (m, 1H), 6.39 – 6.31 (m, 1H), 6.20 – 6.15 (m, 1H), 5.24 (s, 2H, 
exchangeable with deuterium oxide), 4.33 (d, J = 5.7 Hz, 2H). ESI-MS m/z: 




1H NMR (300 MHz, DMSO) δ 9.83 (t, J = 5.5 Hz, 1H, exchangeable with 
deuterium oxide), 8.33 – 8.29 (m, 1H), 7.98 – 7.88 (m, 1H), 7.86 – 7.77 (m, 
1H), 7.43 – 7.30 (m, 3H), 7.30 – 7.22 (m, 1H), 7.20 – 7.08 (m, 1H), 6.88 – 
6.72 (m, 2H), 6.62 – 6.51 (m, 1H), 5.42 (s, 2H, exchangeable with deuterium 
oxide), 4.52 (d, J = 5.5 Hz, 2H), 4.27 (q, J = 7.0 Hz, 2H), 1.28 (t, J = 7.0 Hz, 
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General Procedure for reduction of nitrile group 108b and 108d 
Example: Synthesis of  1-(3-(aminomethyl)phenyl)-N-benzyl-1H-pyrrole-
2-carboxamide (109b).  
 
To a solution of NiSO4•6H2O (0.041 g, 0.16 mmol), and 5b (0.470 g, 1.56 
mmol) in a mixture of MeOH (30 ml) was added NaBH4 (0.424 g, 10.92 
mmol) portionwise. The mixture was left to stir, at room temperature, for 3 h 
and then water was added (50 mL).  The aqueous layer was extracted with 
EtOAc (3 x 50 mL). The combined layers were washed with brine, dried 
(Na2SO4), and filtered. Vacuum evaporation of the solvent gave a compound 
108b (0.44 g, 90%) as a slurry which was directly used in the next step.  1H 
NMR (300 MHz, DMSO) δ 8.71 – 8.54 (m, 1H, exchangeable with deuterium 
oxide), 7.40 – 7.16 (m, 9H), 7.16 – 6.99 (m, 3H), 6.98 – 6.83 (m, 1H), 6.27 – 
6.15 (m, 1H), 4.43 – 4.29 (m, 2H), 3.83 – 3.62 (m, 2H). ESI-MS m/z: 306.08 





1H NMR (300 MHz, DMSO): δ 9.88 – 9.78 (m, 1H), 8.16 – 8.06 (m, 1H), 8.09 
– 7.84 (m, 1H), 7.84 – 7.66 (m, 1H), 7.65 – 7.58 (m, 1H), 7.53 – 7.17 (m, 7H), 
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4.53 (d, J = 4.9 Hz, 2H), 4.27 (q, J = 6.6 Hz, 2H), 3.83 – 3.78 (m, 2H), 1.30 (t, 
J = 6.6 Hz, 3H). ESI-MS m/z: 378.06 (M + 1) +. 
 
 
General procedure for coupling reaction 110 a – d and ent-110a – d  
Example: Synthesis of (S)-tert-butyl (1-((3-(2-(benzylcarbamoyl)-1H-
pyrrol-1-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate (110a).   
 
To a solution of 109a (0.300 g, 1.30 mmol) , DMAP (0.013 g,0.130 mmol), 
and Boc-L-AlaOH (0.368 g,1.95 mmol) in dichlorometane dry (20 mL) was 
added DCC (0.402 g, 1.95 mmol) under N2 atmosphere. The reaction was left 
to stir at room temperature overnight, filtered, and concentrated in vacuum. 
The residue was dissolved in dichlorometane (100 mL) and washed with 
saturated aqueous solution of NaHCO3 (3 x 30 mL), and brine. The organic 
phase was dried (Na2SO4), filtered and concentrated in vacuo. The residue was 
purified by silica gel chromatography (ethyl acetate : petroleum ether, 1:1) to 
give the title compound as a yellow solid (0.420 g, 70 %), mp 116 – 118 °C. 
[α]D -40.3 (c 0.3, MeOH). 
1H NMR (300 MHz, DMSO): δ 10.05 (s, 1H, 
exchangeable with deuterium oxide), 8.66 (t, J = 5.6 Hz, 1H, exchangeable 
with deuterium oxide), 7.68 – 7.63 (m, 1H), 7.55 – 7.46 (m, 1H), 7.37 – 7.27 
(m, 3H), 7.27 – 7.20 (m, 3H), 7.09 (d, J = 6.8 Hz, 1H), 7.06 – 7.00 (m, 1H), 
6.96 – 6.85 (m, 2H), 6.26 – 6.20 (m, 1H, exchangeable with deuterium oxide), 
4.32 (d, J = 5.6 Hz, 2H), 4.18 – 4.06 (m, 1H), 1.38 (s, 9H), 1.26 (d, J = 6.8 Hz, 
3H). ESI-MS m/z: 462.83 (M + 1)+ 






Yellow solid (0.420 g, 70 %), mp 116 – 118 °C, [α]D +39.0 (c 0.3, MeOH).
 1H 
NMR (300 MHz, DMSO): δ 10.05 (s, 1H, exchangeable with deuterium 
oxide), 8.66 (t, J = 5.6 Hz, 1H, exchangeable with deuterium oxide), 7.68 – 
7.63 (m, 1H), 7.55 – 7.46 (m, 1H), 7.37 – 7.27 (m, 3H), 7.27 – 7.20 (m, 3H), 
7.09 (d, J = 6.8 Hz, 1H), 7.06 – 7.00 (m, 1H), 6.96 – 6.85 (m, 2H), 6.26 – 6.20 
(m, 1H, exchangeable with deuterium oxide), 4.32 (d, J = 5.6 Hz, 2H), 4.18 – 






White solid (0.340 g, 50%), mp 120 – 122 °C. [α]D - 6.7 (c 0.3, MeOH). 
1H 
NMR (300 MHz, DMSO): δ 8.68 (t, J = 5.9 Hz, 1H, exchangeable with 
deuterium oxide), 8.34 (t, J = 5.1 Hz, 1H, exchangeable with deuterium 
oxide), 7.37 – 7.25 (m, 5H), 7.25 – 7.16 (m, 3H), 7.15 – 7.08 (m, 1H), 7.06 – 
7.02 (m, 1H), 6.99 – 6.88 (m, 2H, 1H exchangeable with deuterium oxide), 
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6.26 – 6.22 (m, 1H), 4.38 – 4.27 (m, 4H), 4.00 (s, 1H), 1.38 (s, 9H), 1.21 (d, J 





White solid (0.340 g, 50%), mp 120 – 122 °C, [α]D + 6.9 (c 0.3, MeOH). 
1H 
NMR (300 MHz, DMSO): δ 8.68 (t, J = 5.9 Hz, 1H, exchangeable with 
deuterium oxide), 8.34 (t, J = 5.1 Hz, 1H, exchangeable with deuterium 
oxide), 7.37 – 7.25 (m, 5H), 7.25 – 7.16 (m, 3H), 7.15 – 7.08 (m, 1H), 7.06 – 
7.02 (m, 1H), 6.99 – 6.88 (m, 2H, 1H exchangeable with deuterium oxide), 
6.26 – 6.22 (m, 1H), 4.38 – 4.27 (m, 4H), 4.00 (s, 1H), 1.38 (s, 9H), 1.21 (d, J 
= 7.0 Hz, 3H). ESI-MS m/z: 499.05 (M +Na)+, 476.81 (M + 1)+. 
 
Ethyl (S)-5-(benzylcarbamoyl)-1-(3-(2-((tert-butoxycarbonyl)amino)  
propanamido) phenyl)-1H-pyrrole-3-carboxylate (110c) 
 
 
White solid (0.120 g, 83%), mp 150 – 151 °C. [α]D – 38.3(c 0.3, MeOH). 
1H 
NMR (300 MHz, CDCl3) δ 8.79 – 8.67 (m, 1H, exchangeable with D2O), 7.79 
– 7.76 (m, 1H), 7.50 – 7.48 (m, 1H), 7.38 – 7.25 (m, 8H), 7.15 – 7.12 (m, 1H), 
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7.09 – 7.04 (m, J = 7.1 Hz, 1H, exchangeable with D2O), 6.25 (t, J = 5.6 Hz, 
1H, exchangeable with D2O), 5.08 – 4.99 (m, 1H), 4.50 (d, J = 5.7 Hz, 2H), 
4.30 (q, J = 7.1 Hz, 2H), 1.48 (s, 9H), 1.42 (d, J = 7.0 Hz, 3H), 1.35 (t, J = 7.1 





White solid (0.120 g, 83%), mp 150 – 151 °C. [α]D +29.7 (c 0.3, MeOH). 
1H 
NMR (300 MHz, CDCl3) δ 8.79 – 8.67 (m, 1H, exchangeable with D2O), 7.79 
– 7.76 (m, 1H), 7.50 – 7.48 (m, 1H), 7.38 – 7.25 (m, 8H), 7.15 – 7.12 (m, 1H), 
7.09 – 7.04 (m, J = 7.1 Hz, 1H, exchangeable with D2O), 6.25 (t, J = 5.6 Hz, 
1H, exchangeable with D2O), 5.08 – 4.99 (m, 1H), 4.50 (d, J = 5.7 Hz, 2H), 
4.30 (q, J = 7.1 Hz, 2H), 1.48 (s, 9H), 1.42 (d, J = 7.0 Hz, 3H), 1.35 (t, J = 7.1 





White solid (0.073 g, 50%), mp 86 – 88 °C. [α]D – 6.00 (c 0.3, MeOH). 
1H 
NMR (300 MHz, CDCl3) δ 7.50 – 7.47 (m, 1H), 7.44 – 7.23 (m, 10H), 7.15 – 
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7.13 (m, 1H), 6.63 (t, J = 4.8 Hz, 1H), 6.21 (t, J = 6.1 Hz, 1H), 5.08 – 4.97 (m, 
1H), 4.60 – 4.39 (m, 4H), 4.31 (q, J = 7.1 Hz, 2H), 4.22 – 4.10 (m, 1H), 1.41 
(s, 9H), 1.40 – 1.32 (m, 6H).  ESI-MS m/z: 549.07 (M + 1)+. 
 
Ethyl (R)-5-(benzylcarbamoyl)-1-(3-((2-((tert- butoxycarbonyl)amino) 
propanamido) methyl)phenyl)-1H-pyrrole-3-carboxylate Ent-110d: 
 
White solid (0.073 g, 50%), mp 86 – 88 °C. [α]D + 7.8 (c 0.3, MeOH). 
1H 
NMR (300 MHz, CDCl3) δ 7.50 – 7.47 (m, 1H), 7.44 – 7.23 (m, 10H), 7.15 – 
7.13 (m, 1H), 6.63 (t, J = 4.8 Hz, 1H), 6.21 (t, J = 6.1 Hz, 1H), 5.08 – 4.97 (m, 
1H), 4.60 – 4.39 (m, 4H), 4.31 (q, J = 7.1 Hz, 2H), 4.22 – 4.10 (m, 1H), 1.41 
(s, 9H), 1.40 – 1.32 (m, 6H).  ESI-MS m/z: 549.07 (M + 1)+. 
 
General procedures for acids 110e, f and ent-110e, f. 




 LiOH (0.053 g, 2.22 mmol) was added to a solution of 110c (0.200 g, 0.37 
mmol) in THF−H2O (4:1, 10 mL). The reaction was stirred at 45 °C for 5 h 
and then concentrated in vacuo. The residue was dissolved in water (20 mL), 
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washed with CH2Cl2 (3× 10 mL), and acidified to pH 5 with 1N HCl and 
extracted with ethyl acetate (3 x 10 mL).  The combined organic layers were 
washed with brine, dried (Na2SO4), filtered and evaporated under reduced 
pressure. Purification by crystallization (MeOH/H2O) gave the title compound 
as a white solid (0.131 g, 85%), mp 224 – 227 °C. [α]D – 16.0 (c 0.3, MeOH).  
1H NMR (300 MHz, DMSO) δ 12.26 (bs, 1H, exchangeable with D2O), 10.14 
– 10.05 (m, 1H, exchangeable with D2O), 8.96 – 8.82 (m, 1H, exchangeable 
with D2O), 7.72 – 7.67 (m, 1H), 7.57 – 7.49 (m, 2H), 7.39 – 7.16 (m, 6H), 7.14 
– 7.07 (m, 1H, ), 7.03 – 6.96 (m, 1H, exchangeable with D2O), 4.32 (d, J = 5.6 
Hz, 2H), 4.17 – 4.04 (m, 1H), 1.38 (s, 9H), 1.26 (d, J = 6.9 Hz, 3H). ESI-MS 
m/z: 529.01 (M + Na)+. 
(R)-5-(benzylcarbamoyl)-1-(3-(2-((tert-butoxycarbonyl)amino)  
propanamido)phenyl)-1H-pyrrole-3-carboxylic acid (Ent-110e) 
 
White solid (0.131 g, 85%), mp 224 – 227 °C, [α]D + 17.7 (c 0.3, MeOH). 
1H 
NMR (300 MHz, DMSO) δ 12.26 (bs, 1H, exchangeable with D2O), 10.14 – 
10.05 (m, 1H, exchangeable with D2O), 8.96 – 8.82 (m, 1H, exchangeable 
with D2O), 7.72 – 7.67 (m, 1H), 7.57 – 7.49 (m, 2H), 7.39 – 7.16 (m, 6H), 7.14 
– 7.07 (m, 1H, ), 7.03 – 6.96 (m, 1H, exchangeable with D2O), 4.32 (d, J = 5.6 
Hz, 2H), 4.17 – 4.04 (m, 1H), 1.38 (s, 9H), 1.26 (d, J = 6.9 Hz, 3H). ESI-MS 
m/z: 529.01 (M + Na)+. 
General procedures for amino derivatives 111 a – f  and ent-111a – f. 
Example: synthesis of (S)-1-(3-(2-aminopropanamido)phenyl)-N-benzyl-
1H-pyrrole-2-carboxamide 2,2,2-trifluoroacetate (111a). 




 A mixture of TFA and CH2Cl2 (1:9, 12 mL) was added to compound 110a 
(0.200 g, 0.43 mmol). The reaction  was stirred at room temperature for 1h and 
then concentrated in vacuo to give the title compound as a white solid (0.200 
g, 99%), mp 119 - 122 °C. [α]D + 5.3 (c 0.3, MeOH). 
1H NMR (400 MHz, 
DMSO) δ 10.54 (bs, 1H, exchangeable with D2O), 8.71 (t, J = 6.1 Hz, 1H, 
exchangeable with D2O), 8.16 (s, 3H, exchangeable with D2O), 7.61 – 7.59 
(m, 1H), 7.57 – 7.53 (m, 1H), 7.41 – 7.35 (m, 1H), 7.34 – 7.28 (m, 3H), 7.27 – 
7.20 (m, 2H), 7.05 (dd, J = 2.6, 1.8 Hz, 1H), 7.03 – 6.99 (m, 1H), 6.93 (dd, J = 
3.8, 1.8 Hz, 1H), 6.26 (dd, J = 3.8, 2.6 Hz, 1H), 4.33 (d, J = 6.1 Hz, 2H), 4.04 
– 3.97 (m, 1H). ESI-MS m/z: 363.01 (M + 1)+. 
(R)-1-(3-(2-aminopropanamido)phenyl)-N-benzyl-1H-pyrrole-2-
carboxamide 2,2,2-trifluoroacetate ent-111a:  
 
White solid (yield 99%), mp 124 – 125 °C. [α]D – 6.9 (c 0.3, MeOH). 
1H NMR 
(400 MHz, DMSO) δ 8.91 (t, J = 5.9 Hz, 1H, exchangeable with D2O), 8.72 (t, 
J = 6.1 Hz, 1H, exchangeable with D2O), 8.05 (s, 3H, exchangeable with D2O 
), 7.40 – 7.29 (m, 3H), 7.29 – 7.19 (m, 5H), 7.17 – 7.12 (m, J = 7.9 Hz, 1H), 
7.04 (dd, J = 2.5, 1.8 Hz, 1H), 6.93 (dd, J = 3.8, 1.8 Hz, 1H), 6.26 (dd, J = 3.8, 
2.5 Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 4.33 (d, J = 6.1 Hz, 2H), 3.91 – 3.83 (m, 
J = 6.9 Hz, 1H), 1.38 (d, J = 7.0 Hz, 3H). ESI-MS m/z: 363.01 (M + 1)+. 




carboxamide 2,2,2-trifluoroacetate 111b  
 
White solid (99%), mp 136 – 138 °C. [α]D + 6.7 (c 0.3, MeOH). 
1H NMR (400 
MHz, DMSO) δ 8.91 (t, J = 5.9 Hz, 1H, exchangeable with D2O), 8.72 (t, J = 
6.1 Hz, 1H, exchangeable with D2O), 8.05 (s, 3H, exchangeable with D2O ), 
7.40 – 7.29 (m, 3H), 7.29 – 7.19 (m, 5H), 7.17 – 7.12 (m, J = 7.9 Hz, 1H), 
7.04 (dd, J = 2.5, 1.8 Hz, 1H), 6.93 (dd, J = 3.8, 1.8 Hz, 1H), 6.26 (dd, J = 3.8, 
2.5 Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 4.33 (d, J = 6.1 Hz, 2H), 3.91 – 3.83 (m, 
J = 6.9 Hz, 1H), 1.38 (d, J = 7.0 Hz, 3H). ESI-MS m/z: 377.11 (M + 1)+ 
(R)-1-(3-((2-aminopropanamido)methyl)phenyl)-N-benzyl-1H-pyrrole-2-
carboxamide 2,2,2-trifluoroacetate ent-111b 
 
White solid (99%), mp 136 – 138 °C. [α]D – 6.2 (c 0.3, MeOH). 
1H NMR (400 
MHz, DMSO) δ 8.91 (t, J = 5.9 Hz, 1H), 8.72 (t, J = 6.1 Hz, 1H), 8.05 (s, 1H), 
7.40 – 7.29 (m, 2H), 7.29 – 7.19 (m, 4H), 7.17 – 7.12 (m, J = 7.9 Hz, 1H), 
7.04 (dd, J = 2.5, 1.8 Hz, 1H), 6.93 (dd, J = 3.8, 1.8 Hz, 1H), 6.26 (dd, J = 3.8, 
2.5 Hz, 1H), 4.38 (d, J = 5.9 Hz, 2H), 4.33 (d, J = 6.1 Hz, 2H), 3.91 – 3.83 (m, 
J = 6.9 Hz, 1H), 1.38 (d, J = 7.0 Hz, 3H). ESI-MS m/z: 377.11 (M + 1)+ 
 




pyrrole-3-carboxylate 2,2,2-trifluoroacetate 111c 
 
 
White solid (99%), mp 199 – 200 °C. [α]D + 5.9 (c 0.3, MeOH). 
1H NMR (400 
MHz, DMSO) δ 10.13 (s, 1H, exchangeable with D2O), 8.51 (t, J = 6.1 Hz, 
1H, exchangeable with D2O), 7.73 (s, 3H, exchangeable with D2O), 7.20 – 
7.17 (m, 2H), 7.17 – 7.12 (m, 1H), 7.01 – 6.94 (m, 1H), 6.90 – 6.84 (m, 3H), 
6.82 – 6.75 (m, 3H), 6.67 – 6.58 (m, 1H), 3.87 (d, J = 6.0 Hz, 2H), 3.78 (q, J = 
7.1 Hz, 2H), 3.60 – 3.53 (m, 1H), 1.01 (d, J = 7.0 Hz, 3H), 0.83 (t, J = 7.1 Hz, 
3H). ESI-MS m/z: 435.06 (M + 1)+. 
(R)-ethyl 1-(3-(2-aminopropanamido)phenyl)-5-(benzylcarbamoyl)-1H-
pyrrole-3-carboxylate 2,2,2-trifluoroacetate ent-111c 
 
White solid (99%), mp 199 – 200 °C. [α]D – 3.33 (c 0.3, MeOH). 
1H NMR 
(400 MHz, DMSO) δ 10.13 (s, 1H, exchangeable with D2O), 8.51 (t, J = 6.1 
Hz, 1H, exchangeable with D2O), 7.73 (s, 3H, exchangeable with D2O), 7.20 – 
7.17 (m, 2H), 7.17 – 7.12 (m, 1H), 7.01 – 6.94 (m, 1H), 6.90 – 6.84 (m, 3H), 
6.82 – 6.75 (m, 3H), 6.67 – 6.58 (m, 1H), 3.87 (d, J = 6.0 Hz, 2H), 3.78 (q, J = 
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7.1 Hz, 2H), 3.60 – 3.53 (m, 1H), 1.01 (d, J = 7.0 Hz, 3H), 0.83 (t, J = 7.1 Hz, 
3H). ESI-MS m/z: 435.06 (M + 1)+. 
Synthesis of (S)-ethyl 1-(3-((2-aminopropanamido)methyl)phenyl)-5-
(benzylcarbamoyl)-1H-pyrrole-3-carboxylate 2,2,2-trifluoroacetate 111d 
 
White solid (yield 99%), mp 123 – 126 °C. [α]D + 12.3 (c 0.3, MeOH). 
1H 
NMR (400 MHz, DMSO) δ 8.97 (t, J = 5.9 Hz, 1H, exchangeable with D2O), 
8.90 (t, J = 5.7 Hz, 1H, exchangeable with D2O), 8.06 (s, 3H, exchangeable 
with D2O), 7.64 – 7.57 (m, 1H), 7.43 – 7.37 (m, 1H), 7.36 – 7.27 (m, 9H), 4.47 
– 4.37 (m, 2H), 4.32 (d, J = 5.9 Hz, 2H), 4.24 (q, J = 7.1 Hz, 2H), 3.92 – 3.85 
(m, J = 6.8 Hz, 1H), 1.39 (d, J = 6.9 Hz, 2H), 1.28 (t, J = 7.1 Hz, 2H). ESI-MS 
m/z: 449.02 (M + 1)+ 




White solid (yield 99%), mp 123 – 126 °C. [α]D + 12.3 (c 0.3, MeOH). 
1H 
NMR (400 MHz, DMSO) δ 8.97 (t, J = 5.9 Hz, 1H, exchangeable with D2O), 
8.90 (t, J = 5.7 Hz, 1H, exchangeable with D2O), 8.06 (s, 3H, exchangeable 
with D2O), 7.64 – 7.57 (m, 1H), 7.43 – 7.37 (m, 1H), 7.36 – 7.27 (m, 9H), 4.47 
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– 4.37 (m, 2H), 4.32 (d, J = 5.9 Hz, 2H), 4.24 (q, J = 7.1 Hz, 2H), 3.92 – 3.85 
(m, J = 6.8 Hz, 1H), 1.39 (d, J = 6.9 Hz, 2H), 1.28 (t, J = 7.1 Hz, 2H). ESI-MS 
m/z: 449.02 (M + 1)+. 
Synthesis of (S)-1-((3-(2-(benzylcarbamoyl)-4-carboxy-1H-pyrrol-1- 
yl)phenyl)amino)- 1- oxopropan-2-aminium 2,2,2-trifluoroacetate 111e. 
 
 White solid (0.051 g, 99%), 219 – 220 °C. [α]D  + 3.7 (c 0.3, MeOH).
 1H 
NMR (400 MHz, DMSO) δ 10.57 (s, 1H, exchangeable with D2O), 8.93 (t, J = 
6.1 Hz, 1H, exchangeable with D2O), 8.40 (s, 3H, exchangeable with D2O), 
7.65 – 7.61 (m, 1H), 7.62 – 7.54 (m, 2H), 7.45 – 7.38 (m, 1H), 7.35 – 7.27 (m, 
2H), 7.28 – 7.20 (m, 3H), 7.11 – 7.05 (m, 2H), 4.32 (d, J = 6.0 Hz, 2H), 4.04 – 
3.97 (m, J = 7.0 Hz, 1H), 1.46 (d, J = 7.0 Hz, 3H). ESI-MS m/z:  407.05 (M + 
1)+. 
Synthesis of (R)-1-((3-(2-(benzylcarbamoyl)-4-carboxy-1H-pyrrol-1- 
yl)phenyl)amino)- 1- oxopropan-2-aminium 2,2,2-trifluoroacetate ent-
111e. 
 
White solid (99%), 219 – 220 °C. [α]D  - 1.7  (c 0.3, MeOH). 
1H NMR (400 
MHz, DMSO) δ 10.57 (s, 1H, exchangeable with D2O), 8.93 (t, J = 6.1 Hz, 
1H, exchangeable with D2O), 8.40 (s, 3H, exchangeable with D2O), 7.65 – 
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7.61 (m, 1H), 7.62 – 7.54 (m, 2H), 7.45 – 7.38 (m, 1H), 7.35 – 7.27 (m, 2H), 
7.28 – 7.20 (m, 3H), 7.11 – 7.05 (m, 2H), 4.32 (d, J = 6.0 Hz, 2H), 4.04 – 3.97 
(m, J = 7.0 Hz, 1H), 1.46 (d, J = 7.0 Hz, 3H). ESI-MS m/z:  407.05 (M + 1)+. 
Synthesis of (S)-1-((3-(2-(benzylcarbamoyl)-4-carboxy-1H-pyrrol-1-
yl)benzyl)amino)-1-oxopropan-2-aminium 2,2,2-trifluoroacetate  111f.  
 
White solid (0.069 g, 99%), 203 – 205 °C. [α]D + 13.00  (c 0.3, MeOH). 
1H 
NMR (400 MHz, DMSO) δ 10.57 (s, 1H, exchangeable with D2O), 8.94 (t, J = 
6.1 Hz, 1H), 8.89 (t, J = 5.9 Hz, 1H), 8.76 (s, 3H), 7.56 – 7.53 (m, 1H), 7.42 – 
7.35 (m, 1H), 7.35 – 7.29 (m, 2H), 7.29 – 7.25 (m, 5H), 7.24 – 7.18 (m, 2H), 
4.45 – 4.36 (m, 2H), 4.33 (d, J = 6.0 Hz, 2H), 3.91 – 3.82 (m, 1H), 1.38 (d, J = 
7.0 Hz, 3H). ESI-MS m/z:  421.08 (M + 1)+. 
Synthesis of (R)-1-((3-(2-(benzylcarbamoyl)-4-carboxy-1H-pyrrol-1-
yl)benzyl)amino)-1-oxopropan-2-aminium 2,2,2-trifluoroacetate ent-111f.  
 
White solid (99%), mp 200 – 202 °C. [α]D – 12.7  (c 0.3, MeOH). 
1H NMR 
(400 MHz, DMSO) δ 10.57 (s, 1H, exchangeable with D2O), 8.94 (t, J = 6.1 
Hz, 1H), 8.89 (t, J = 5.9 Hz, 1H), 8.76 (s, 3H), 7.56 – 7.53 (m, 1H), 7.42 – 
7.35 (m, 1H), 7.35 – 7.29 (m, 2H), 7.29 – 7.25 (m, 5H), 7.24 – 7.18 (m, 2H), 
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4.45 – 4.36 (m, 2H), 4.33 (d, J = 6.0 Hz, 2H), 3.91 – 3.82 (m, 1H), 1.38 (d, J = 
7.0 Hz, 3H). ESI-MS m/z:  421.08 (M + 1)+. ESI-MS m/z:  421.08 (M + 1)+ 
Synthesis of ethyl 2-((3-nitrobenzyl)amino)acetate (113a) 167.  
 
To a solution of glycine ethyl ester hydrochloride (5.00 g, 35.82 mmol)  and 
TEA (3.6 g, 35.82 mmol) was added  3-nitrobenzaldehyde (3.60 g, 23.88 
mmol). The mixture was stirred overnight at room temperature and then was 
added NaBH4 (1.80 g, 47.76 mmol) after cooling at 0 °C. The reaction was 
sterred at 0 °C for additional 1 h and quenched with water (30 mL). The 
reaction was concentrated in vacuo and the residue was dissolved in satured 
solution of NaHCO3 (150 mL). The aqueous layer was washed with diethyl 
ether (3x 50 mL), acidified to pH 1 with 6 N HCl and extracted with ethyl 
acetate (3 x 50 mL).  The combined organic layers were washed with Brine, 
dried (Na2SO4), filtered and evaporated under vacuum to give the title 
compound as a yellow oil (4.62 g, 81 %). 1H NMR (300 MHz, CDCl3): δ 8.27 
– 8.20 (m, 1H), 8.15 – 8.10 (m, 1H), 7.74 – 7.66 (m, 1H), 7.56 – 7.46 (m, 1H), 
4.21 (q, J = 7.1 Hz, 2H), 3.92 (s, 2H), 3.42 (s, 2H), 1.80 (s, 1H, exchangeable 
with D2O), 1.29 (t, J = 7.1 Hz, 3H). ESI-MS m/z: 239.10 (M + 1)
+ 
Synthesis of ethyl 2-((3-cyanobenzyl)amino)acetate (113b). 168  
 
Compound 113b was obtained as a yellow oil (3.44 g, 66%) from 3-
cianobenzaldehyde (3.0 g, 22.8 mmol), according to the procedure used for 
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113a. 1H NMR (300 MHz, CDCl3): δ 7.70 – 7.64 (m, 1H), 7.62 – 7.53 (m, 
2H), 7.47 – 7.39 (m, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.84 (s, 2H), 3.39 (s, 2H), 
1.75 (s, 1H, scambiato con D2O), 1.28 (t, J = 7.1 Hz, 3H). ESI-MS m/z:219.07 
(M + 1)+. 
Synthesis of ethyl 2-(N-(3-nitrobenzyl)formamido)acetate (114a). 
 
To a mixture of 113a (4.00 g, 16.97 mmol) and formic acid (9.06 g, 200 
mmol) was added dropwise over about 15 minutes acetic anhydride (10.60 g, 
100 mmol) while cooling and stirring. The mixture was continuosly stirred for 
one hour at 0 °C and two hours at room temperature. The reaction mixture was 
concentrated under vacuum and the residue was dissolved in ethyl acetate (200 
mL). The organic layer was washed with a saturated aqueous solution of 
NaHCO3  (3 x 50 mL), HCl 1 N (3 x 50 mL) and Brine. The organic phase was 
dried (Na2SO4), filtered and concentrated in vacuo to obtain the title 
compound (11a) as a yellow oil (3.57 g, 80%). 1H NMR (300 MHz, CDCl3): δ 
8.39 (s, 1H, exchangeable with D2O), 8.26 – 8.05 (m, 2H), 7.64 – 7.45 (m, 
2H), 4.71, 4.65 (2s, 2H), 4.18 (q, J = 7.1 Hz, 2H), 3.97, 3.91 (2s, 2H), 1.26 (t, 
J = 7.1 Hz, 3H). ESI-MS m/z:  239.10 (M + 1)+. 
Synthesis of ethyl 2-(N-(3-cyanobenzyl)formamido)acetate (114b).  
 
Compound 114b was obtained as a yellow oil (3.01 g, 91%) from compound 
113b (3.00 g, 13.7 mmol), according to the procedure used for 114a. 1H NMR 
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(300 MHz, CDCl3) δ 8.36, 8.21 (2s, 1H), 7.69 – 7.57 (m, 1H), 7.57 – 7.40 (m, 
3H), 4.64, 4.58 (2s, 2H), 4.18 (q, J = 7.1 Hz, 2H), 3.95, 3.87 (2s, 2H), 1.26 (t, 
J = 7.1 Hz, 3H). ESI-MS m/z:   267.91 (M + 1)+. 
Synthesis of 2-(N-(3-nitrobenzyl)formamido)acetic acid (115a).  
 
An aqueous solution of sodium hydroxide 2N (16mL) was added to a solution 
of 11a (3.00 g, 11.27 mmol) in ethanol (12 mL) . The reaction was stirred at 
room temperature for 30 minutes,and  water (20 ml) was added. The aqueous 
phase was washed with chloroform (3 x 50 mL) and acidified to pH 1 with 6 N 
HCl and extracted with ethyl acetate (3 x 50 mL).  The combined organic 
layers were washed with Brine, dried (Na2SO4), filtered and evaporated under 
vacuum to give the title compound as a yellow solid (1.88 g, 70%); mp 138 – 
140 °C. 1H NMR (300 MHz, DMSO): δ 12.82 (s, 1H, exchangeable with 
D2O), 8.42 (s, 1H, exchangeable with D2O ), 8.24 – 8.17 (m, 1H), 8.17 – 8.09 
(m, 1H), 7.82 – 7.76 (m, 1H), 7.75 – 7.58 (m, 1H), 4.68, 4.58 (2s, 2H), 4.09, 
3.83 (2s, 2H). ESI-MS m/z:   444.50 (M x 2)- 
Synthesis of 2-(N-(3-cyanobenzyl)formamido)acetic acid (115b).  
 
Compound 12b was obtained as a white solid (2.18 g, 82%) from compound 
11b (3.0 g, 12.18 mmol), according to the procedure used for 12a, m. p. 121 – 
123 °C. 1H NMR (300 MHz, DMSO):δ 12.82 (s, 1H, exchangeable with D2O), 
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8.37, 8.17 (s, 1H, exchangeable with D2O), 7.86 – 7.63 (m, 2H), 7.63 – 7.46 
(m, 2H), 4.58, 5.50 (2s, 2H), 4.06, 3.80 (s, 2H). ESI-MS m/z:  239.03 (M + 
1)+. 
Synthesis of ethyl 1-(3-nitrobenzyl)-1H-pyrrole-3-carboxylate (116a). 
 
A solution of 115a (1.40 g, 5.88 mmol) and ethyl propiolate (1.73 g, 17.64 
mmol) in acetic acid (7 mL) was stirred at 130 °C for 5 h. The reaction was 
concentrated under vacuum. The residue was dissolved with ethyl acetate (150 
mL) and washed with satured aqueous solution of NaHCO3 (3 x 50 mL), 
Brine, dried (Na2SO4), filtered and evaporated under vacuum. The residue was 
purified by silica gel chromatography (ethyl acetate : petroleum ether, 3:7 ) to 
give the title compound as a yellow solid (0.790 g, 73 %); m. p. 76 – 78 °C. 1H 
NMR (300 MHz, CDCl3): δ 8.18 (d, J = 8.3 Hz, 1H), 8.04 – 8.01 (m, 1H), 7.58 
– 7.49 (m, 1H), 7.43 – 7.37 (m, 1H), 7.36 – 7.30 (m, 1H), 6.73 – 6.65 (m,  
2H), 5.17 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). ESI-MS 
m/z:  255.62 (M+ 1)+ 
 Synthesis of  ethyl 1-(3-cyanobenzyl)-1H-pyrrole-3-carboxylate (116b).  
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Compound 116b was obtained as a white solid (1.40 g, 60%) from compound 
115b (2.0 g, 9.16 mmol), according to the procedure used for 116a, m. p. 87 – 
89 °C. 1H NMR (300 MHz, CDCl3) δ 7.63 – 7.57 (m, 1H), 7.50 – 7.42 (m, 
1H), 7.39 (s, 1H), 7.35 – 7.28 (m, 2H), 6.70 – 6.57 (m, 1H), 5.10 (s, 2H), 4.27 
(q, J = 7.0 Hz, 2H), 1.33 (t, J = 7.0 Hz, 3H). ESI-MS m/z:  275.07 (M + 1)+ 
Synthesis of  ethyl 1-(3-nitrobenzyl)-5-(2,2,2-trichloroacetyl)-1H-pyrrole-
3-carboxylate (117a).  
 
Compound 117a was obtained as a yellow solid (0.34 g, 88%) from compound 
116a (0.300 g, 1.03 mmol), according to the procedure used for 104a, m. p. 84 
– 86 °C. 1H NMR (300 MHz, CDCl3)δ 8.20 – 8.13 (m, 1H), 7.98 (d, J = 1.1 
Hz, 1H), 7.97 – 7.94 (m, 1H), 7.69 (d, J = 1.1 Hz, 1H), 7.57 – 7.49 (m, 1H), 
7.46 – 7.40 (m, 1H), 5.66 (s, 2H), 4.34 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 
3H). ESI-MS m/z:  418.07 (M + 1)+ 
Synthesis of  ethyl 1-(3-cyanobenzyl)-5-(2,2,2-trichloroacetyl)-1H-pyrrole-
3-carboxylate (117b).  
 
Compound 117b was obtained as a white solid (1.27 g, 81%) from compound 
116b (1.0 g, 3.90 mmol), according to the procedure used for 104a, m. p. 109 
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– 110 °C. 1H NMR (300 MHz, CDCl3): δ 7.97 (d, J = 1.1 Hz, 1H), 7.66 (d, J = 
1.1 Hz, 1H), 7.63 – 7.56 (m, 1H), 7.50 – 7.42 (m, 1H), 7.38 – 7.31 (m, 2H), 
5.63 (s, 2H), 4.34 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H).ESI-MS m/z: 
399.01 (M + 1)+. 
Synthesis of  ethyl 5-(benzylcarbamoyl)-1-(3-nitrobenzyl)-1H-pyrrole-3-
carboxylate (118a).  
 
Compound 118a was obtained as a yellow solid (0.43 g, 88%) from compound 
117a (0.500 g, 1.19 mmol), according to the procedure used for 108a, m. p. 
136 – 137 °C. 1H NMR (300 MHz, CDCl3): δ 8.20 – 8.09 (m, 1H), 8.05 – 7.95 
(m, 1H), 7.54 – 7.41 (m, 3H), 7.37 – 7.16 (m, 5H), 7.09 – 7.04 (m, 1H), 6.39 – 
6.21 (m, 1H, exchangeable with D2O), 5.71 (s, 2H), 4.50 (d, J = 4.6 Hz, 2H), 
4.26 (q, J = 6.9 Hz, 2H), 1.32 (t, J = 6.9 Hz, 3H). ESI-MS m/z: 408.11 (M + 
1)+. 
Synthesis of  ethyl 5-(benzylcarbamoyl)-1-(3-cyanobenzyl)-1H-pyrrole-3-
carboxylate (118b).  
 
Compound 118b was obtained as a yellow solid (0.51 g, 45%) from compound 
117b (1.15 g, 2.9 mmol), according to the procedure used for 108a, m. p. 150 
– 153 °C. 1H NMR (300 MHz, CDCl3): δ 7.62 – 7.53 (m, 1H), 7.49 – 7.37 (m, 
4H), 7.37 – 7.19 (m, 5H), 7.08 – 7.01 (m, 1H), 6.23 (t,  J = 5.2 Hz , 1H, 
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exchangeable with D2O), 5.65 (s, 2H), 4.51 (d, J = 5.2 Hz, 2H), 4.27 (q, J = 
7.0 Hz, 2H), 1.33 (t, J = 7.0 Hz, 3H). ESI-MS m/z: 388.15 (M + 1)+ 
 
Synthesis of  ethyl 1-(3-aminobenzyl)-5-(2,2,2-trichloroacetyl)-1H-pyrrole-
3-carboxylate (119a).  
 
Compound 118a was obtained as a yellow solid (0.132 g, 73%) from 
compound 117a (0.200 g, 0.50 mmol), according to the procedure used for 
109a. 1H NMR (300 MHz, DMSO): δ 8.78 (t, J = 5.7 Hz, 1H, exchangeable 
with deuterium oxide), 7.71 – 7.55 (m, 1H), 7.38 – 7.12 (m, 6H), 7.00 – 6.81 
(m, 1H), 6.48 – 6.38 (m, 1H), 6.35 – 6.29 (m, 1H), 6.28 – 6.22 (m, 1H), 5.48 
(s, 2H), 5.03 (bs, 2H, exchangeable with deuterium oxide), 4.36 (d, J = 5.7 Hz, 
2H), 4.19 (d, J = 7.0 Hz, 2H), 1.25 (t, J = 7.0 Hz, 3H). ESI-MS m/z: 744.88 
(M x 2)+. 
Synthesis of  ethyl 1-(3-(aminomethyl)benzyl)-5-(benzylcarbamoyl)-1H-
pyrrole-3-carboxylate (119b). 
 
 Compound 119b was obtained as a slurry (0.270 g, 90%) from compound 
118b (0.300 g, 0.77 mmol), according to the procedure used for 109b. 1H 
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NMR (300 MHz, DMSO): δ 8.83 (t, J = 5.1 Hz, 1H, exchangeable with 
deuterium oxide), 8.35 – 8.14 (m, 2H), 7.85 – 7.64 (m, 1H), 7.46 – 7.15 (m, 
9H), 7.16 – 7.01 (m, 1H), 5.66 (s, 2H, exchangeable with deuterium oxide), 
4.35 (d, J = 5.1 Hz, 2H), 4.20 (q, J = 6.5 Hz, 2H), 4.02 – 3.90 (m, 2H), 1.24 (t, 
J = 6.5 Hz, 3H). ESI-MS m/z: 329.10 (M + 1)+. 




Compound 120a was obtained as a white solid (0.121, 82%) from compound 
119a (0.121 g, 0.27  mmol), according to the procedure used for 110a, mp 139 
– 142 °C. [α]D  -31.0 (c 0.3, MeOH).
1H NMR (300 MHz, DMSO):δ 9.89 (s, 
1H, exchangeable with deuterium oxide), 8.78 (t, J = 5.5 Hz, 1H, 
exchangeable with deuterium oxide), 7.74 (s, 1H), 7.62 – 7.51 (m, 1H), 7.31 – 
7.26 (m, 3H), 7.25 – 7.23 (m, 1H), 7.23 – 7.20 (m, 1H), 7.20 – 7.14 (m, 3H), 
7.02 (d, J = 6.8 Hz, 1H, exchangeable with deuterium oxide), 6.80 – 6.73 (m, 
1H), 5.61 (s, 2H), 4.33 (d, J = 5.5 Hz, 2H), 4.19 (q, J = 7.0 Hz, 2H), 4.12 – 
4.01 (m, 1H), 1.36 (s, 9H), 1.30 – 1.16 (m, 6H). ESI-MS m/z: 548.84 (M + 1)+ 
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Compound ent-120a was obtained as a white solid (0.121, 82%) from 
compound 119a (0.121 g, 0.27  mmol), according to the procedure used for 
ent-110a, mp 136 – 138 °C. [α]D  +27.0  (c 0.3, MeOH). 
1H NMR (300 MHz, 
DMSO) δ 9.89 (s, 1H, exchangeable with deuterium oxide), 8.78 (t, J = 5.5 
Hz, 1H, exchangeable with deuterium oxide), 7.74 (s, 1H), 7.62 – 7.51 (m, 
1H), 7.31 – 7.26 (m, 3H), 7.25 – 7.23 (m, 1H), 7.23 – 7.20 (m, 1H), 7.20 – 
7.14 (m, 3H), 7.02 (d, J = 6.8 Hz, 1H, exchangeable with deuterium oxide), 
6.80 – 6.73 (m, 1H), 5.61 (s, 2H), 4.33 (d, J = 5.5 Hz, 2H), 4.19 (q, J = 7.0 Hz, 
2H), 4.12 – 4.01 (m, 1H), 1.36 (s, 9H), 1.30 – 1.16 (m, 6H). ESI-MS m/z: 
548.84 (M + 1)+. 
Synthesis of  (S)-ethyl 5-(benzylcarbamoyl)-1-(3-((2-((tert- 
butoxycarbonyl)amino)propanamido)methyl)benzyl)-1H-pyrrole-3-
carboxylate (120b).  
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Compound 120b was obtained as a white solid (0.207 g, 52%) from compound 
119b (0.400 g, 0.71  mmol), according to the procedure used for 110a, 141 – 
144 °C.  [α]D  - 7.4 (c 0.3, MeOH). 
1H NMR (300 MHz, DMSO): δ 8.81 (t, J = 
5.0 Hz, 1H, exchangeable with deuterum oxide), 8.26 (t, J = 5.6 Hz, 1H, 
exchangeable with deuterum oxide), 7.72 (s, 1H), 7.35 – 7.26 (m, 3H), 7.27 – 
7.18 (m, 4H), 7.17 – 7.10 (m, 1H), 7.11 - 7.07 (m, 1H), 7.01 – 6.94 (m, 1H), 
6.88 (d, J = 5.6 Hz, 1H, exchangeable with deuterum oxide), 5.61 (s, 2H), 4.36 
(d, J = 5.0 Hz, 2H), 4.27 – 4.13 (m, 4H), 3.96 (s, 1H), 1.39 (s, 9H), 1.25 (t, J = 
6.6 Hz, 3H), 1.17 (d, J = 6.6 Hz, 3H). ESI-MS m/z: 585.16 (M + Na)+ 
Synthesis of  (R)-ethyl 5-(benzylcarbamoyl)-1-(3-((2-((tert-
butoxycarbonyl)amino)propanamido)methyl)benzyl)-1H-pyrrole-3-
carboxylate (ent-120b).  
 
Compound ent-120b was obtained as a white solid (0.207 g, 52%) from 
compound 119b (0.400 g, 0.71  mmol), according to the procedure used for 
ent-110a, mp 140 – 143 °C. [α]D  + 9.8 (c 0.3, MeOH). 
1H NMR (300 MHz, 
DMSO): δ 8.81 (t, J = 5.0 Hz, 1H, exchangeable with deuterum oxide), 8.26 (t, 
J = 5.6 Hz, 1H, exchangeable with deuterum oxide), 7.72 (s, 1H), 7.35 – 7.26 
(m, 3H), 7.27 – 7.18 (m, 4H), 7.17 – 7.10 (m, 1H), 7.11 – 7.07 (m, 1H), 7.01 – 
6.94 (m, 1H), 6.88 (d, J = 5.6 Hz, 1H, exchangeable with deuterum oxide), 
5.61 (s, 2H), 4.36 (d, J = 5.0 Hz, 2H), 4.27 – 4.13 (m, 4H), 3.96 (s, 1H), 1.39 
(s, 9H), 1.25 (t, J = 6.6 Hz, 3H), 1.17 (d, J = 6.6 Hz, 3H). ESI-MS m/z: 585.16 
(M + Na)+. 
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Synthesis of  (S)-5-(benzylcarbamoyl)-1-(3-(2-((tert- butoxycarbonyl) 
amino) propanamido)benzyl)-1H-pyrrole-3-carboxylic acid (120c).  
 
Compound 120c was obtained as a white solid (0.160 g, 85%) from compound 
120a (0.200 g, 0.36 mmol), according to the procedure used for 110e, mp 232 
– 234 °C. [α]D  -16.3 (c 0.3, MeOH). 
1H NMR (300 MHz, DMSO) δ: δ 12.05 
(bs, 1H, exchangeable with deuterum oxide), 9.99 – 9.80 (m, 1H, 
exchangeable with deuterium oxide), 8.75 (t, J = 5.8 Hz, 1H, exchangeable 
with deuterium oxide), 7.69 – 7.63 (m, 1H), 7.61 – 7.54 (m, 1H), 7.34 – 7.28 
(m, 2H), 7.28 – 7.20 (m, 4H), 7.20 – 7.14 (m, 2H), 7.02 (d, J = 7.2 Hz, 1H, 
exchangeable with deuterium oxide), 6.80 – 6.74 (m, 1H), 5.59 (s, 2H), 4.34 
(d, J = 5.8 Hz, 2H), 4.15 – 4.04 (m, 1H), 1.37 (s, 9H), 1.22 (d, J = 7.0 Hz, 3H). 
ESI-MS m/z: 1040.90 (M x 2)+.  
 
Synthesis of  (R)-5-(benzylcarbamoyl)-1-(3-(2-((tert-
butoxycarbonyl)amino)propanamido)benzyl)-1H-pyrrole-3-carboxylic 
acid (ent-120c).  
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Compound ent-120c was obtained as a white solid (0.160 g, 85%) from 
compound ent-119a (0.200 g, 0.36 mmol), according to the procedure used for 
110e, mp 163 – 166 °C. [α]D  +14.2 (c 0.3, MeOH).
1H NMR (300 MHz, 
DMSO): δ 12.05 (bs, 1H, exchangeable with deuterum oxide), 9.99 – 9.80 (m, 
1H, exchangeable with deuterium oxide), 8.75 (t, J = 5.8 Hz, 1H, 
exchangeable with deuterium oxide), 7.69 – 7.63 (m, 1H), 7.61 – 7.54 (m, 
1H), 7.34 – 7.28 (m, 2H), 7.28 – 7.20 (m, 4H), 7.20 – 7.14 (m, 2H), 7.02 (d, J 
= 7.2 Hz, 1H, exchangeable with deuterium oxide), 6.80 – 6.74 (m, 1H), 5.59 
(s, 2H), 4.34 (d, J = 5.8 Hz, 2H), 4.15 – 4.04 (m, 1H), 1.37 (s, 9H), 1.22 (d, J = 
7.0 Hz, 3H). ESI-MS m/z: 1040.90 (M x 2)+.  
Synthesis of  (S)-5-(benzylcarbamoyl)-1-(3-((2-((tert-
butoxycarbonyl)amino)propanamido)methyl)benzyl)-1H-pyrrole-3-
carboxylic acid (120d).  
 
Compound 120d was obtained as a white solid (0.160 g, 85%) from compound 
120b (0.200 g, 0.36 mmol), according to the procedure used for 110e, mp 181 
– 184 °C. [α]D  -9.7 (c 0.3, MeOH). 
1H NMR (300 MHz, DMSO): δ 12.06 (bs, 
1H, exchangeable with deuterium oxide), 8.77 (t, J = 5.5 Hz, 1H, 
exchangeable with deuterium oxide), 8.27 (t, J = 5.3 Hz, 1H, exchangeable 
with deuterium oxide), 7.68 – 7.59 (m, 1H), 7.35 – 7.18 (m, 7H), 7.17 – 7.11 
(m, 1H), 7.10 – 7.05 (m, 1H), 7.01 – 6.92 (m, 1H), 6.88 (d, J = 7.0 Hz, 1H, 
exchangeable with deuterium oxide), 5.60 (s, 2H), 4.36 (d, J = 5.5 Hz, 2H), 
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4.26 – 4.13 (m, 2H), 4.02 – 3.92 (m, 1H), 1.37 (s, 9H), 1.17 (d, J = 6.9 Hz, 
3H). ESI-MS m/z: 534.87 (M + 1)+ 
Synthesis of  (R)-5-(benzylcarbamoyl)-1-(3-((2-((tert-
butoxycarbonyl)amino)propanamido)methyl)benzyl)-1H-pyrrole-3-
carboxylic acid (ent-120d).  
 
Compound ent-120d was obtained as a white solid (0.160 g, 85%) from 
compound ent-120b (0.200 g, 0.36 mmol), according to the procedure used for 
110e, 176 – 179 °C. [α]D  + 12.9 (c 0.3, MeOH). 
1H NMR (300 MHz, DMSO) 
δ : δ 12.06 (bs, 1H, exchangeable with deuterium oxide), 8.77 (t, J = 5.5 Hz, 
1H, exchangeable with deuterium oxide), 8.27 (t, J = 5.3 Hz, 1H, 
exchangeable with deuterium oxide), 7.68 – 7.59 (m, 1H), 7.35 – 7.18 (m, 
7H), 7.17 – 7.11 (m, 1H), 7.10 – 7.05 (m, 1H), 7.01 – 6.92 (m, 1H), 6.88 (d, J 
= 7.0 Hz, 1H, exchangeable with deuterium oxide), 5.60 (s, 2H), 4.36 (d, J = 
5.5 Hz, 2H), 4.26 – 4.13 (m, 2H), 4.02 – 3.92 (m, 1H), 1.37 (s, 9H), 1.17 (d, J 
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Synthesis of  (S)-1-((3-((2-(benzylcarbamoyl)-4-(ethoxycarbonyl)-1H-
pyrrol-1-yl)methyl)phenyl)amino)-1-oxopropan-2-aminium 2,2,2-
trifluoroacetate (121a).  
 
Compound 121a was obtained as a white solid (0.051 g, 99%) from compound 
120a (0.050 g, 0.09 mmol), according to the procedure used for 110a, mp 232 
– 234 °C. [α]D  + 5.3 (c 0.3, MeOH). 
1H NMR (300 MHz, DMSO): δ 10.34 (s, 
1H, exchangeable with deuterium oxide), 8.77 (t, J = 5.4 Hz, 1H, 
exchangeable with deuterium oxide), 8.19 – 8.06 (m, 3H, exchangeable with 
deuterium oxide), 7.77 (s, 1H), 7.60 – 7.52 (m, 1H), 7.34 – 7.31 (m, 1H), 7.31 
– 7.24 (m, 4H), 7.24 – 7.22 (m, 1H), 7.21 – 7.14 (m, 2H), 6.92 – 6.84 (m, 1H), 
5.63 (s, 2H), 4.34 (d, J = 5.4 Hz, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.97 – 3.90 (m, 
1H), 1.41 (d, J = 6.8 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H). ESI-MS m/z: 449.03 
(M + 1)+. 
Synthesis of (R)-1-((3-((2-(benzylcarbamoyl)-4-(ethoxycarbonyl)-1H-
pyrrol-1-yl)methyl)phenyl)amino)-1-oxopropan-2-aminium 2,2,2-
trifluoroacetate (ent-121a).  
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Compound ent-121a was obtained as a white solid (0.051 g, 99%) from 
compound ent-120a (0.050 g, 0.09 mmol), according to the procedure used for 
110a, mp 228 – 230. [α]D  - 3.0  (c 0.3, MeOH). 
1H NMR (300 MHz, DMSO): 
δ 10.34 (s, 1H, exchangeable with deuterium oxide), 8.77 (t, J = 5.4 Hz, 1H, 
exchangeable with deuterium oxide), 8.19 – 8.06 (m, 3H, exchangeable with 
deuterium oxide), 7.77 (s, 1H), 7.60 – 7.52 (m, 1H), 7.34 – 7.31 (m, 1H), 7.31 
– 7.24 (m, 4H), 7.24 – 7.22 (m, 1H), 7.21 – 7.14 (m, 2H), 6.92 – 6.84 (m, 1H), 
5.63 (s, 2H), 4.34 (d, J = 5.4 Hz, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.97 – 3.90 (m, 
1H), 1.41 (d, J = 6.8 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H). ESI-MS m/z: 449.03 
(M + 1)+. 
Synthesis of  (S)-1-((3-((2-(benzylcarbamoyl)-4-(ethoxycarbonyl)-1H-
pyrrol-1-yl)methyl)benzyl)amino)-1-oxopropan-2-aminium 2,2,2-
trifluoroacetate (121b).  
 
Compound 121b  was obtained as a white solid (0.057 g, 99%) from 
compound 120b (0.050 g, 0.10 mmol), according to the procedure used for 
110, 155 – 158 °C. [α]D  +7.3  (c 0.3, MeOH). 
1H NMR (300 MHz, DMSO): δ 
8.88 – 8.75 (m, 2H, exchangeable with deuterium oxide), 8.10 – 7.96 (m, 3H, 
exchangeable with deuterium oxide), 7.73 (s, 1H), 7.35 – 7.25 (m, 4H), 7.27 – 
7.14 (m, 4H), 7.12 – 7.07 (m, 1H), 7.08 – 6.96 (m, 1H), 5.63 (s, 2H), 4.35 (d, J 
= 5.5 Hz, 2H), 4.29 – 4.14 (m, 4H), 3.86 – 3.77 (m, 1H), 1.35 (d, J = 6.5 Hz, 
3H), 1.26 (t, J = 6.9 Hz, 3H). ESI-MS m/z: 462.54 (M + 1)+. 
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Synthesis of  (R)-1-((3-((2-(benzylcarbamoyl)-4-(ethoxycarbonyl)-1H-
pyrrol-1-yl)methyl)benzyl)amino)-1-oxopropan-2-aminium 2,2,2-
trifluoroacetate (ent-121b).  
 
Compound ent-121b  was obtained as a white solid (0.057 g, 99%) from 
compound ent-120b (0.050 g, 0.10 mmol), according to the procedure used for 
110a, 154 – 157 °C. [α]D  - 6.3  (c 0.3, MeOH).
 1H NMR (300 MHz, DMSO): 
δ 8.88 – 8.75 (m, 2H, exchangeable with deuterium oxide), 8.10 – 7.96 (m, 
3H, exchangeable with deuterium oxide), 7.73 (s, 1H), 7.35 – 7.25 (m, 4H), 
7.27 – 7.14 (m, 4H), 7.12 – 7.07 (m, 1H), 7.08 – 6.96 (m, 1H), 5.63 (s, 2H), 
4.35 (d, J = 5.5 Hz, 2H), 4.29 – 4.14 (m, 4H), 3.86 – 3.77 (m, 1H), 1.35 (d, J = 
6.5 Hz, 3H), 1.26 (t, J = 6.9 Hz, 3H). ESI-MS m/z: 462.54 (M + 1)+. 




Compound 121c  was obtained as a white solid (0.071 g, 99%) from 
compound 120c (0.070 g, 0.13 mmol), according to the procedure used for 
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110a, 215 – 217 °C. [α]D  + 3.0  (c 0.3, MeOH). 
1H NMR (300 MHz, DMSO): 
δ 12.10 (s, 1H, exchangeable with deuterium oxide), 10.34 (s, 1H, 
exchangeable with deuterium oxide), 8.74 (t, J = 5.5 Hz, 1H, exchangeable 
with deuterium oxide), 8.19 – 8.04 (m, 3H, exchangeable with deuterium 
oxide), 7.63 – 7.65 (m, 1H), 7.60 – 7.50 (m, 1H), 7.33 – 7.24 (m, 5H), 7.24 – 
7.22 (m, 1H), 7.21 – 7.15 (m, 2H), 6.95 – 6.84 (m, 1H), 5.62 (s, 2H), 4.34 (d, J 
= 5.5 Hz, 2H), 4.01 – 3.87 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H). ESI-MS m/z: 
421.05 (M + 1)+  




Compound ent-121c  was obtained as a white solid (0.071 g, 99%) from 
compound ent-120c (0.070 g, 0.13 mmol), according to the procedure used for 
110a, mp 210 – 212 °C. [α]D  -1.8  (c 0.3, MeOH). 
1H NMR (300 MHz, 
DMSO): δ 12.10 (s, 1H, exchangeable with deuterium oxide), 10.34 (s, 1H, 
exchangeable with deuterium oxide), 8.74 (t, J = 5.5 Hz, 1H, exchangeable 
with deuterium oxide), 8.19 – 8.04 (m, 3H, exchangeable with deuterium 
oxide), 7.63 – 7.65 (m, 1H), 7.60 – 7.50 (m, 1H), 7.33 – 7.24 (m, 5H), 7.24 – 
7.22 (m, 1H), 7.21 – 7.15 (m, 2H), 6.95 – 6.84 (m, 1H), 5.62 (s, 2H), 4.34 (d, J 
= 5.5 Hz, 2H), 4.01 – 3.87 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H). ESI-MS m/z: 
421.04 (M + 1)+ 
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Compound 121d  was obtained as a white solid (0.070 g, 99%) from 
compound 120d (0.070 g, 0.13 mmol), according to the procedure used for 
110a, mp 204 – 206 °C.  [α]D  +2.8  (c 0.3, MeOH). 
1H NMR (300 MHz, 
DMSO):δ 11.95 (s, 1H, scambiato con D2O), 8.87 – 8.59 (m, 2H, scambiato 
con D2O),8.23 – 8.19 (m, 2H, scambiato con D2O), 7.65 (s, 1H),7.33 – 7.14 
(m, 8H),7.04 – 6.98 (m, 1H), 5.62 (s, 2H),4.36 (d, J = 5.7 Hz, 2H), 4.32 – 4.20 
(m, 2H), 3.86 – 3.73 (m, 1H), 1.34 (d, J = 6.5 Hz, 3H). ESI-MS m/z:435.14 
(M + 1)+. 




 Compound ent-121d  was obtained as a white solid (0.070 g, 99%) from 
compound ent-120d (0.070 g, 0.13 mmol), according to the procedure used for 
110a, 204 – 206 °C. [α]D  -3.1  (c 0.3, MeOH). 
1H NMR (300 MHz, 
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DMSO):δ11.95 (s, 1H, scambiato con D2O),8.87 – 8.59 (m, 2H, scambiato con 
D2O),8.23 – 8.19 (m, 2H, scambiato con D2O), 7.65 (s, 1H),7.33 – 7.14 (m, 
8H),7.04 – 6.98 (m, 1H), 5.62 (s, 2H),4.36 (d, J = 5.7 Hz, 2H), 4.32 – 4.20 (m, 
2H), 3.86 – 3.73 (m, 1H), 1.34 (d, J = 6.5 Hz, 3H). ESI-MS m/z:435.14 (M + 
1)+. 
 
7.3. Bisubstrate inhibitors. 
General procedures for peptides synthesis: 123, 126, 139 – 144. 
Peptides 123, 126, 139 – 144 were prepared following standard Fmoc SPPS 
protocols. The required N-modified L-arginine building blocks were prepared 
from a common thiourea precursor as previously described.161 Peptides were 
assembled on the 2-chlorotrityl resin working at 0.1 mmol scale, peptide 
couplings were performed using 4.0 equiv of protected Fmoc amino acid, 4.0 
equiv of BOP reagent, and 8.0 equiv of DIPEA in a total volume of 10 mL of 
DMF at RT for 1 h. Alternatively, incorporation of the N-modified L-arginine 
building residues was performed using 2.0 equiv of the N-modified L-arginine 
building blocks, 2.0 equiv of BOP reagent, and 4.0 equiv of DIPEA in a total 
volume of 10 mL of DMF at RT overnight. Peptide couplings were verified 
using the Kaiser and bromophenol blue tests. Upon completion of SPPS, 
peptides were cleaved from the resin and deprotected using a mixture of 
95:2.5:2.5 TFA/TIS/H2O followed by Et2O precipitation to yield the crude 
peptides. Each peptide was purified to homogeneity using RP-HPLC, 
employing a Prosphere C18 column (250 22 mm, 300 Å, 10 m) with a gradient 
of 5 to 95% acetonitrile (0.1% TFA) in 90 min at a flow rate of 11.5 mL min-1 
. Peptide identity was confirmed by MALDI-MS analysis, in each case 
providing the expected mass.  
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General procedures for removal of Aloc protecting group:124 and 127  
For removal of the Aloc protecting group of peptides 123 and 126, the resin 
was first washed with CH2Cl2 (2 × 10 mL) under argon after which PhSiH3 
(0.74 mL, 6.0 mmol) in CH2Cl2 (4 mL) and Pd- (PPh3)4 (74 mg, 0.06 mmol) in 
CH2Cl2 (12 mL) were added and the mixture swirled under argon for 1 hour. 
The reaction mixture was drained and the procedure was repeated. To remove 
residual palladium catalyst, the resin was then washed with CH2Cl2 (5 × 10 
mL), a 0.5% solution of diethyldithiocarbamic acid trihydrate sodium salt in 
DMF (5 × 10 mL), and DMF (5 × 10 mL). After Aloc removal, peptides 124 
and 127 not cleaved from the resin were used for coupling with adenosine 
fragments. 
Synthesis of 2-{(3aR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2- 




To a well stirred suspension of ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-
2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol (128) (758 mg, 
2.47 mmol) and PPh3 (1.617 g, 6.166 mmol) in THF (12.4 cm
3), acetone 
cyanohydrins (0.57 cm3, 6.2 mmol) was added. Within 5 min, DEAD (0.98 
cm3, 97%, 6.1 mmol) was added at 0 °C. The solution was stirred at 0 °C for 
50 min and further at 20 °C for 16 h. Evaporation in vacuo and column 
chromatography (SiO2; EtOAc– MeOH (96:4)) afforded 129 (698 mg, 89%) as 
a brown oil; δH(200 MHz; CDCl3) 1.42 (3 H, s), 1.64 (3 H, s), 2.84–3.08 (2 H, 
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m),4.51–4.60 (1 H, m), 5.16 (1 H, dd, J 6.2, 3.3), 5.50 (1 H, dd, J 6.2, 2.1), 
5.71 (2 H, br s), 6.12 (1 H, d, J 2.1); 7.93 (1 H, s); 8.38 (s, 1 H). 
 




To a 0.1 M solution of 129 in THF (11 cm3, 1.1 mmol), glacial  acetic acid (20 
cm3) and PtO2 (200 mg) were added. The suspension was hydrogenated (4 bar 
H2) for 19 h. The catalyst was removed by filtration and the solvent 
evaporated in vacuo. The product was used in the next step without further 
purification. 
Synthesis of Ethyl (E)-3-{(3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2- 
dimethylperhydrofuro[3,4-d ][1,3]dioxol-4-yl}prop-2-enoate (132) 163 
 
To 128 (12.3 g, 40 mmol) in Me2SO (100 cm3), Ph3P=CHCO2Et (42.8 g, 100 
mmol) and o-iodoxybenzoic acid (IBX) (27.8 g,100 mmol) were added. The 
mixture was stirred at 20 °C for 72 h. Water (500 cm3) was added and the 
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mixture extracted with EtOAc (2 × 500 cm3). The combined organic phases 
were dried (Na2SO4) and concentrated to a residue which was purified by 
column chromatography (SiO2; EtOAc–MeOH (96:4)) to give 132 (10.5 g, 
70%) as colorless crystals, mp 102 °C (EtOH) (lit., 104–106 _C); δH(300 
MHz; CDCl3) 1.22 (3 H, t, J 7.2), 1.40 (3 H, s), 1.63 (3 H, s), 4.11 (2 H, q, J 
7.2), 4.79–4.83 (1 H, m), 5.14 (1 H, dd, J 6.2, 3.4), 5.56 (1 H, dd, J 6.2, 1.9), 
5.81 (1 H, dd, J 15.9, 1.7), 6.13 (1 H, d, J 1.9), 6.96 (1 H, dd, J 15.9, 5.6), 7.87 
(1 H, s), 8.33 (1 H, s). 
Synthesis of (E)-3-{(3aR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-
dimethylperhydrofuro[3,4-d ][1,3]dioxol-4-yl}prop-2-en-1-ol (133) 163. 
 
To 132 (375 mg, 1 mmol) in CH2Cl2 (3 cm3), a 1 M solution of DIBAL-H in 
hexane (8 cm3, 8 mmol) was added dropwise. The mixture was stirred at - 78 
°C for 2 h and then quenched with MeOH (5 cm3). A saturated aqueous 
solution of potassium sodium tartrate monohydrate (Rochelle salt, 50 cm3) 
was added, and the resulting suspension was stirred vigorously for 16 h at 20 
°C, then extracted with EtOAc (3 × 50 cm3). The combined organic phases 
were dried (Na2SO4) and evaporated to dryness in vacuo to afford 4 (328 mg, 
98%) as a colorless foam; [α]20D 17.8 (c. 1 in CHCl3); δH(300 MHz; CDCl3) 
1.40 (3 H, s), 1.63 (3 H, s), 4.07 (2 H, s), 4.72 (1 H, dd, J 4.1, 2.5), 5.02 (1 H, 
dd, J 6.2, 4.1), 5.54 (1 H, dd, J 6.2, 2.2), 5.56 (2 H, s), 5.85–5.87 (2 H, m), 
6.10 (1 H, d, J 2.2), 7.88 (1 H, s), 8.37 (1 H, s). 
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 Synthesis of 2-(E)-3-{(3aR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2- 
dimethylperhydrofuro [3,4-d][1,3]dioxol-4-l}prop-2-enyl-2,3-dihydro-1H-
isoindole-1,3-dione (134) 163 
 
DEAD (0.234 cm3, 97%, 1.46 mmol) was added dropwise to a stirred 
suspension of 133(490 mg, 1.46 mmol), phthalimide (215 mg, 1.46 mmol) and 
Ph3P (383 mg, 1.46 mmol) in THF (7 cm3). After stirring for 1.5 h at 20 °C, a 
colorless solid started to precipitate. Stirring was continued for 1 h, after 
which the mixture was cooled to 0 °C and filtered. The residue was washed 
with Et2O and dried in vacuo to give 134 (461 mg, 68%) as colorless crystals, 
mp 215 °C (MeOH); [α]20D 9.0 (c. 1 in CHCl3); δH(300 MHz;CDCl3) 1.36 (3 
H, s), 1.59 (3 H, s), 4.19 (2 H, d, J 5.3), 4.69(1 H, dd, J 6.5, 3.1), 4.98 (1 H, 
dd, J 6.2, 3.1), 5.49 (1 H,dd, J 6.2, 2.0), 5.59 (2 H, br s), 5.73 (1 H, dt, J 15.6, 
5.3), 5.84(1 H, dd, J 15.6, 6.5), 6.07 (1 H, d, J 2.0), 7.71–7.76 (2 H, m),7.80–
7.86 (3 H, m), 8.24 (1 H, s). 
Synthesis of 9-{(3aR,4R,6R,6aR)-6-[(E)-3-Aminoprop-1-enyl]-2,2- 
dimethylperhydrofuro[ 3,4-d ][1,3]dioxol-4-yl}-9H-purin-6-amine (135) 163   
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To phthalimide 134 (885 mg, 1.91 mmol), a solution of 33% MeNH2 in EtOH 
(30 cm3) was added and the mixture was stirred at 20 °C for 16 h. After 
evaporation in vacuo, the residue was dissolved in CHCl3 (25 cm3) and 
extracted with 10% aqueous AcOH (30 cm3). The aqueous phase was washed 
with CHCl3 (3 × 25 cm3), adjusted to pH > 12 with 2 N NaOH and then 
extracted again with CHCl3 (4 × 25 cm3). The combined organic phases were 
dried (Na2SO4) and evaporated to give 7 (605 mg, 95%) as a colorless foam; 
[α]20D 30.8 (c. 1 in CHCl3); δH (300 MHz; CDCl3) 1.39 (3 H, s), 1.62 (3 H, s), 
3.22 (2 H, d, J 5.1), 4.68 (1 H, dd, J 7.3, 3.4), 4.99 (1 H, dd, J 6.2, 3.4), 5.53 (1 
H, dd, J 6.2, 2.2), 5.71 (1 H, dd, J 15.6, 7.3), 5.83 (1 H, dt, J 15.6, 5.1), 5.87 (2 




The allylic amine 135 (125 mg, 0.376 mmol) in EtOH (10 cm3 ) was 
hydrogenated (4 bar H2) in the presence of 10% Pd/C (100 mg) for 18 h. The 
catalyst was removed by filtration and the solvent evaporated in vacuo. TFA–
H2O (5:2, 30 cm3 ) was added and the mixture stirred for 1 h at 20 C, then 
evaporated to dryness to give 136 (94 mg, 84%) as a yellow foam; [α] 20 D 
δH(300 MHz; CD3OD) 1.75–1.87 (4 H, m), 2.97 (2 H, t, J 7.5), 4.00–4.05 (1 
H, m), 4.21 (1 H, t, J 5.0), 4.78 (1 H, t, J 5.0), 5.97 (1 H, d, J 5.0), 8.19 (1 H, 
s), 8.24 (1 H, s). 
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General procedures for thiourea building blocks 131, 137 and 138. 





A solution of 130 (0.31 mmol, 0.100 g) in DCM (1 mL) was treated with a 0.1 
M solution of Pbf-NCS in DCM (0.62 mmol, 6.2 mL) followed by addition of 
TEA (0.93 mmol, 0.2 mL). After stirring 1 h at ambient temperature TLC 
analysis revealed complete consumption of the PbfNCS with formation of the 
desired product. The mixture was concentrated and applied directly to a silica 
column, eluting with 9:1 DCM/MeOH. Following solvent removal the title 
compound was obtained as a yellow solid (0.097 g, 50%)  and directly used in 
the next step given the high instability at room temperature. ESI-MS m/z: 
632.5 (M + 1)+.  
N-(((E)-3-((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)allyl)carbamothioyl)-
2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonamide 137  
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Yellow solid (0.155, 80%). ESI-MS m/z: 645.4 (M + 1)+.  
 
General procedure for preparation of final compounds 80 – 85  
The resin bearing peptide 124 or 127 (0.1 mmol) was first washed with DCM 
(2 × 10 mL) under N2 after which a solution of thiourea precursor (0.3 mmol 
of 131, 137 or 138) and EDCI (0.3 mmol) in DCM (10 mL) was added and the 
mixture swirled under nitrogen for 2 hours. The reaction mixture was drained 
and the resin was washed with DCM (3 x 10 mL), DMF (3 x 10 mL) and again 
with DCM (3 x 10 mL).  The protected peptide was deprotected and cleaved 
using a mixture of 95:2.5:2.5 TFA/TIS/H2O followed by Et2O precipitation to 
yield the crude peptides. Each peptide was purified to homogeneity using RP-
HPLC, employing a Prosphere C18 column (250 22 mm, 300 Å, 10 m) with a 
gradient of 5 to 95% acetonitrile (0.1% TFA) in 90 min at a flow rate of 11.5 
mL min-1 . Peptide identity was confirmed by MALDI-MS analysis, in each 
case providing the expected mass.  
80:  
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7.4. Indole derivatives 
Synthesis of 2-(5-nitro-1H-indol-3-yl)-2-oxoacetyl chloride 150 
 
To 5-nitro indole (1.50 g, 9.25 mmol) in EtOH (100 mL) was added dropwise 
at 0 °C oxalyl chloride (1.50 g, 9.25 mmol). The reaction was left to stirr at 
room temperature for 48 h. The desired product was obtain as yellow solid 
after filtration (2.29, 97 %) 






Compound 150 was suspended in 60 mL of H2O and KOH (2.55, 45.a mmol). 
The reaction was heated at 120 °C for 24 h. After cooling the reaction was 
acidified with HCl 12 N until pH 1. The title compound was recovered after 
filtration as yellow solid (2.10 g, 99%). 
Synthesis of 5-nitro-1H-indole-3-carboxylic acid (152) 
 
Compound 151 was dissolved in 150 mL of aqueous solution of H2O2 and 
heated at 100 °C for 24 h. Compound152 was obtained as yellow solid (2.10 g, 
9.08 mmol) after filtration, mp 287 – 290 °C. 1H NMR (300 MHz, DMSO): δ 
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12.47 (br s, 2H, exchangeable with D2O); 8.91 (d, J = 2 Hz, 1H); 8.29 (s, 1H); 
8.11 (dd, J1 = 9 Hz, J2 = 2 Hz, 1H); 7.68 (d, J = 9 Hz, 1H). ESI m/z: 207 [M + 
H]+.  
Synthesis of ethyl 5-nitro-1H-indole-3-carboxylate (149b) 
 
To a solution of 152 (1.60 g, 7.73 mmol) in EtOH absolute (95 mL) was added 
H2SO4 (1 mL) and heated at reflux. The mixture was concentrated under 
reduced pressure, the residue was dissolved with AcOEt (100 mL) and washed 
with NaOH 2N (3 x 30 mL) and Brine. The organic layer was dried with 
Na2SO4, filtered and evaporated under reduced pressure. Compound 149 was 
obtained as yellow solid (1.59 g, 88%), mp 229 – 230 °C. 1H NMR (300 MHz, 
DMSO-d6): δ 11.90 (s, 1H exchangeable with D2O); 9.18 (d, J = 1.4 Hz, 1H); 
8.46 (s 1H), 8.25 (dd, J1 = 7.5 Hz, J2 = 1.15 Hz, 1H); 7.59 (d, J = 7.5 Hz, 1H); 
4.29 (q, J = 5.8 Hz, 2H); 1.30 (t, J = 5.9 Hz, 3H).  ESI m/z: 234.21 [M + H]+. 
Synthesis of ethyl (E)-2-(2-(4-nitrophenyl)hydrazono)propanoate 153 
 
A solution of 4-nitro-phenylhydrazine (4.20 g, 27.4 mmol) in glacial AcOH 
(52 mL) was heated at 55 °C for 1 h and then was added ethyl piruvate (3 mL, 
27.4 mmol). After 5 h were added 100 mL of saturated solution of Ca2CO3. 
The aqueous solution was extracted with AcOEt (3 x 200 mL), then the 
combined organic layers were washed with Brine, dried with Na2SO4, filtered 
and evaporated inder reduced pressure. Compound 153 was obtained as brown 
                                                                        Chapter 7: Experimental section  
212 
 
solid (6.58 g, 95 %) after trituration with hexane, mp 156.8 - 157.2 °C. 1H 
NMR (300 MHz, CDCl3): δ 8.21 (d, J = 9 Hz, 2H); 7.98 (s, 1H, exchangeable 
with D2O); 7.27 (d, J = 9 Hz, 2H); 4.34 (q, J = 14 Hz, 2H); 2.17 (s, 3H); 1.39 
(t, J = 14 Hz, 3H). ESI m/z: 252 [M + H]+. 
Synthesis of ethyl 5-nitro-1H-indole-2-carboxylate 149c 
 
To a solution of 153 (2.00 g, 7.96 mmol) in tolene 200 mL was added PPA 
(12.5 g) and the reaction wa left to stir at 115 °C for 12 h and 100 mL of 
saturated aqueous solution of NaHCO3  and 100 mL of NaOH 6N were added. 
The basic aqueous solution was extracted with toluene (5 x 100 mL)  and the 
combined organic layers were washed with brine dried, filtered and evaporated 
under reduced pressure. Compound 149c was obtained as yellow solid (1.40 g, 
75 %) after purification by flash chromatography (AcOEt : hexane 1:1); mp 
209 – 212 °C. 1H NMR (300 MHz, CDCl3): δ 9.24 (s, 1H exchangeable with 
D2O); 8.69 (d, J = 2 Hz, 1H); 8.23 (dd, J1 = 9 Hz, J2 = 2 Hz, 1H); 7.49 (d, J = 9 
Hz, 1H); 7.39 – 7.38 (m, 1H); 4.45 (q, J = 14 Hz, 2H); 1.44 (t, J = 14 Hz, 3H).  
ESI m/z: 235 [M + H]+. 
 
Continuous-flow processing for the reduction of 155a – c  using the H-
Cube Pro™ hydrogenator. Example: synthesis of 1H-indol-5-amine (155a) 
 
A 124 mL stock solution of 149a  0.03 M concentration in EtOH/AcOEt 1:1 
was prepared. The reaction parameters (full-H2 mode, 30 °C, 10 bar and 1 mL 
min_1 floow rate) were selected on the H-Cube-Pro™ hydrogenator. The 
instrument was setted with a 30 mm Pd/C 10% CatCart and the processing was 
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started, whereby initially only pure solvent was pumped through the system 
until the instrument had achieved the desired reaction parameters and stable 
processing. At that point, the sample inlet line was switched to the vial 
containing the substrate. A total reaction volume of 124 mL was collected and 
the cartridge subsequently washed with pure solvent for 5 min to remove any 
substrate/product still adsorbed on the catalyst. Evaporation of the solvent 
afforded the desired product 155a (0.810 g, 99%), mp 131 – 133 °C. 1H NMR 
(300 MHz, DMSO-d6) δ 10.56 (s, 1H exchangeable with D2O), 7.11 (t, J = 2.7 
Hz, 1H), 7.07 (d, J = 8.5 Hz, 1H), 6.72 – 6.63 (m, 1H), 6.47 (dd, J = 8.5, 2.0 
Hz, 1H), 6.14 – 6.08 (m, 1H), 4.62 (s, 2H exchangeable with D2O). ESI-MS 
m/z: 133 [M+H]+.   
 
Ethyl 5-amino-1H-indole-3-carboxylate 155b 
 
Yellow solid (0.872 g, resa 99%), mp 120 – 121 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 11.78 (s, 1H exchangeable with D2O), 8.35 (s, 1H), 7.33 (d, J = 
1.5 Hz, 1H), 7.11 (d, J = 7.4 Hz, 1H), 4.33 – 4.23 (m, 4H exchangeable with 
D2O), 1.30 (t, J = 5.9 Hz, 3H). ESI m/z: 205 [M + H]
+ 
Ethyl 5-amino-1H-indole-2-carboxylate 155c 
 
Yellow solid (0.872 g, 99%), 113.6 – 114.9 °C. 1H NMR (300 MHz, DMSO): 
δ 11.39 (s, 1H, exchangeable with D2O); 7.16 (d, J = 9 Hz, 1H); 6.84 (s, 1H); 
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6.71 - 6.68 (m, 2H); 4.65 (s, 2H, exchangeable with D2O); 4.30 (q, J = 14 Hz, 
2H); 1.32 (t, J = 14 Hz, 3H). ESI m/z: 205 [M + H]+. 
Synthesis of Series I derivatives  
General procedures for coupling reaction (156a – c). Example: synthesis 
of (9H-fluoren-9-yl)methyl (2-((1H-indol-5-yl)amino)-2-oxoethyl) 
carbamate (156a) 
 
To a solution of HOBt (1.36 g, 8.93 mmol), HBTU (3.38 g, 8.93 mmol), 
DIPEA (10.93 mL, 17.85 mmol) and Fmoc-Gly-OH (1.66 g, 5.58 mmol) in 
THF/DMF 4:1 (41 mL) was added a solution of 155a (0.491g, 3.72 mmol) ) in 
THF/DMF  4:1 (12 mL). The reaction was left to stir at room temperature for 
12 h and then was concentrated under reduced pressure. The residue was 
dissolved with AcOEt (100 mL) and washed with ) s.s. of NaHCO3 (3 x 10 
mL), NaCl and dried over Na2SO4. Filtration, evaporation under vacuum 
follone by chromatography purification (AcOEt/DCM, 1:9) afford the desired 
product 156a as white solid (0.760 g, 50%), mp 105-110 °C. 1H NMR (300 
MHz, DMSO-d6) δ 10.99 (s, 1H exchangeable with D2O), 9.73 (s, 1H 
exchangeable with D2O), 7.91 – 7.85 (m, 3H), 7.75 – 7.73 (m, 2H), 7.64 – 
7.60 (m, 1H), 7.45 – 7.40 (m, 2H), 7.36 – 7.29 (m, 4H), 7.21 – 7.17 (m, 1H), 
6.37 (t, J = 5.5 Hz, 1H, exchangeable with D2O), 4.– 4.25 (m, 3H), 3.80 (d, J = 








carboxylate  156b 
 
Compound 156b was obtained as white solid (0.955 g, 50%)  starting from 
155b (1.24 g, 5.29 mmol) and Boc-Gly-OH (1.85 g, 10.58 mmol) following 
the synthetic procedures used for 156a; mp 134 – 138 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 11.84 (s, 1H exchangeable with D2O), 9.85 (s, 1H exchangeable 
with D2O), 8.26 (s, 1H), 8.01 (d, J = 2.6 Hz, 1H), 7.45 – 7.37 (m, 2H), 7.03 (t, 
J = 6.2 Hz, 1H exchangeable with D2O), 4.28 (q, J = 7.1 Hz, 2H), 3.73 (d, J = 
6.2 Hz, 2H), 1.42 (s, 9H), 1.35 (t, J = 7.1 Hz, 3H). ESI m/z: 362 [M + H]+. 
Ethyl 5-(2-((tert-butoxycarbonyl)amino)acetamido)-1H-indole-2-
carboxylate  156c 
 
Compound 156c was obtained as white solid (0.955 g, 50%)  starting from 
155c (1.24 g, 5.29 mmol) and Boc-Gly-OH (1.85 g, 10.58 mmol) following 
the synthetic procedures used for 156a; 193 – 194 °C 1H NMR (300 MHz, 
DMSO-d6) δ 11.79 (s, 1H exchangeable with D2O), 9.78 (s, 1H exchangeable 
with D2O), 7.99 (s, 1H), 7.39-7.31 (m, 2H), 7.058 (d, J = 2.1 Hz, 1H), 6.99 (t, 
J = 5.2 Hz, 1H exchangeable with D2O), 4.31 (q, J = 6.9 Hz, 2H), 3.70 (d, J = 
5.2 Hz, 2H), 1.38 (s, 9H), 1.32 (t, J = 6.9 Hz, 3H). ESI m/z: 362 [M + H]+. 
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Synthesis of 2-amino-N-(1H-indol-5-yl)acetamide 157a 
 
Compound 156a was dissolved in 50 mL of DCM/piperidine mixture (8:2 ). 
The reaction was left to stir at room temperature for 30 min. The mixture was 
concentrated under reduced pressure, Et2O was added (30 mL) and the product 
was recovered after filtration as white solid (0.349, 99%), mp 152 – 154 °C. 
1H NMR (300 MHz, DMSO-d6) δ  11.05 (s, 1H exchangeable with D2O), 9.71 
(s, 1H exchangeable with D2O), 7.95 (d, J = 2.0 Hz, 1H), 7.38 – 7.26 (m, 3H), 
6.42 – 6.41 (m, 1H), 2.91 (s, 2H), 2.76 (brs, 2H exchangeable with D2O). ESI 
m/z: 190 [M + H]+. 
Synthesis of ethyl 5-(2-aminoacetamido)-1H-indole-3-carboxylate 2,2,2-
trifluoroacetate 157b 
 
Compound 156 b was treated with a mixture of DCM/TFA 9:1 (10 mL). The 
reaction was left to stir at room temperature for 30 min. Evaporation of solvent 
under vacuum gave the desired product  157b as white solid (0.517 g, 99%); 
mp 140 – 142 °C.1H NMR (300 MHz, DMSO-d6) δ 11.93 (s, 1H exchangeable 
with D2O), 10.34 (s, 1H exchangeable with D2O), 8.31 (d, J = 1.9 Hz, 1H), 
8.20 – 7.99 (m, 4H, 2H exchangeable with D2O), 7.49 – 7.41 (m, 2H), 4.27 (q, 
J = 7.0 Hz, 2H), 3.78 (s, 2H), 1.33 (t, J = 7.0 Hz, 3H). ESI m/z: 262 [M + H]+. 
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Synthesis of ethyl 5-(2-aminoacetamido)-1H-indole-2-carboxylate 2,2,2-
trifluoroacetate (157c) 
 
Compound 157c was obtained as white solid (0.600 g, 99%) starting from 
156c (0.583 g, 1.61 mmol) according to the procedure used for 157b; mp 206 
– 208 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.87 (s, 1H exchangeable with 
D2O), 10.31 (s, 1H exchangeable with D2O), 8.18 – 8.03 (m, 3H, 2H 
exchangeable with D2O), 8.00 (s, d, J = 1.3 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H), 
7.34 (7.34 (dd, J = 7.9, 1.3 Hz, 1H), 7.14 (s, 1H), 4.33 (q, J = 7.0 Hz, 2H), 
3.77 (s, 2H), 1.33 (t, J = 7.0 Hz, 3H). ESI m/z: 262 [M + H]+ 
General procedures for preparation of 4methyl-phenyl substituted ureidic 
derivatives 159a – c. 
Example: synthesis of  N-(1H-indol-5-yl)-2-(3-(p-tolyl)ureido)acetamide 
159a 
 
To a suspension of 157a (0.169 g, 0.894 mmol) and TEA (0.31 mL, 2.23 
mmol) in THF dry (25 mL) was added dropwise a solution of p-tolil-
isocyanate (0.17 mL, 1.34 mmol) in THF dry (14 ml). The reaction was left to 
stir at room temperature for 12h. The mixture of reaction was evaporated 
under vacuum and crystallization with THF afford the desired product 159 
(0.144, 50 %) as white solid; mp 203 – 204 °C.1H NMR (300 MHz, DMSO-
d6) δ 11.00 (s, 1H exchangeable with D2O), 9.82 (s, 1H exchangeable with 
D2O), 8.71 (s, 1H), 7.85 (s, 1H), 7.42 – 7.24 (m, 4H), 7.20 (d, J = 8.8 Hz, 1H), 
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7.12 – 6.96 (7.03 (d, J = 8.3 Hz, 2H)), 6.38 – 6.34 (m, 2H), 3.93 (d, J = 5.4 
Hz, 2H), 2.22 (s, 3H). ESI m/z: 323 [M + H]+. 
Ethyl 5-(2-(3-(p-tolyl)ureido)acetamido)-1H-indole-3-carboxylate 159b 
 
White solid (0.050 g, 60%); 240 – 242 °C. H NMR (300 MHz, DMSO) δ 
11.85 (s, 1H, exchangeable with D2O), 9.98 (s, 1H exchangeable with D2O), 
8.71 (s, 1H exchangeable with D2O), 8.28 (s, 1H), 8.05 – 7.99 (m, 1H), 7.49 – 
7.36 (m, 2H), 7.29 (d, J = 8.0 Hz, 2H), 7.03 (d, J = 8.0 Hz, 2H), 6.39 (t, J = 
5.1 Hz, 1H exchangeable with D2O), 4.27 (q, J = 7.0 Hz, 2H), 3.94 (d, J = 5.1 
Hz, 2H), 2.21 (s, 3H), 1.33 (t, J = 7.0 Hz, 3H). ESI m/z: 395 [M + H]+. 
Ethyl 5-(2-(3-(p-tolyl)ureido)acetamido)-1H-indole-2-carboxylate 159c 
 
White solid (0.100 g, 60%); 267 – 268 °C. H NMR (300 MHz, DMSO) δ 
11.80 (s, 1H exchangeable with D2O), 9.92 (s, 1H exchangeable with D2O), 
8.70 (s, 1H exchangeable with D2O), 7.99 (s, 1H),7.40 – 7.33 (m, 2H), 7.28 (d, 
J = 8.1 Hz, 2H), 7.11 – 7.08 (m, 1H), 7.02 (d, J = 8.1 Hz, 2H), 6.37 (t, J = 5.1 
Hz, 1H exchangeable with D2O), 4.36 (q, J = 7.0 Hz, 2H), 3.93 (d, J = 5.1 Hz, 
2H), 2.21 (s, 3H), 1.35 (t, J = 7.0 Hz, 3H). ESI m/z: 395 [M + H]+ 
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General procedures for ureidic function formation through CDI (161a – c 
and 163a – c ). 
Example: synthesis of N-(1H-indol-5-yl)-2-(3-(2-(piperidin-1-yl)ethyl) 
ureido)acetamide 161a 
 
To a cooled solution of N-aminoethyl-piperidine 160 (0.12 ml, 0.868 mmol) 
and TEA (0.35, 2.55 mmol) in DCM dry (9 mL), was added CDI (0.198 g, 
1.22 mmol) and a solution 157a (0.109g, 0.579 mmol) in THF dry (2.2 mL). 
The reaction was left to stir at room temperature for 12 h. The mixture of 
reaction was concentrated under reduced pressure and purification by flash 
chromatography (DCM/MeOH/TEA, 9:1:0.5) afford the desired product as 
white product; 234 – 237 °C. 1H NMR (300 MHz, DMSO-d6) δ 10.98 (s, 1H 
exchangeable with D2O), 9.69 (s, 1H exchangeable with D2O), 7.83 (s, 1H), 
7.32 – 7.27 (m, 2H), 7.18 (d, J = 8.4 Hz, 1H), 6.43 – 6.31 (m, 2H 
exchangeable with D2O), 6.11 (t, J = 4.7 Hz, 1H exchangeable with D2O), 
3.82 (d, J = 4.7 Hz, 2H), 3.17 – 3.07 (m, 2H), 2.41 – 2.26 (m, 5H), 1.55 – 1.45 




Compound 161b was obtained as white solid (0.070 g, 64%) starting from 
157b (0.100 g, 0.266 mmol) according to the procedure used for 161a; mp 168 
- 170 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.83 (s, 1H exchangeable with 
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D2O), 9.85 (s, 1H exchangeable with D2O), 8.26 (s, 1H), 8.01 (s, 1H), 7.49 – 
7.30 (m, 2H), 6.37 (s, 1H exchangeable with D2O), 6.10 (t, J = 4.8 Hz, 1H 
exchangeable with D2O), 4.26 (q, J = 6.9 Hz, 2H), 3.83 (d, J = 5.2 Hz, 2H), 
3.11 (q, J = 5.7 Hz, 2H), 2.38 – 2.23 (m, 6H), 1.56 – 1.44 (m, 4H), 1.42 – 1.38 




Compound 161c was obtained as white solid (0.070 g, 64%) starting from 
157c (0.100 g, 0.266 mmol) according to the procedure used for 161a; mp 182 
– 184 °C. 1H NMR (300 MHz, DMSO) δ 11.81 (s, 1H exchangeable with 
D2O), 9.83 (s, 1H exchangeable with D2O), 7.99 (s, 1H), 7.43 – 7.30 (m, 2H), 
7.14 – 7.06 (m, 1H), 6.37 (t, J = 5.0 Hz, 1H exchangeable with D2O), 6.10 (t, J 
= 6.0 Hz, 1H exchangeable with D2O), 4.34 (q, J = 6.9 Hz, 2H), 3.82 (d, J = 
5.2 Hz, 2H), 3.16 – 3.06 (m, 2H), 2.39 – 2.24 (m, 6H), 1.56 – 1.44 (m, 4H), 
1.43 – 1.29 (m, 5H). ESI m/z: 416 [M + H]+ 
2-(3-(2-azidoethyl)ureido)-N-(1H-indol-5-yl)acetamide 163a 
 
Compound 163a was obtained as white solid (0.156 g,  40%) starting from 
157a (0.244 g, 1.29 mmol) and 2-azidoethan-1-amine (0.236 g, 1.93 mmol) 
according to the procedure used for 161a; mp 154 – 157 °C. 1H NMR (300 
MHz, DMSO) δ 10.97 (s, 1H exchangeable with D2O), 9.68 (s, 1H 
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exchangeable with D2O), 7.84 (s, 1H), 7.37 – 7.24 (m, 2H), 7.18 (dd, J = 8.7, 
1.5 Hz, 1H), 6.45 (t, J = 5.6 Hz, 1H exchangeable with D2O), 6.40 – 6.33 (m, 
1H), 6.29 (t, J = 5.4 Hz, 1H exchangeable with D2O), 3.84 (d, J = 5.5 Hz, 2H), 
3.35 (d, J = 5.8 Hz, 2H), 3.26 – 3.16 (m, 2H). ESI m/z: 302 [M + H]+. 
Ethyl 5-(11,11-dimethyl-4,9-dioxo-10-oxa-3,5,8-triazadodecanamido)-1H-
indole-3-carboxylate 163b  
 
Compound 163b was obtained as white solid (0.350 g, 75%) starting from 
157b (0.391 g, 1.04 mmol) and tert-butyl (2-aminoethyl)carbamate (0.250 g, 
1.56 mmol) according to the procedure used for 161a; 166 – 170 °C. 1H NMR 
(300 MHz, DMSO-d6) δ 11.83 (s, 1H exchangeable with D2O), 9.85 (s, 1H 
exchangeable with D2O), 8.26 (s, 1H), 8.01 (s, 1H), 7.47 – 7.34 (m, 2H), 6.83 
– 6.73 (m, 1H exchangeable with D2O), 6.33 – 6.18 (m, 2H exchangeable with 
D2O), 4.26 (q, J = 6.9 Hz, 2H), 3.83 (d, J = 4.8 Hz, 2H), 3.10 – 3.00 (m, 2H), 
3.00 – 2.91 (m, 2H), 1.37 (s, 9H), 1.31 (t, J = 6.8 Hz, 3H). ESI m/z: 448 [M + 
H]+. 
Ethyl 5-(11,11-dimethyl-4,9-dioxo-10-oxa-3,5,8-triazadodecanamido)-1H-
indole-2-carboxylate 163c  
 
Compound 163c was obtained as white solid ((0.110 g, 63%) starting from 
157b (0.146 g, 0.389 mmol) and tert-butyl (2-aminoethyl)carbamate (0.250 g, 
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1.56 mmol) according to the procedure used for 161a; 194 - 196 °C. 1H NMR 
(300 MHz, DMSO) δ 11.79 (s, 1H, exchangeable with D2O), 9.80 (s, 1H 
exchangeable with D2O), 7.99 (s, 1H), 7.42 – 7.31 (m, 2H), 7.12 – 7.04 (m, 
1H), 6.78 (t, J = 5.2 Hz, 1H exchangeable with D2O), 6.32 – 6.18 (m, 2H 
exchangeable with D2O), 4.33 (q, J = 7.0 Hz, 2H), 3.82 (d, J = 5.2 Hz, 2H), 
3.10 – 3.00 (m, 2H), 2.99 – 2.90 (m, 2H), 1.38 (s, 9H), 1.32 (t, J = 7.0 Hz, 
3H). ESI m/z: 448 [M + H]+. 
Synthesis of 2-(3-(2-aminoethyl)ureido)-N-(1H-indol-5-yl)acetamide 164a 
 
Compound 163a (0.062 g, 0.205 mmol) was dissolved in MeOH (10 mL). The 
reaction parameters of H-Cube-Pro™ hydrogenator (full-H2 mode, 30 °C, 10 
bar and 1 mL min_1 floow rate)  were selected on the H-Cube-Pro™ 
hydrogenator. The instrument was setted with a 30 mm Pd/C 10% CatCart and 
the processing was started, whereby initially only pure solvent was pumped 
through the system until the instrument had achieved the desired reaction 
parameters and stable processing. At that point, the sample inlet line was 
switched to the vial containing the substrate. A total reaction volume of 10 mL 
was collected and the cartridge subsequently washed with pure solvent for 5 
min to remove any substrate/product still adsorbed on the catalyst. 
Evaporation of the solvent afforded the desired product 164a (0.052 g, 93%); 
150 - 152 °C. 1H NMR (300 MHz, DMSO-d6) δ 10.98 (s, 1H exchangeable 
with D2O), 9.69 (s, 1H exchangeable with D2O), 7.84 (s, 1H), 7.35 – 7.26 (m, 
2H), 7.22 – 7.14 (m, 1H), 6.41 – 6.33 (m, 1H), 6.32 – 6.14 (m, 2H 
exchangeable with D2O), 3.82 (d, J = 5.6 Hz, 2H), 3.17 (s, 1H), 3.00 (q, J = 
6.1 Hz, 2H), 2.55 (t, J = 6.2 Hz, 2H). ESI m/z: 276 [M + H]+. 
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Compound 163b (0.097 g, 0.217 mmol) was treated with a solution of 
DCM/TFA 9:1  (5 mL) and the reaction was left to stir at room temperature for 
30 min. Evaporation under vacuum of reaction solvent afford the desired 
product 164b as white solid; 124 – 126 °C. 1H NMR (300 MHz, DMSO-d6) δ 
12.04 (s, 1H exchangeable with D2O), 11.81 (s, 1H exchangeable with D2O), 
10.62 (s, 1H), 9.13 (s, 1H), 8.37 (s, 1H exchangeable with D2O), 8.22 (s, 2H), 
8.10 (s, 1H), 7.61 (d, J = 1.1 Hz, 2H), 7.36 (s, 1H), 4.29 (q, J = 5.9 Hz, 2H), 
4.10 (s, 2H exchangeable with D2O), 3.22 (t, J = 7.4 Hz, 2H), 2.79 (t, J = 7.4 
Hz, 2H), 1.30 (t, J = 5.9 Hz, 3H). ESI m/z: 348 [M + H]+. 
 
 
Synthesis of ethyl 5-(2-(3-(2-aminoethyl)ureido)acetamido)-1H-indole-3-
carboxylate 164c 
 
Compound 164c was obtained as white solid (0.079 g, 77%) starting from 
163c (0.099 g, 0.222 mmol) according to the procedures used for 164b; 215 – 
217 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.81 (s, 1H exchangeable with 
D2O), 9.84 (s, 1H exchangeable with D2O), 7.99 (s, 1H), 7.72 (s, 2H 
exchangeable with D2O), 7.44 – 7.28 (m, 2H), 7.10 (s, 1H), 6.56 – 6.39 (m, 2H 
exchangeable with D2O), 4.33 (q, J = 7.0 Hz, 2H), 3.85 (d, J = 5.0 Hz, 2H), 
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3.28 – 3.20 (m, 2H), 2.90 – 2.80 (m, 2H), 1.33 (t, J = 7.0 Hz, 3H). ESI m/z: 
348 [M + H]+. 
 
Series II derivatives 
Synthesis of ethyl ((1H-indol-5-yl)carbamoyl)glycinate 165a 
 
 
To a cooled solution of ethyl ester glycine chlorohydrate (0.351 g, 2.52 mmol) 
and TEA (0.35 mL, 7.40 mmol) in DCM dry  (40 mL) were added CDI  
(0.432 g, 2.69 mmol) and a solution of 155a (0.222 g, 1.68 mmol) in THF dry 
(5.7 mL). The reaction was left to stir at room temperature for 12h. The 
mixture of reaction was concentrated under reduced pressure, the residue was 
dissolved with AcOEt (100 mL) and washed with HCl 1N (3 x 20 mL), s.s. of 
NaHCO3. The organic phase was dried over Na2SO4, filtered and evaporated 
under reduced pressure. The desired product 165a was obtained  as white solid 
(0.307 g, 70%) after crystallization in CHCl3;  mp 157 – 160 °C. 
1H NMR (300 
MHz, DMSO-d6) δ 10.88 (s, 1H exchangeable with D2O), 8.45 (s, 1H 
exchangeable with D2O), 7.60 (d, J = 2.0 Hz, 1H), 7.33 – 7.21 (m, 2H), 7.01 
(dd, J = 8.7, 2.0 Hz, 1H), 6.35 – 6.24 (m, 2H exchangeable with D2O), 4.11 (q, 
J = 7.1 Hz, 2H), 3.86 (d, J = 5.9 Hz, 2H), 1.21 (t, J = 7.1 Hz, 3H). ESI m/z: 
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Synthesis of ethyl 5-(3-(2-(tert-butoxy)-2-oxoethyl)ureido)-1H-indole-3-
carboxylate 165b 
 
Compound 165b was obtained white solid (0.720 g, 50%) according to the 
procedure used for 165a, starting from 155b (0.813 g, 3.98 mmol) and  tert 
butyl-glycine ester (0.626 g, 4.77 mmol); mp 145 - 147 °C . 1H NMR (300 
MHz, DMSO-d6) δ 11.74 (s, 1H exchangeable with D2O), 8.65 (s, 1H 
exchangeable with D2O), 8.00 (s, 1H), 7.96 (d, J = 2.8 Hz, 1H), 7.37 – 7.24 
(m, 2H), 6.23 (t, J = 6.0 Hz, 1H exchangeable with D2O), 4.26 (q, J = 7.1 Hz, 
2H), 3.76 (d, J = 5.8 Hz, 2H), 1.43 (s, 9H), 1.32 (t, J = 7.1 Hz, 3H). ESI m/z: 
362 [M + H]+ 
Synthesis of ethyl 5-(3-(2-(tert-butoxy)-2-oxoethyl)ureido)-1H-indole-2-
carboxylate 165c 
 
Compound 165c was obtained white solid (0.720 g, 50%) according to the 
procedure used for 165a, starting from 155c (0.813 g, 3.98 mmol) and  tert 
butyl-glycine ester (0.626 g, 4.77 mmol); mp 135 - 140 °C. 1H NMR (300 
MHz, DMSO-d6) δ 11.68 (s, 1H exchangeable with D2O), 8.58 (s, 
exchangeable with D2O), 7.75 (s, 1H), 7.32 (d, J = 9.0 Hz, 1H), 7.23 – 7.14 
(m, 1H), 7.08 – 7.01 (m, 1H), 6.26 (t, J = 5.8 Hz, 1H exchangeable with D2O), 
4.32 (q, J = 7.1 Hz, 2H), 3.75 (d, J = 5.6 Hz, 2H), 1.42 (s, 9H), 1.33 (t, J = 6.9 
Hz, 3H). ESI m/z: 362 [M + H]+. 
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Synthesis of ((1H-indol-5-yl)carbamoyl)glycine 166a 
 
To a solution of 165a (0.100 g, 0.38 mmol) in EtOH (1 mL) was added NaOH 
2N (2 eq). The reaction was left to stir for 2h and then was concentrated under 
reduced pressure. The residue was dissolved with s. s. of NaHCO3 (100 mL) 
and washed with CHCl3. The aqueous phase was acidified with HCl 0.3 N until 
pH 1 and extracted with AcOEt (3 x 20 mL). The organic phase was washed 
with brine, dried with Na2SO4, filtered and evaporated under vacuum. The 
desired product was obtained as white solid (0.070 g, 80 %) and was used in 
the next step without further purification; mp 205 - 207 °C. 1H NMR (300 
MHz, DMSO-d6) δ 12.51 (s, 1H exchangeable with D2O), 10.87 (s, 1H 
exchangeable with D2O), 8.43 (s, 1H exchangeable with D2O), 7.60 (d, J = 2.0 
Hz, 1H), 7.31 – 7.21 (m, 2H), 7.01 (dd, J = 8.7, 2.1 Hz, 1H), 6.36 – 6.27 (m, 
1H), 6.20 (t, J = 5.8 Hz, 1H exchangeable with D2O), 3.79 (d, J = 5.7 Hz, 2H). 
ESI m/z: 234 [M + H]+. 
 
Synthesis of ((3-(ethoxycarbonyl)-1H-indol-5-yl)carbamoyl)glycine 166b 
 
A solution of DCM/TFA (8:2, 13 mL) was added to 165b. The reaction was 
left to stir at room temperature for 1h. Evaporation of mixture reaction under 
vacuum affar the desired product as yellow solid (0.227 g, resa 98%), which 
was used in the next step without further purification. Mp 250 - 255 °C. 1H 
NMR (300 MHz, DMSO-d6) δ 12.33 (s, 1H exchangeable with D2O), 11.85 (s, 
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1H exchangeable with D2O), 9.40 (s, 1H exchangeable with D2O), 9.13 (s, 1H 
exchangeable with D2O), 8.38 (s, 1H), 7.93 (s, 3H), 4.29 (q, J = 5.9 Hz, 2H), 
4.00 (s, 2H), 1.30 (t, J = 5.9 Hz, 3H). ESI m/z: 306 [M + H]+ 
 
Synthesis of ((2-(ethoxycarbonyl)-1H-indol-5-yl)carbamoyl)glycine 166c 
 
Compound 166c was obtained as white solid starting from 165c (0.200 g, 
0.553 mmol) according to the procedure described for 166b. Mp 173 - 176 °C;  
1H NMR (300 MHz, DMSO-d6) δ 11.68 (s, 1H exchangeable with D2O), 8.60 
(s, 1H exchangeable with D2O), 7.76 (s, 1H), 7.32 (d, J = 8.9 Hz, 1H), 7.18 (d, 
J = 8.7 Hz, 1H), 7.03 (s, 1H), 6.39 (s, 1H exchangeable with D2O), 6.33 – 6.22 
(m, 1H exchangeable with D2O), 4.32 (q, J = 7.1 Hz, 2H), 3.70 (s, 1H), 1.33 (t, 
J = 7.1 Hz, 3H). ESI m/z: 306 [M + H]+. 
 
General procedure for coupling reaction (168a – c; 169a – c and 170a – c) 
Example: synthesis 2-(3-(1H-indol-5-yl)ureido)-N-(p-tolyl)acetamide 168a   
  
To a solution of 164 a (0.132 g, 0.565 mmol) and TBTU (0.237 g, 0.738 
mmol) in DMF dry (2 mL) was added a solution of  p-methyl-aniline (0.073 g, 
0.678 mmo) and TEA (0.24 mL, 1.71 mmol) in DMF (2 mL). The reaction 
was left to stirr at room temperature for 12 h. The reaction was concentrated 
under reduced pressure, the residue was dissolved with AcOEt  (50 mL) and 
washed with satuturated aqueous solution of NaHCO3 and brine. The organic 
phase was dried over Na2SO4, filtered and evaporated under reduced pressure. 
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Purification by by silica gel chromatography DCM/MeOH, 95:5 gave the 
desired product 168a as white solid (0.110 g, resa 60%). 1H NMR (300 MHz, 
DMSO) δ 10.88 (s, 1H, exchangeable with D2O), 9.92 (s, 1H exchangeable 
with D2O), 8.50 (s, 1H exchangeable with D2O), 7.62 (s, 1H), 7.60 – 7.39 (m, 
2H), 7.33 – 7.20 (m, 2H), 7.11 (d, J = 8.0 Hz, 2H), 7.02 (d, J = 8.4 Hz, 1H), 
6.35 – 6.24 (m, 2H exchangeable with D2O), 3.92 (d, J = 5.1 Hz, 2H), 2.25 (s, 




Compound 168b was obtained as white solid (0.160 g, 50%) starting from 
166b (0.340 g, 0.811 mmol) according to the procedure described for 168a; 
mp 214 – 216 °C. 1H NMR (300 MHz, DMSO-d6) δ 13.68 (s, 1H 
exchangeable with D2O), 11.88 (s, 1H exchangeable with D2O), 9.38 (s, 1H 
exchangeable with D2O), 9.13 (s, 1H exchangeable with D2O), 8.43 – 8.29 (m, 
2H), 8.18 (d, J = 1.4 Hz, 1H), 7.52 – 7.39 (m, 3H), 7.15 – 7.05 (m, 2H), 4.29 
(q, J = 5.9 Hz, 2H), 4.10 (s, 2H), 2.32 (d, J = 1.1 Hz, 3H), 1.30 (t, J = 5.9 Hz, 
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Compound 168c was obtained as white solid (0.168 g, 60%) starting from 
166c (0.297 g, 0.709 mmol) according to the procedure described for 168a; 
mp 233 – 236 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.69 (s, 1H 
exchangeable with D2O), 9.94 (s, 1H exchangeable with D2O), 8.72 (s, 1H 
exchangeable with D2O), 7.78 (s, 1H), 7.55 – 7.42 (m, 2H), 7.32 (d, J = 8.8 
Hz, 1H), 7.19 (d, J = 8.8 Hz, 1H), 7.15 – 7.07 (m, 2H), 7.05 – 7.01 (m, 1H), 
6.41 (t, J = 4.8 Hz, 1H exchangeable with D2O), 4.32 (q, J = 7.0 Hz, 2H), 3.92 




Compound 169a was obtained as white solid  starting from 166a (0.150 g, 
0.643 mmol) and 2-aminoethyl-piperidine (0.263 g, 0.83 mmol) according to 
the procedure described for 168a; mp 157 – 159 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 10.87 (s, 1H exchangeable with D2O), 8.46 (s, 1H exchangeable 
with D2O), 7.84 (s, 1H exchangeable with D2O), 7.60 (s, 1H), 7.32 – 7.20 (m, 
2H), 7.05 – 6.97 (m, 1H), 6.33 – 6.28 (m, 1H), 6.23 (t, J = 4.8 Hz, 1H 
exchangeable with D2O), 3.70 (d, J = 4.8 Hz, 2H), 3.26 – 3.15 (m, 2H), 2.47 – 











Compound 169b was obtained as white solid (0.121g, 60%)  starting from 
166b (0.200 g, 0.477 mmol) according to the procedure described for 169a; 
mp 189 – 190 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.73 (s, 1H 
exchangeable with D2O), 8.66 (s, 1H, exchangeable with D2O), 8.07 – 7.92 
(m, 2H), 7.88 – 7.77 (m, 1H exchangeable with D2O), 7.42 – 7.23 (m, 2H), 
6.24 (t, J = 5.0 Hz, 1H exchangeable with D2O), 4.25 (d, J = 6.6 Hz, 2H), 3.71 
(d, J = 4.6 Hz, 2H), 3.24 – 3.14 (m, J = 5.9 Hz, 2H), 2.41 – 2.24 (m, 6H), 1.55 





Compound 169c was obtained as white solid (0.121g, 60%)  starting from 
166c (0.200 g, 0.477 mmol) according to the procedure described for 169a; 
mp 202 – 204 °C. 1H NMR (300 MHz, DMSO) δ 11.68 (s, 1H, exchangeable 
with D2O), 8.60 (s, 1H exchangeable with D2O), 7.80 (t, J = 5.4 Hz, 1H 
exchangeable with D2O), 7.76 (s, 1H), 7.32 (d, J = 8.8 Hz, 1H), 7.17 (dd, J = 
8.9, 1.7 Hz, 1H), 7.03 (s, 1H), 6.27 (t, J = 5.2 Hz, 1H exchangeable with D2O), 
4.32 (q, J = 7.0 Hz, 2H), 3.70 (d, J = 5.2 Hz, 2H), 3.23 – 3.12 (m, 2H), 2.40 – 
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Compound 170a was obtained as white solid (0.206 g, 53%) starting from 
166a (0.300 g, 1.28 mmol) and 2-azidoethan-1-amine (0.205 g, 1.68 mmol) 
according to the procedure described for 168a; mp 165 – 167 °C. 1H NMR 
(300 MHz, DMSO-d6) δ 10.88 (s, 1H exchangeable with D2O), 8.46 (s, 1H 
exchangeable with D2O), 8.17 (t, J = 5.4 Hz, 1H exchangeable with D2O), 
7.63 – 7.61 (m, 1H), 7.28 – 7.26 (m, 1H), 7.26 – 7.24 (m, 1H), 7.02 (dd, J = 
8.6, 2.1 Hz, 1H), 6.34 – 6.30 (m, 1H), 6.22 (t, J = 5.5 Hz, 1H exchangeable 
with D2O), 3.74 (d, J = 5.4 Hz, 2H), 3.39 (t, J = 5.7 Hz, 2H), 3.29 (t, J = 5.7 






Compound 170b was obtained as white solid (0.100 g, 76%) starting from 
166b (0.116 g, 0.274 mmol) and tert-butyl (2-aminoethyl)carbamate (0.105 g, 
0.602 mmol) according to the procedure described for 168a;  157 – 160 °C.  
1H NMR (300 MHz, DMSO-d6) δ 11.73 (s, 1H exchangeable with D2O), 8.67 
(s, 1H exchangeable with D2O), 8.00 (s, 1H ), 7.98 – 7.95 (m, 2H 
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exchangeable with D2O), 7.40 – 7.22 (m, 2H), 6.89 – 6.76 (m, 1H, 
exchangeable with D2O), 6.31 – 6.13 (m, 1H, exchangeable with D2O), 4.25 
(q, J = 6.9 Hz, 2H), 3.72 (d, J = 4.6 Hz, 2H), 3.17 – 3.06 (m, 2H), 3.05 – 2.93 







Compound 170c was obtained as white solid (0.130 g, 60%) starting from 
166b (0.190 g, 0.450 mmol) and tert-butyl (2-aminoethyl)carbamate (0.250 g, 
1 mmol) according to the procedure described for 168a; 210 – 212 °C. 1H 
NMR (300 MHz, DMSO-d6) δ 11.67 (s, 1H exchangeable with D2O), 8.61 (s, 
1H exchangeable with D2O), 8.04 – 7.88 (m, 1H exchangeable with D2O), 
7.76 (s, 1H), 7.38 – 7.26 (m, 1H), 7.21 – 7.12 (m, 1H), 7.03 (s, 1H), 6.86 – 
6.74 (m, 1H exchangeable with D2O), 6.31 – 6.18 (m, 1H exchangeable with 
D2O), 4.32 (q, J = 6.9 Hz, 2H), 3.71 (d, J = 4.4 Hz, 2H), 3.18 – 3.04 (m, 2H), 
3.03 – 2.92 (m, 2H), 1.37 (s, 9H), 1.32 (t, J = 7.1 Hz, 3H). ESI m/z: 478 [M + 
H]+. 
 
Synthesis of 2-(3-(1H-indol-5-yl)ureido)-N-(2-aminoethyl)acetamide171a 
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Compound 171a was obtained as white solid starting from 170a (0.070 g, 
0.230 mmol) according to the procedure described for 164a; mp 126 – 128 °C. 
1H NMR (300 MHz, DMSO-d6) δ 10.88 (s, 1H exchangeable with D2O), 8.48 
(s, 1H exchangeable with D2O), 7.90 (t, J = 5.7 Hz, 1H exchangeable with 
D2O), 7.62 (d, J = 1.9 Hz, 1H), 7.26 (dd, J = 5.9, 3.1 Hz, 2H), 7.03 (dd, J = 
8.6, 2.0 Hz, 1H), 6.34 – 6.30 (m, 1H), 6.23 (t, J = 5.4 Hz, 1H exchangeable 
with D2O), 3.73 (d, J = 5.3 Hz, 2H), 3.19 (s, 2H exchangeable with D2O), 3.11 
(q, J = 6.2 Hz, 2H), 2.61 (t, J = 6.4 Hz, 2H). ESI m/z: 276 [M + H]+. 
Synthesis of ethyl 5-(3-(2-((2-aminoethyl)amino)-2-oxoethyl)ureido)-1H-
indole-3-carboxylate 2,2,2-trifluoroacetate 171b 
 
Compound 171 b was obtained as white solid (0.070 g, resa 85%) starting 
from 170b (0.080 g, 0.178 mmol) according to the procedure described for 
164b; 188 – 190 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.75 (s, 1H 
exchangeable with D2O), 8.73 (s, 1H exchangeable with D2O), 8.10 (t, J = 5.1 
Hz, 1H exchangeable with D2O), 8.02 (s, 1H), 7.97 (d, J = 2.1 Hz, 1H), 7.69 
(s, 2H exchangeable with D2O), 7.33 (d, J = 8.7 Hz, 1H), 7.30 (dd, J = 8.7, 1.2 
Hz, 1H), 6.29 (t, J = 5.1 Hz, 1H exchangeable with D2O), 4.25 (q, J = 7.0 Hz, 
2H), 3.76 (d, J = 5.2 Hz, 2H), 2.88 (t, J = 6.1 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H). 
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Synthesis of Ethyl 5-(3-(2-((2-aminoethyl)amino)-2-oxoethyl)ureido)-1H-
indole-2-carboxylate 2,2,2-trifluoroacetate 171c 
 
Compound 171c was obtained as white solid (0.050 g, resa 60%) starting from 
170c (0.080 g, 0.180 mmol) according to the procedure described for 164b; 
mp 183 – 185 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.69 (s, 1H 
exchangeable with D2O), 8.68 (s, 1H exchangeable with D2O), 8.11 (s, 1H 
exchangeable with D2O), 7.88 – 7.64 (m, 3H exchangeable with D2O), 7.33 (d, 
J = 8.6 Hz, 1H), 7.18 (d, J = 8.6 Hz, 1H), 7.10 – 6.98 (m, 1H), 6.33 (t, J = 4.8 
Hz, 1H exchangeable with D2O), 4.32 (q, J = 7.0 Hz, 2H), 3.75 (d, J = 4.4 Hz, 
2H), 2.96 – 2.81 (m, 2H), 1.33 (t, J = 7.0 Hz, 3H). ESI m/z: 348 [M + H]+ 
 
Synthesis of Series III derivatives 
Synthesis of 1-(2-hydroxyethyl)-3-(p-tolyl)urea 173a 
 
To a cooled solution of p-tolilisocyanate (0.94 mL, 7.51 mmol) and TEA (2.06 
mL, 15.02 mmol) in THF dry was added dropwise a solution of 2-amino-
ethanol (0.90 mL, 15.02 mmol) in THF dry (16 mL). The reaction was left to 
stir at room temperature for 12 h and then was concentrated under vacuum. 
The residue was dissolved in AcOEt (150 mL) and washed with HcL 1n (3 x 
50mL) and brine.The organic phase was dried with Na2SO4 and evaporated 
under vacuum. The desired product 173a was obtained as white solid (1.20 g, 
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resa 82%) after crystallization with AcOEt; mp 130 -132 °C. 1H NMR (300 
MHz, DMSO-d6) δ 8.42 (s, 1H, exchangeable with D2O), 7.24 (d, J = 8.0 Hz, 
2H), 7.01 (d, J = 8.0 Hz, 2H), 6.11 (t, J = 5.6 Hz, 1H, exchangeable with 
D2O), 4.74 (t, J = 5.2 Hz, 1H), 3.42 (q, J = 5.5 Hz, 2H), 3.34 (s, 1H, 
exchangeable with D2O), 2.20 (s, 3H). ESI m/z: 195 [M + H]
+ 
Synthesis of 1-(2-hydroxyethyl)-3-(2-(piperidin-1-yl)ethyl)urea 173b 
 
To a solution of N-(2aminoethyl)-piperidine (1.11 mL, 7.80 mmol) in AcOE 
(16 mL) and TEA (1.19 mL, 8.58 mmol) was added dropwise phenyl-
chloroformate  (1.2 mL, 8.58) and was left to stir at room temperature for 4h, 
Water (5 mL) was added, the two phase were separated and the organic phase 
was washed with water (2 x 5 mL) and Brine. The organic phase was dried, 
filtered and evaporated under vacuum. Purification by silica gel 
chromatography (DCM/MEOH 9:1) afford phenyl (2-(piperidin-1-
yl)ethyl)carbamate intermediate (172a)  as yellow oil (1.93 g, 52%). 
Compound 172a was dissolved in 1, 2-dichloroethane (10 mL) and then were 
added TEA (0.56 mL, 4.05 mmol) and 2-amino-ethanol (0.24 mL, 4.05 
mmol). The reaction was left to stirr at 120 °C for 2 h. The mixture of reaction 
was concentrated under reduced pressure and purified by silica gel 
chromatography (DCM/MeOH/NH3, 9:1:0.1) to afford the desired product 
173b  as yellow oil (0.226 g, 78%). 1H NMR (500 MHz, Chloroform-d) δ 6.21 
(s, 1H, exchangeable with D2O), 5.24 (s, 1H, exchangeable with D2O), 3.69 (t, 
J = 4.8 Hz, 2H), 3.33 (q, J = 5.2 Hz, 2H), 3.24 (q, J = 5.5 Hz, 2H), 2.44 (t, J = 
5.5 Hz, 2H), 2.40 (m, 4H, exchangeable with D2O), 1.56 (m, J = 5.7 Hz, 5H), 
1.48 – 1.40 (m, 2H). ESI m/z: 216 [M + H]+. 
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Synthesis of 1-(2-azidoethyl)-3-(2-hydroxyethyl)urea 173c 
 
Compound 173c was obtained as colourless oil (0.600 g, 72%) starting from 2-
azidoethan-1-amine  (1.00 g, 8.16 mmol) according to the procedures reported 
for 173b. 1H NMR (300 MHz, DMSO-d6) δ 6.16 (t, J = 5.8 Hz, 1H, 
exchangeable with D2O), 5.98 (t, J = 5.8 Hz, 1H, exchangeable with D2O), 
4.64 (t, J = 5.2 Hz, 1H, exchangeable with D2O), 3.39 – 3.34 (m, 2H), 3.29 (d, 
J = 5.6 Hz, 1H), 3.17 (q, J = 5.8 Hz, 2H), 3.05 (q, J = 5.8 Hz, 2H). ESI m/z: 
174 [M + H]+. 
Synthesis of 1-(2-methoxyethyl)-3-(p-tolyl)urea 174a 
 
To a cooled solution of 173a  (0.500 g, 2.57 mmol) in THF dry (26 mL) were 
added dropwise TEA (0.53 mL, 3.86 mmol) and mesyl chloride (0.30 mL, 
3.86 mmol). The reaction was left to stir at room temperature for 1 h and was 
directly used for preparation of 175a – c. 
Synthesis of 1-(2-methoxyethyl)-3-(2-(piperidin-1-yl)ethyl)urea 174b 
 
Compound 174b was obtained starting from 173b (0.150g, 0.70 mmol)  
according to the procedure used for 174a. The mixture of reaction was directly 
used for the preparation of 175a – c. 
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Synthesis of 1-(2-azidoethyl)-3-(2-methoxyethyl)urea 174c 
 
Compound 174c was obtained starting from 173c (0.150 g, 0.866 mmol) 
according to the procedures described for 174a. 
Synthesis of 1-(2-((1H-indol-5-yl)amino)ethyl)-3-(p-tolyl)urea 175a 
 
To a mixture of reaction of 174a were added 155a (0.255 g, 1.92 mmol) and 
TEA (0.26 mL, 1.92 mmol). The reaction was left to stir at 50 °C for 1 h. The 
reaction was concentrated under vacuum, the residue was dissolved with 
AcOEt (100 mL) and washed with brine (3 x 35 mL). The organic layer was 
dried over Na2SO4, filtered and evaporated under reduced pressure. 
Purification by silica gel chromatography (Hex/AcOEt, 1:1) gave the desired 
product 175a as white solid (0.150 g, 40%); mp 160- 162 °C. 1H NMR (300 
MHz, DMSO-d6) δ 10.60 (s, 1H, exchangeable with D2O), 8.43 (s, 1H, 
exchangeable with D2O), 7.27 (d, J = 8.0 Hz, 2H), 7.15 – 7.10 (m, 2H), 7.01 
(d, J = 7.9 Hz, 2H), 6.66 (s, 1H), 6.56 – 6.51 (m, 1H), 6.21 (t, J = 5.4 Hz, 1H, 
exchangeable with D2O), 6.17 (s, 1H,), 5.02 (t, J = 5.1 Hz, 1H, exchangeable 
with D2O), 3.32 – 3.26 (m, 2H), 3.08 (q, J = 6.1 Hz, 2H), 2.21 (s, 3H). ESI 
m/z: 309 [M + H]+ 
 
 
                                                                        Chapter 7: Experimental section  
238 
 
Synthesis of ethyl 5-((2-(3-(p-tolyl)ureido)ethyl)amino)-1H-indole-3-
carboxylate 175b 
 
Compound 175b was obtained as white solid (0.131 g, resa 53%) starting from 
155b (0.200g, 0.98 mmol) and 174a (0.65 mol) according to the procedure 
reported for 175a; 145 – 146 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.52 (s, 
1H, exchangeable with D2O), 8.47 (s, 1H, exchangeable with D2O), 7.82 (s, 
1H), 7.27 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.7 Hz, 1H), 7.14 (d, J = 2.3 Hz, 
1H), 7.01 (d, J = 8.0 Hz, 2H), 6.62 (dd, J = 8.9, 2.3 Hz, 1H), 6.28 – 6.22 (m, 
1H, exchangeable with D2O), 5.40 (t, J = 5.7 Hz, 1H, exchangeable with D2O), 
4.23 (q, J = 7.1 Hz, 2H), 3.31 (m, 2H)3.12 (q, J = 6.2 Hz, 2H), 2.21 (s, 3H), 
1.31 (t, J = 7.1 Hz, 3H). ESI m/z: 381 [M + H]+. 
 
Synthesis of ethyl 5-((2-(3-(p-tolyl)ureido)ethyl)amino)-1H-indole-2-
carboxylate 175c 
 
Compound 175b was obtained as white solid (0.110g, resa 42%) starting from 
155c (0.200g, 0.98 mmol) and 174a (0.65 mol) according to the procedure 
reported for 175a, 130 – 132 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.44 (s, 
1H, exchangeable with D2O), 8.44 (s, 1H, exchangeable with D2O), 7.27 (d, J 
= 8.1 Hz, 2H), 7.20 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 8.1 Hz, 2H), 6.87 (s, 1H), 
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6.75 (dd, J = 8.1, 1.5 Hz, 1H), 6.65 (s, 1H), 6.21 (t, J = 5.4 Hz, 1H, 
exchangeable with D2O), 5.33 (t, J = 6.1 Hz, 1H, exchangeable with D2O), 
4.30 (q, J = 7.1 Hz, 2H), 3.54 – 3.39 (m, 2H), 3.16 – 3.05 (m, 2H), 2.21 (s, 
3H), 1.32 (t, J = 7.0 Hz, 3H). ESI m/z: 381 [M + H]+. 
Synthesis of 1-(2-((1H-indol-5-yl)amino)ethyl)-3-(2-(piperidin-1-
yl)ethyl)urea 176a  
 
Compound 176a was obtained as white solid (0.109 g, 40%) starting from 
155a (0.138 g, 1.05 mmol) and 146b (0.7 mmol) according to the procedure 
reported for 175a; 125 – 127 °C.  1H NMR (300 MHz, DMSO-d6) δ 11.53 (s, 
1H, exchangeable with D2O), 7.77 (s, 1H, exchangeable with D2O), 7.43 (d, J 
= 7.5 Hz, 1H), 7.34 – 7.22 (m, 2H), 6.69 – 6.51 (m, 3H, exchangeable with 
D2O), 5.94 (s, 1H, exchangeable with D2O), 3.58 (t, J = 4.8 Hz, 2H), 3.51 – 
3.36 (m, 4H), 2.52 – 2.37 (m, 6H), 1.55 – 1.33 (m, 6H). ESI m/z: 275 [M + 
H]+. 
Synthesis of ethyl 5-((2-(3-(2-(piperidin-1-yl)ethyl)ureido)ethyl)amino)-
1H-indole-3-carboxylate 176b 
 
Compound 176b was obtained as white solid (0.150 g, 54%) starting from 
155b (0.212 g, 1.04 mmol) and 174b (0.69 mmol) according the procedure 
described for 175a; mp 120 – 121 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.58 
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(s, 1H, exchangeable with D2O), 9.89 (s, 1H, exchangeable with D2O), 7.83 (s, 
1H, exchangeable with D2O), 7.18 (d, J = 28.9 Hz, 2H), 6.63 (s, 1H), 5.22 – 
4.99 (m, 1H, exchangeable with D2O), 4.23 (q, J = 7.1 Hz, 2H), 3.10 – 3.02 
(m, 8H), 1.31 (t, J = 7.1 Hz, 3H), 1.21 – 1.14 (m, 10H). ESI m/z: 402 [M + 
H]+. 
Synthesis of ethyl 5-((2-(3-(2-(piperidin-1-yl)ethyl)ureido)ethyl)amino)-
1H-indole-2-carboxylate 176c 
 
Compound 176c was obtained as white solid (0.100 g, 57%) starting from 
155c (0.133 g, 0.65 mmol) and 174b (0.43 mmol) according the procedure 
described for 175a; mp 145 – 147 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.45 
(s, 1H, exchangeable with D2O), 9.27 (s, 1H, exchangeable with D2O), 6.87 (s, 
1H, exchangeable with D2O), 6.72 (d, J = 8.9 Hz, 1H), 6.64 (s, 1H), 6.43 – 
6.31 (m, 2H), 5.33 – 5.22 (m, 1H, exchangeable with D2O), 4.30 (q, J = 7.0 
Hz, 2H), 3.55 – 3.42 (m, 3H), 3.30 – 3.18 (m, 3H), 3.14 – 3.02 (m, 6H), 2.96 – 
2.80 (m, 2H), 1.88 – 1.73 (m, 2H), 1.73 – 1.53 (m, 2H), 1.32 (t, J = 7.0 Hz, 
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